{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "CRTX.L",
  "generated_at": "2026-02-11T14:22:07.626612Z",
  "top_card": {
    "ticker": "CRTX.L",
    "company_name": "CRISM Therapeutics Corporation",
    "sector": "Healthcare",
    "market_cap_gbp": 7398143,
    "days_active": 342,
    "apex_score_100": 41,
    "confidence_score_100": 40,
    "ai_final_score_25": 12,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 41/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "CRISM Therapeutics Corporation",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 7398143,
      "current_close_price": 14.3
    },
    "basics": {
      "ticker": "CRTX.L",
      "current_price": 14.3,
      "ath": 712.9565,
      "atl": 5.0,
      "ath_date": "2022-01-25",
      "atl_date": "2024-06-19",
      "week_52_high": 29.4,
      "week_52_low": 5.64,
      "week_52_high_date": "2025-05-02",
      "week_52_low_date": "2025-03-06",
      "drawdown_from_ath_pct": 97.99,
      "data_start": "2020-01-02",
      "data_end": "2026-02-11",
      "total_bars": 1360
    },
    "latest_signal": {
      "date": "2025-03-06",
      "scan_date": "2026-01-26",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "price": 6.5,
      "drawdown_pct": 85.99,
      "ai_score": 10.0,
      "rsi": 0.0,
      "cycle_position": 0.1352,
      "holding_period_days": 342,
      "current_pnl_pct": 120.0,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -59.29,
      "Rally_Count": 1,
      "days_since_last_high": 17,
      "last_high_date": "2026-01-09",
      "lock_in_reached": true,
      "lock_in_date": "2025-06-13",
      "best_rally_pct": 269.23
    },
    "best_historical_signal": {
      "signal_date": "2024-06-26",
      "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
      "signal_color": "PURPLE",
      "entry_price": 5.25,
      "peak_price": 30.9,
      "peak_date": "2024-07-03",
      "rally_pct": 488.57,
      "days_to_peak": 7,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "CRTX.L_2023-06-01",
        "signal_date": "2023-06-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 37.6,
        "current_price": 9.77,
        "current_return_pct": -74.02,
        "best_rally_pct": 21.28,
        "best_rally_date": "2023-06-15",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -78.57,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 970,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-06-02",
        "signal_date": "2023-06-02",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 40.0,
        "current_price": 9.77,
        "current_return_pct": -75.57,
        "best_rally_pct": 14.0,
        "best_rally_date": "2023-06-15",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -78.57,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 969,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-06-05",
        "signal_date": "2023-06-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 38.4,
        "current_price": 9.77,
        "current_return_pct": -74.56,
        "best_rally_pct": 18.75,
        "best_rally_date": "2023-06-15",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -78.57,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 966,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-06-14",
        "signal_date": "2023-06-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 36.0,
        "current_price": 9.77,
        "current_return_pct": -72.86,
        "best_rally_pct": 26.67,
        "best_rally_date": "2023-06-15",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -78.57,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 957,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-06-15",
        "signal_date": "2023-06-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 45.6,
        "current_price": 9.77,
        "current_return_pct": -78.57,
        "best_rally_pct": -12.28,
        "best_rally_date": "2023-06-16",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 956,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-06-16",
        "signal_date": "2023-06-16",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 40.0,
        "current_price": 9.77,
        "current_return_pct": -75.57,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-06-22",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 955,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-08-15",
        "signal_date": "2023-08-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 20.0,
        "current_price": 9.77,
        "current_return_pct": -51.15,
        "best_rally_pct": 20.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 895,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-08-29",
        "signal_date": "2023-08-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 16.0,
        "current_price": 9.77,
        "current_return_pct": -38.94,
        "best_rally_pct": 50.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 881,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-08-31",
        "signal_date": "2023-08-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 16.0,
        "current_price": 9.77,
        "current_return_pct": -38.94,
        "best_rally_pct": 50.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 879,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-09-05",
        "signal_date": "2023-09-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.4,
        "current_price": 9.77,
        "current_return_pct": -32.15,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-06-13",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 874,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2023-09-06",
        "signal_date": "2023-09-06",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 14.4,
        "current_price": 9.77,
        "current_return_pct": -32.15,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-06-13",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 873,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-06-06",
        "signal_date": "2024-06-06",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 8.25,
        "current_price": 9.77,
        "current_return_pct": 18.42,
        "best_rally_pct": 190.91,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 599,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-06-11",
        "signal_date": "2024-06-11",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.25,
        "current_price": 9.77,
        "current_return_pct": 34.76,
        "best_rally_pct": 231.03,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 594,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-06-20",
        "signal_date": "2024-06-20",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.5,
        "current_price": 9.77,
        "current_return_pct": 77.64,
        "best_rally_pct": 336.36,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 585,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-06-26",
        "signal_date": "2024-06-26",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 5.25,
        "current_price": 9.77,
        "current_return_pct": 86.1,
        "best_rally_pct": 357.14,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 579,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-07-01",
        "signal_date": "2024-07-01",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 6.0,
        "current_price": 9.77,
        "current_return_pct": 62.83,
        "best_rally_pct": 300.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 574,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-09-19",
        "signal_date": "2024-09-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 12.0,
        "current_price": 9.77,
        "current_return_pct": -18.58,
        "best_rally_pct": 100.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 494,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-09-20",
        "signal_date": "2024-09-20",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 11.0,
        "current_price": 9.77,
        "current_return_pct": -11.18,
        "best_rally_pct": 118.18,
        "best_rally_date": "2025-06-13",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 493,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-09-27",
        "signal_date": "2024-09-27",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 9.5,
        "current_price": 9.77,
        "current_return_pct": 2.84,
        "best_rally_pct": 152.63,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 486,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-10-23",
        "signal_date": "2024-10-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.5,
        "current_price": 9.77,
        "current_return_pct": 14.94,
        "best_rally_pct": 182.35,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 460,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-11-21",
        "signal_date": "2024-11-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.5,
        "current_price": 9.77,
        "current_return_pct": 2.84,
        "best_rally_pct": 152.63,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 431,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-11-25",
        "signal_date": "2024-11-25",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 9.5,
        "current_price": 9.77,
        "current_return_pct": 2.84,
        "best_rally_pct": 152.63,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 427,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2024-11-26",
        "signal_date": "2024-11-26",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 9.0,
        "current_price": 9.77,
        "current_return_pct": 8.56,
        "best_rally_pct": 166.67,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 426,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-01-10",
        "signal_date": "2025-01-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.5,
        "current_price": 9.77,
        "current_return_pct": 2.84,
        "best_rally_pct": 152.63,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 381,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-01-15",
        "signal_date": "2025-01-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.0,
        "current_price": 9.77,
        "current_return_pct": 8.56,
        "best_rally_pct": 166.67,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 376,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-01-20",
        "signal_date": "2025-01-20",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 8.5,
        "current_price": 9.77,
        "current_return_pct": 14.94,
        "best_rally_pct": 182.35,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 371,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-01-28",
        "signal_date": "2025-01-28",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.5,
        "current_price": 9.77,
        "current_return_pct": 14.94,
        "best_rally_pct": 182.35,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 363,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-02-10",
        "signal_date": "2025-02-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.0,
        "current_price": 9.77,
        "current_return_pct": 22.13,
        "best_rally_pct": 200.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 350,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-02-21",
        "signal_date": "2025-02-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 9.77,
        "current_return_pct": 30.27,
        "best_rally_pct": 220.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 339,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-02-24",
        "signal_date": "2025-02-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 9.77,
        "current_return_pct": 30.27,
        "best_rally_pct": 220.0,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 336,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-02-25",
        "signal_date": "2025-02-25",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.0,
        "current_price": 9.77,
        "current_return_pct": 39.57,
        "best_rally_pct": 242.86,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 335,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-02-27",
        "signal_date": "2025-02-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.0,
        "current_price": 9.77,
        "current_return_pct": 39.57,
        "best_rally_pct": 242.86,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 333,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-03-04",
        "signal_date": "2025-03-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.5,
        "current_price": 9.77,
        "current_return_pct": 50.31,
        "best_rally_pct": 269.23,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 328,
        "status": "historical"
      },
      {
        "signal_id": "CRTX.L_2025-03-06",
        "signal_date": "2025-03-06",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.5,
        "current_price": 9.77,
        "current_return_pct": 50.31,
        "best_rally_pct": 269.23,
        "best_rally_date": "2025-06-13",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -59.29,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 326,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 34,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 208.74,
      "median_rally_pct": 218.07,
      "best_rally_pct": 488.57,
      "worst_rally_pct": 1.75
    },
    "splits": [
      {
        "date": "2024-05-31",
        "detected_at": "2026-01-26T17:45:59.996723",
        "market": "LSE_AIM",
        "ratio": 0.00625,
        "ratio_display": "1/160",
        "source": "yahoo",
        "type": "stock_split"
      }
    ],
    "split_risk": {
      "split_detected": true,
      "risk_level": "HIGH",
      "confidence": "HIGH",
      "latest_split": {
        "date": "2024-05-31",
        "detected_at": "2026-01-26T17:45:59.996723",
        "market": "LSE_AIM",
        "ratio": 0.00625,
        "ratio_display": "1/160",
        "source": "yahoo",
        "type": "stock_split"
      }
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-11 14:06:39 UTC",
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 41/100 indicates moderate opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 1 rallies, 269% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "CRTX.L",
      "latest": [
        {
          "title": "Japanese Patent Grant",
          "announcement_date": "20th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "20 Jan 2026 07:00\nRNS Number : 5029P\nCRISM Therapeutics Corporation\n20 January 2026\n20 January 2026\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nJapanese Patent Grant for ChemoSeed\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent\n(\n7800909\n) b\ny the\u00a0Japanese Patent Office.\nThe patent relates to the Company's lead product, ChemoSeed\u00ae, for chemotherapeutic drug implants and more, particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan. ChemoSeed was invented by Professor\u00a0Chris McConville, CRISM's Chief Scientific Officer.\nThe patent covers the manufacturing processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours such as glioblastoma.\nCommenting on the patent grant, CRISM Therapeutics' CEO, Andrew Webb, said:\n\"We are pleased to have started 2026 by strengthening our IP position through the grant of this patent in Japan, which we view as a key market. This latest patent grant broadens our appeal to potential commercial partners. We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\nregistration-grade Phase 2 clinical trial\nof\nirinotecan-ChemoSeed\u2122\nin patients with\nsurgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEAXFNFSXKEFA",
          "rns_number": "RNS Number : 5029P"
        },
        {
          "title": "Results of Shareholder Analysis",
          "announcement_date": "9th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "9 Jan 2026 07:00\nRNS Number : 2488O\nCRISM Therapeutics Corporation\n09 January 2026\n09 January 2026\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nResults of Shareholder Analysis\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 31 December 2025, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company (\"Ordinary Shares\").\nShareholder\nNo. of Ordinary Shares\n% interest in the ordinary share capital of the Company\nAndrew Webb\n7,297,190\n14.10%\nChristopher McConville\n4,992,033\n9.65%\nBrian Murray\n4,908,700\n9.49%\nDavid Lawton\n4,802,416\n9.28%\nZeus Dynamic Opportunities Fund\n1,900,000\n3.67%\nFollowing the issue of the placing and retail offer shares (as announced on 10 and 15 December 2025 respectively) neither Linista Group Inc. or Spreadex hold a disclosable shareholding in the Company.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\nregistration-grade Phase 2 clinical trial\nof\nirinotecan-ChemoSeed\u2122\nin patients with\nsurgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBPMBTMTBMTPF",
          "rns_number": "RNS Number : 2488O"
        },
        {
          "title": "Result of Retail Offer",
          "announcement_date": "15th Dec 2025",
          "release_time": "2:29 pm",
          "source": "RNS",
          "content": "15 Dec 2025 14:29\nRNS Number : 6299L\nCRISM Therapeutics Corporation\n15 December 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS INCORPORATED INTO UK\u00a0LAW BY THE\u00a0EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"UK MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\u00a0IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n15 December 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nResult of Retail Offer\nFurther to the announcement by the Company in respect of the Retail Offer dated 10 December 2025, CRISM Therapeutics Corporation announces that, following the closing of the Retail Offer on the BookBuild platform today at 12.00 p.m., the Company has raised gross proceeds of \u00a359,610 (the \"\nRetail Offer\n\") by way of a subscription of 662,332 Retail Offer Shares at the Issue Price of 9 pence per share.\nThe proceeds of the Retail Offer together with the Placing announced on 10 December 2025 (together the \"\nProceeds\n\"), will enable the Company to progress its MHRA approved, Phase 2 open-label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma, with first patients expected to be dosed in Q1 2026.\nAdmission and Total Voting Rights\nApplication has been made to the London Stock Exchange for admission of the Retail Offer Shares (\"\nAdmission\n\"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 16 December 2025, or such later date as may be agreed between the Company and SP Angel. The Retail Offer Shares will rank\npari passu\nwith the Company's existing ordinary shares.\nFollowing the issue of the Retail Offer Shares, the total issued share capital of the Company will consist of 51,735,266 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 51,735,266 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\nOther than where defined, capitalised terms used in this Announcement have the meanings given to them in the announcements of 10 December 2025.\n-Ends-\n\u200b\nEnquiries:\n\u200b\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, Ex\nec. Chair\nChris McConville, CSO\nRichard Morrison (Corp Fin)\nAdam Cowl (Corp Fin)\nVadim Alexandre (Sales)\nRob Rees (Sales)\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\u00a0registration-grade Phase 2 clinical trial\u00a0of\u00a0irinotecan-ChemoSeed\u2122\u00a0in patients with\u00a0surgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nROITABITMTTBBIA",
          "rns_number": "RNS Number : 6299L"
        },
        {
          "title": "Retail Offer",
          "announcement_date": "10th Dec 2025",
          "release_time": "7:25 am",
          "source": "RNS",
          "content": "10 Dec 2025 07:25\nRNS Number : 9161K\nCRISM Therapeutics Corporation\n10 December 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CRISM THERAPEUTICS CORPORATION). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION.\n10 December 2025\nCRISM THERAPEUTICS CORPORATION\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nRetail Offer to raise up to \u00a3100,000\nCRISM Therapeutics Corporation (the \"\nCompany\n\") is pleased to announce a retail offer via BookBuild (the \"\nRetail Offer\n\") of new ordinary shares (\"\nOrdinary Shares\n\") of nil par value each in the capital of the Company (the \"\nRetail Offer Shares\n\") at an issue price of 9 pence per Retail Offer Share (the \"\nIssue Price\n\") to raise up to \u00a3100,000.\nIn addition to the Retail Offer, the Company is also conducting a placing of new ordinary shares (the \"\nPlacing Shares\n\" and together with the Retail Offer Shares, the \"\nNew Ordinary Shares\n\") at the Issue Price (the \"\nPlacing\n\" and together with the Retail Offer, the \"\nIssue\n\"). A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the Retail Offer is not part of the Placing.\nThe Retail Offer is conditional on the New Ordinary Shares to be issued pursuant to the Retail Offer being admitted to trading on the AIM market operated by the London Stock Exchange (\"\nAdmission\n\"). Admission of the New Ordinary Shares pursuant to the Retail Offer is expected to take place at\n16 December 2025\n. Completion of the Retail Offer is conditional, inter alia, upon the completion of the Placing.\nThe net proceeds from the Retail Offer and the Placing will allow the Company to progress its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma.\nInvestor Meet Company Presentation\nAndrew Webb, CEO of CRISM Therapeutics, will host a live presentation and Q&A in connection with the Retail Offer via Investor Meet Company on Thursday 11 December 2025 at 12.00pm GMT.\nInvestors can sign up, free of charge, to\u00a0Investor Meet Company\u00a0and add to meet CRISM Therapeutics via:\nhttps://www.investormeetcompany.com/crism-therapeutics-corporation/register\nInvestors who already follow the Company on the Investor Meet Company platform will automatically be invited.\nExpected Timetable in relation to the Retail Offer\nRetail Offer opens\n10/12/2025, 07:30\nLatest time and date for commitments under the Retail Offer\n15/12/2025, 12:00\nResults of the Retail Offer announced\n15/12/2025\nAdmission and dealings in New Ordinary Shares issuedpursuant to the Retail Offer commence\n16/12/2025\nAny changes to the expected timetable set out above will be notified by the Company through a Regulatory Information Service. References to times are to London times unless otherwise stated.\nDealing Codes\nTicker\nCRTX\nISIN for the Ordinary Shares\nVGG042401262\nSEDOL for the Ordinary Shares\nBS60QF6\nRetail Offer\nThe Company values its retail shareholder base. Given the support of retail shareholders, the Company believes that it is appropriate to provide its retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website:\nhttps://www.bookbuild.live/deals/2Q39JQ/authorised-intermediaries\nSP Angel Corporate Finance LLP will be acting as retail offer coordinator in relation to this Retail Offer (the \"\nRetail Offer Coordinator\n\").\nExisting retail shareholders can contact their broker or wealth manager (\"\nIntermediary\n\") to participate in the Retail Offer. In order to participate in the Retail Offer, each intermediary must be on-boarded onto the BookBuild platform and agree to the final terms and the retail offer terms and conditions, which regulate, inter alia, the conduct of the Retail Offer on market standard terms and provide for the payment of commission to any intermediary that elects to receive a commission and/or fee (to the extent permitted by the FCA Handbook Rules) from the Retail Offer Coordinator (on behalf of the Company).\nAny expenses incurred by any intermediary are for its own account. Investors should con\ufb01rm separately with any intermediary whether there are any commissions, fees or expenses that will be applied by such intermediary in connection with any application made through that intermediary pursuant to the Retail Offer.\nThe Retail Offer will be open to eligible investors in the United Kingdom at\n7:30am on 10/12/2025\n. The Retail Offer is expected to close at\n12:00pm on 15/12/2025\n. Investors should note that financial intermediaries may have earlier closing times. The Retail Offer may close early if it is oversubscribed.\nIf any intermediary has any questions about how to participate in the Retail Offer on behalf of existing retail shareholders, please contact BookBuild at email: support@bookbuild.live.\nThe Retail Offer the subject of this announcement is and will, at all times, only be made to, directed at and may only be acted upon by those persons who are, shareholders in the Company. To be eligible to participate in the Retail Offer, applicants must meet the following criteria before they can submit an order for Retail Offer Shares: (i) be a customer of one of the participating intermediaries listed on the above website; (ii) be resident in the United Kingdom and (iii) be a shareholder in the Company (which may include individuals aged 18 years or over, companies and other bodies corporate, partnerships, trusts, associations and other unincorporated organisations and includes persons who hold their shares in the Company directly or indirectly through a participating intermediary).\nThe Company reserves the right to scale back any order at its discretion. The Company reserves the right to reject any application for subscription under the Retail Offer without giving any reason for such rejection.\nIt is vital to note that once an application for Retail Offer Shares has been made and accepted via an intermediary, it cannot be withdrawn.\nThe New Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with existing Ordinary Shares including the right to receive all dividends and other distributions declared, made or paid after their date of issue.\nThe Retail Offer is an offer to subscribe for transferable securities, the terms of which ensure that the Company is exempt from the requirement to issue a prospectus under Regulation (EU) 2017/1129 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. It is a term of the Retail Offer that the aggregate total consideration payable for the Retail Offer Shares will not exceed\n\u00a3100,000\n(or the equivalent in Euros). The exemption from the requirement to publish a prospectus, set out in section 86(1)(e) of the Financial Services and Markets Act 2000 (as amended), will apply to the Retail Offer.\nThe Retail Offer is not being made into any jurisdiction other than the United Kingdom or to US Persons (as defined in Regulation S of the US Securities Act 1933, as amended).\nNo offering document, prospectus or admission document has been or will be prepared or submitted to be approved by the Financial Conduct Authority (or any other authority) in relation to the Retail Offer, and investors' commitments will be made solely on the basis of the information contained in this announcement and information that has been published by or on behalf of the Company prior to the date of this announcement by notification to a Regulatory Information Service in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and the Market Abuse Regulation (EU Regulation No. 596/2014) (\"MAR\") as it forms part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018 (as amended).\nThere is a minimum subscription of\n\u00a3100.00\nper investor under the terms of the Retail Offer which is open to investors in the United Kingdom subscribing via the intermediaries which will be listed, subject to certain access restrictions, on the following website:\nhttps://www.bookbuild.live/deals/2Q39JQ/authorised-intermediaries\nThere is no maximum application amount to apply in the Retail Offer. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges.\nInvestors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.\nIt should be noted that a subscription for Retail Offer Shares and investment in the Company carries a number of risks. Investors should take independent advice from a person experienced in advising on investment in securities such as the Retail Offer Shares if they are in any doubt.\nFor further information, please contact:\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, Ex\nec Chair.\nChris McConville, CSO\nRichard Morrison (Corp Fin)\nAdam Cowl (Corp Fin)\nVadim Alexandre (Sales)\nRob Rees (Sales)\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nFurther information on the Company can be found on its website at: https://www.crismtherapeutics.com/\nThe Company's LEI is\n213800XFW6MKVCHHPW88\n.\nThis announcement should be read in its entirety. In particular, the information in the \"Important Notices\" section of the announcement should be read and understood.\nImportant Notices\nThe Retail Offer is only open to investors in the United Kingdom who fall within Article 43 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes an existing member of the Company).\nThis announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the \"United States\" or \"US\")), Australia, Canada, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.\nThe Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the \"US Securities Act\") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States or to or for the account or bene\ufb01t of any US person (within the meaning of Regulation S under the US Securities Act) (a \"US Person\"). No public o\ufb00ering of the Retail Offer Shares is being made in the United States. The Retail Offer Shares are being o\ufb00ered and sold outside the United States in \"o\ufb00shore transactions\", as de\ufb01ned in, and in compliance with, Regulation S under the US Securities Act. In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.\nThis announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Retail Offer Shares in the United States, Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.\nThe distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.\nSP Angel Corporate Finance LLP (\"Corporate Finance Bank\") is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the Retail Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the Retail Offer, Admission and the other arrangements referred to in this announcement.\nThe value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.\nCertain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as \"aim\", \"anticipate\", \"believe\", \"intend\", \"estimate\", \"expect\" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.\nThese forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. Each of the Company and SP Angel Corporate Finance LLP expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Conduct Authority, the London Stock Exchange or applicable law.\nThe information in this announcement is for background purposes only and does not purport to be full or complete. None of SP Angel Corporate Finance LLP or any of its affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. Each of the SP Angel Corporate Finance LLP and its affiliates, accordingly disclaims all and any liability whether arising in tort, contract or otherwise which it might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.\nAny indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.\nNeither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.\nUK Product Governance Requirements\nSolely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the \"UK MiFIR Product Governance Requirements\"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any \"manufacturer\" (for the purposes of the UK MiFIR Product Governance Requirements) may otherwise have with respect thereto, the Retail Offer Shares have been subject to a product approval process, which has determined that the Retail Offer Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in paragraphs 3.5 and 3.6 of COBS; and (ii) eligible for distribution through all permitted distribution channels (the \"Target Market Assessment\"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Retail Offer Shares may decline and investors could lose all or part of their investment; the Retail Offer Shares offer no guaranteed income and no capital protection; and an investment in the Retail Offer Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Retail Offer.\nFor the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A respectively of COBS; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Retail Offer Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Retail Offer Shares and determining appropriate distribution channels.\nEU Product Governance Requirements\nSolely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (\"MiFID II\"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the \"MiFID II Product Governance Requirements\"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any \"manufacturer\" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Retail Offer Shares have been subject to a product approval process, which has determined that the Retail Offer Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the \"EU Target Market Assessment\"). Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Retail Offer Shares may decline and investors could lose all or part of their investment; the Retail Offer Shares offer no guaranteed income and no capital protection; and an investment in the Retail Offer Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Retail Offer.\nFor the avoidance of doubt, the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase or take any other action whatsoever with respect to the Retail Offer Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Retail Offer Shares and determining appropriate distribution channels.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCTLBBTMTAMTAA",
          "rns_number": "RNS Number : 9161K"
        },
        {
          "title": "Placing of \u00a31,000,000",
          "announcement_date": "10th Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "10 Dec 2025 07:00\nRNS Number : 9159K\nCRISM Therapeutics Corporation\n10 December 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n10 December 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nPlacing of \u00a31,000,000\nCRISM Therapeutics Corporation (AIM: CRTX),\na UK clinical stage company\nfocused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that it has successfully raised \u00a31,000,000 by way of an oversubscribed placing of 11,111,112 new ordinary shares of no par value each in the Company (\"\nPlacing Shares\n\") at a price of 9 pence per share (the \"\nIssue Price\n\") (the \"\nPlacing\n\"). The Placing Shares each have an attaching grant of warrants (\"Warrants\") on a one for two basis, exercisable at a price of 15 pence per ordinary share, and expiring on 31 December 2026.\nThe Placing Shares will represent approximately 21.76%\nof the Company's enlarged issued share capital following the Placing.\u00a0The Issue Price represents a discount of approximately 18.18\nper cent. to the closing mid-market price of 9\npence per ordinary share on 09 December 2025.\nThe Placing was undertaken by the Company's broker, SP Angel Corporate Finance LLP.\nThe Company values its retail shareholder base and believes that it is appropriate to provide existing retail and other shareholders the opportunity to purchase shares at the Issue Price. The Company intends to carry out a separate retail offer to raise further gross proceeds of up to \u00a3100,000 via the BookBuild Platform (the \"\nRetail Offer\n\"). A further announcement will be made shortly regarding the Retail Offer and its terms.\nHighlights of the Placing:\n- Completion of Placing raising \u00a31,000,000 through the issue of 11,111,112 Placing Shares at 9 pence per share\n- The net proceeds of the Placing will allow the Company to progress its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma. Specifically, funds will be used for:\no\nSterilisation and lot release of GMP of ChemoSeed\no\nQP, quality and audit fees\no\nClinical trial costs - ongoing fees, dose escalation seeking efficacy signal in recurrent patients\no\nOngoing operational costs\n- A separate retail offer to existing holders will be launched shortly\nCRISM Executive Chairman, Andrew Webb, said:\n\"We are delighted by the support of new and existing shareholders in this oversubscribed Placing, which will enable the Company to progress into patient dosing in its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma and to reach the important inflexion point of establishing an efficacy signal in patients with recurrent disease, subject to patient recruitment. We look forward to first patient dosing in Q1 2026.\"\nRationale for the Placing\nThe Placing will enable the Company to progress its Phase 2 open-label clinical trial, with first patients expected to be dosed in Q1 2026. The open label trial design allows for ongoing safety and efficacy monitoring.\nDirectors' Participation and Related Party Transactions\nThe Directors of the Company have participated in the Placing, details of which are in the table below:\nDirector\nNumber of Placing Shares subscribed for\nNumber of ordinary shares held immediately following Admission\n% interest in ordinary shares immediately following Admission\nAndrew Webb\n916,667\n7,297,190\n14.29%\nChris McConville\n83,333\n4,992,033\n9.77%\nGerry Beaney\n111,111\n268,793\n0.53%\nThe participation of Andrew Webb, Chris McConville and Gerry Beaney in the Placing (including the issue of the Warrants referred to below) constitutes related party transactions for the purposes of Rule 13 of the AIM Rules for Companies. As all of the Directors are participating in the Placing, there is no independent director for the purpose of the related party transaction as stipulated by the AIM Rules for Companies.\nThe Company's nominated adviser, SP Angel Corporate Finance LLP, considers that the Directors' participation in, and the terms of, the Placing is fair and reasonable in so far as CRISM's shareholders are concerned.\nWarrants\nThe Company will issue participants of the Placing with one Warrant for every two Placing Shares. As a result, 5,555,551 Warrants will be issued to the placees. Each Warrant will provide the holder with the right to one new ordinary share on its exercise. The Warrants will be exercisable at a price of 15 pence until 31 December 2026.\nAndrew Webb, Chris McConville and Gerry Beaney, have been issued with 458,333, 41,666 and 55,555 Warrants respectively, as a result of their participation in the Placing.\nAdmission and Total Voting Rights\nApplication has been made to the London Stock Exchange for admission of the Placing Shares (\"\nAdmission\n\"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 15 December 2025, or such later date as may be agreed between the Company and SP Angel. The Placing Shares will rank\npari passu\nwith the Company's existing ordinary shares.\nFollowing the issue of the Placing Shares, the total issued share capital of the Company will consist of 51,072,934 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 51,072,934 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, Exec. Chair.\nChris McConville, CSO\nRichard Morrison (Corp Fin)\nAdam Cowl (Corp Fin)\nVadim Alexandre (Sales)\nRob Rees (Sales)\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\u00a0registration-grade Phase 2 clinical trial\u00a0of\u00a0irinotecan-ChemoSeed\u2122\u00a0in patients with\u00a0surgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nDealings by Persons Discharging Managerial Responsibilities\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\n1) Andrew Webb\n2) Gerald Beaney\n3) Chris McConville\n2\nReason for the notification\na)\nPosition/status\n1) Executive Chairman\n2) Non-Executive Director\n3) Chief Scientific Officer\nb)\nInitial notification /Amendment\nInitial Notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nCRISM Therapeutics Corporation\nb)\nLEI\n213800XFW6MKVCHHPW88\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nOrdinary shares with no par value\nIdentification code\nISIN: VGG042401262\nb)\nNature of the transaction\nPurchase of shares\nc)\nPrice(s) and volume(s)\nDirector/PDMR\nPrice (\u00a3)\nVolume\nAndrew Webb\n0.09\n916,667\nGerald Beaney\n0.09\n111,111\nChris McConville\n0.09\n83,333\nd)\nAggregated information\n- Aggregated volume\nN/A\n- Price\nN/A\ne)\nDate of the transaction\n10 December 2025\nf)\nPlace of the transaction\nOutside a trading venue\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\n1) Andrew Webb\n2) Gerald Beaney\n3) Chris McConville\n2\nReason for the notification\na)\nPosition/status\n1) Executive Chairman\n2) Non-Executive Director\n3) Chief Scientific Officer\nb)\nInitial notification /Amendment\nInitial Notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nCRISM Therapeutics Corporation\nb)\nLEI\n213800XFW6MKVCHHPW88\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nOrdinary shares with no par value\nIdentification code\nISIN: VGG042401262\nb)\nNature of the transaction\nIssue of warrants\nc)\nPrice(s) and volume(s)\nDirector/PDMR\nExercise Price\nVolume\nAndrew Webb\n\u00a30.15\n458,333\nGerald Beaney\n\u00a30.15\n55,555\nChris McConville\n\u00a30.15\n41,666\nd)\nAggregated information\n- Aggregated volume\nN/A\n- Price\nN/A\ne)\nDate of the transaction\n10 December 2025\nf)\nPlace of the transaction\nOutside a trading venue\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEAFANESESFAA",
          "rns_number": "RNS Number : 9159K"
        }
      ],
      "themes": [
        "drilling"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 1008,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-20th Jan 2026-japanese",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256726Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Japanese Patent Grant",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/japanese-patent-grant-lgdlwx827y6wlp9.html",
          "rns_number": "RNS Number : 5029P",
          "full_content": "20 Jan 2026 07:00\nRNS Number : 5029P\nCRISM Therapeutics Corporation\n20 January 2026\n20 January 2026\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nJapanese Patent Grant for ChemoSeed\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent\n(\n7800909\n) b\ny the\u00a0Japanese Patent Office.\nThe patent relates to the Company's lead product, ChemoSeed\u00ae, for chemotherapeutic drug implants and more, particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan. ChemoSeed was invented by Professor\u00a0Chris McConville, CRISM's Chief Scientific Officer.\nThe patent covers the manufacturing processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours such as glioblastoma.\nCommenting on the patent grant, CRISM Therapeutics' CEO, Andrew Webb, said:\n\"We are pleased to have started 2026 by strengthening our IP position through the grant of this patent in Japan, which we view as a key market. This latest patent grant broadens our appeal to potential commercial partners. We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\nregistration-grade Phase 2 clinical trial\nof\nirinotecan-ChemoSeed\u2122\nin patients with\nsurgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEAXFNFSXKEFA",
          "content_length": 3470
        },
        "ingested_at": "2026-01-21T02:14:29.256767Z"
      },
      {
        "event_id": "RNS-9th Jan 2026-resultso",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256794Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results of Shareholder Analysis",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/results-of-shareholder-analysis-7nm9ykmabngacd7.html",
          "rns_number": "RNS Number : 2488O",
          "full_content": "9 Jan 2026 07:00\nRNS Number : 2488O\nCRISM Therapeutics Corporation\n09 January 2026\n09 January 2026\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nResults of Shareholder Analysis\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 31 December 2025, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company (\"Ordinary Shares\").\nShareholder\nNo. of Ordinary Shares\n% interest in the ordinary share capital of the Company\nAndrew Webb\n7,297,190\n14.10%\nChristopher McConville\n4,992,033\n9.65%\nBrian Murray\n4,908,700\n9.49%\nDavid Lawton\n4,802,416\n9.28%\nZeus Dynamic Opportunities Fund\n1,900,000\n3.67%\nFollowing the issue of the placing and retail offer shares (as announced on 10 and 15 December 2025 respectively) neither Linista Group Inc. or Spreadex hold a disclosable shareholding in the Company.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\nregistration-grade Phase 2 clinical trial\nof\nirinotecan-ChemoSeed\u2122\nin patients with\nsurgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBPMBTMTBMTPF",
          "content_length": 3204
        },
        "ingested_at": "2026-01-21T02:14:29.256821Z"
      },
      {
        "event_id": "RNS-15th Dec 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256838Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of Retail Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/result-of-retail-offer-z3w7bck37t7jvas.html",
          "rns_number": "RNS Number : 6299L",
          "full_content": "15 Dec 2025 14:29\nRNS Number : 6299L\nCRISM Therapeutics Corporation\n15 December 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS INCORPORATED INTO UK\u00a0LAW BY THE\u00a0EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"UK MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\u00a0IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n15 December 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nResult of Retail Offer\nFurther to the announcement by the Company in respect of the Retail Offer dated 10 December 2025, CRISM Therapeutics Corporation announces that, following the closing of the Retail Offer on the BookBuild platform today at 12.00 p.m., the Company has raised gross proceeds of \u00a359,610 (the \"\nRetail Offer\n\") by way of a subscription of 662,332 Retail Offer Shares at the Issue Price of 9 pence per share.\nThe proceeds of the Retail Offer together with the Placing announced on 10 December 2025 (together the \"\nProceeds\n\"), will enable the Company to progress its MHRA approved, Phase 2 open-label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma, with first patients expected to be dosed in Q1 2026.\nAdmission and Total Voting Rights\nApplication has been made to the London Stock Exchange for admission of the Retail Offer Shares (\"\nAdmission\n\"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 16 December 2025, or such later date as may be agreed between the Company and SP Angel. The Retail Offer Shares will rank\npari passu\nwith the Company's existing ordinary shares.\nFollowing the issue of the Retail Offer Shares, the total issued share capital of the Company will consist of 51,735,266 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 51,735,266 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\nOther than where defined, capitalised terms used in this Announcement have the meanings given to them in the announcements of 10 December 2025.\n-Ends-\n\u200b\nEnquiries:\n\u200b\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, Ex\nec. Chair\nChris McConville, CSO\nRichard Morrison (Corp Fin)\nAdam Cowl (Corp Fin)\nVadim Alexandre (Sales)\nRob Rees (Sales)\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\u00a0registration-grade Phase 2 clinical trial\u00a0of\u00a0irinotecan-ChemoSeed\u2122\u00a0in patients with\u00a0surgica",
          "content_length": 5932
        },
        "ingested_at": "2026-01-21T02:14:29.256856Z"
      },
      {
        "event_id": "RNS-10th Dec 2025-retailof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256869Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Retail Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/retail-offer-tok244ibb0tp931.html",
          "rns_number": "RNS Number : 9161K",
          "full_content": "10 Dec 2025 07:25\nRNS Number : 9161K\nCRISM Therapeutics Corporation\n10 December 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CRISM THERAPEUTICS CORPORATION). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION.\n10 December 2025\nCRISM THERAPEUTICS CORPORATION\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nRetail Offer to raise up to \u00a3100,000\nCRISM Therapeutics Corporation (the \"\nCompany\n\") is pleased to announce a retail offer via BookBuild (the \"\nRetail Offer\n\") of new ordinary shares (\"\nOrdinary Shares\n\") of nil par value each in the capital of the Company (the \"\nRetail Offer Shares\n\") at an issue price of 9 pence per Retail Offer Share (the \"\nIssue Price\n\") to raise up to \u00a3100,000.\nIn addition to the Retail Offer, the Company is also conducting a placing of new ordinary shares (the \"\nPlacing Shares\n\" and together with the Retail Offer Shares, the \"\nNew Ordinary Shares\n\") at the Issue Price (the \"\nPlacing\n\" and together with the Retail Offer, the \"\nIssue\n\"). A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the Retail Offer is not part of the Placing.\nThe Retail Offer is conditional on the New Ordinary Shares to be issued pursuant to the Retail Offer being admitted to trading on the AIM market operated by the London Stock Exchange (\"\nAdmission\n\"). Admission of the New Ordinary Shares pursuant to the Retail Offer is expected to take place at\n16 December 2025\n. Completion of the Retail Offer is conditional, inter alia, upon the completion of the Placing.\nThe net proceeds from the Retail Offer and the Placing will allow the Company to progress its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma.\nInvestor Meet Company Presentation\nAndrew Webb, CEO of CRISM Therapeutics, will host a live presentation and Q&A in connection with the Retail Offer via Investor Meet Company on Thursday 11 December 2025 at 12.00pm GMT.\nInvestors can sign up, free of charge, to\u00a0Investor Meet Company\u00a0and add to meet CRISM Therapeutics via:\nhttps://www.investormeetcompany.com/crism-therapeutics-corporation/register\nInvestors who already follow the Company on the Investor Meet Company platform will automatically be invited.\nExpected Timetable in relation to the Retail Offer\nRetail Offer opens\n10/12/2025, 07:30\nLatest time and date for commitments under the Retail Offer\n15/12/2025, 12:00\nResults of the Retail Offer announced\n15/12/2025\nAdmission and dealings in New Ordinary Shares issuedpursuant to the Retail Offer commence\n16/12/2025\nAny changes to the expected timetable set out above will be notified by the Company through a Regulatory Information Service. References to times are to London times unless otherwise stated.\nDealing Codes\nTicker\nCRTX\nISIN for the Ordinary Shares\nVGG042401262\nSEDOL for the Ordinary Shares\nBS60QF6\nRetail Offer\nThe Company values its retail shareholder base. Given the support of retail shareholders, the Company believes that it is appropriate to provide its retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website:\nhttps://www.bookbuild.live/deals/2Q39JQ/authorised-intermediaries\nSP Angel Corporate Finance LLP will be acting as retail offer coordinator in relation to this Retail Offer (the \"\nRetail Offer Coordinator\n\").\nExisting retail shareholders can contact their broker or wealth manager (\"\nIntermediary\n\") to participate in the Retail Offer. In order to participate in the Retail Offer, each intermediary must be on-boarded onto the BookBuild platform and agree to the final terms and the retail offer terms and conditions, which regulate, inter alia, the",
          "content_length": 23403
        },
        "ingested_at": "2026-01-21T02:14:29.256886Z"
      },
      {
        "event_id": "RNS-10th Dec 2025-placingo",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256901Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Placing of \u00a31,000,000",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/placing-of-1631000000-8oidrarcgu7ce8o.html",
          "rns_number": "RNS Number : 9159K",
          "full_content": "10 Dec 2025 07:00\nRNS Number : 9159K\nCRISM Therapeutics Corporation\n10 December 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n10 December 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nPlacing of \u00a31,000,000\nCRISM Therapeutics Corporation (AIM: CRTX),\na UK clinical stage company\nfocused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that it has successfully raised \u00a31,000,000 by way of an oversubscribed placing of 11,111,112 new ordinary shares of no par value each in the Company (\"\nPlacing Shares\n\") at a price of 9 pence per share (the \"\nIssue Price\n\") (the \"\nPlacing\n\"). The Placing Shares each have an attaching grant of warrants (\"Warrants\") on a one for two basis, exercisable at a price of 15 pence per ordinary share, and expiring on 31 December 2026.\nThe Placing Shares will represent approximately 21.76%\nof the Company's enlarged issued share capital following the Placing.\u00a0The Issue Price represents a discount of approximately 18.18\nper cent. to the closing mid-market price of 9\npence per ordinary share on 09 December 2025.\nThe Placing was undertaken by the Company's broker, SP Angel Corporate Finance LLP.\nThe Company values its retail shareholder base and believes that it is appropriate to provide existing retail and other shareholders the opportunity to purchase shares at the Issue Price. The Company intends to carry out a separate retail offer to raise further gross proceeds of up to \u00a3100,000 via the BookBuild Platform (the \"\nRetail Offer\n\"). A further announcement will be made shortly regarding the Retail Offer and its terms.\nHighlights of the Placing:\n- Completion of Placing raising \u00a31,000,000 through the issue of 11,111,112 Placing Shares at 9 pence per share\n- The net proceeds of the Placing will allow the Company to progress its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma. Specifically, funds will be used for:\no\nSterilisation and lot release of GMP of ChemoSeed\no\nQP, quality and audit fees\no\nClinical trial costs - ongoing fees, dose escalation seeking efficacy signal in recurrent patients\no\nOngoing operational costs\n- A separate retail offer to existing holders will be launched shortly\nCRISM Executive Chairman, Andrew Webb, said:\n\"We are delighted by the support of new and existing shareholders in this oversubscribed Placing, which will enable the Company to progress into patient dosing in its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma and to reach the important inflexion point of establishing an efficacy signal in patients with recurrent disease, subject to patient recruitment. We look forward to first patient dosing in Q1 2026.\"\nRationale for the Placing\nThe Placing will enable the Company to progress its Phase 2 open-label clinical trial, with first patients expected to be dosed in Q1 2026. The open label trial design allows for ongoing safety and efficacy monitoring.\nDirectors' Participation and Related Party Transactions\nThe Directors of the Company have participated in the Placing, details of which are in the table below:\nDirector\nNumber of Placing Shares subscribed for\nNumber of ordinary shares held immediately following Admission\n% interest in ordinary shares immediately following Admission\nAndrew Webb\n916,667\n7,297,190\n14.29%\nChris McConville\n83,333\n4,992,033\n9.77%\nGerry Beaney\n111,111\n268,793\n0.53%\nThe participation of Andrew Webb, Chris McConville and Gerry Beaney in the Placing (including the issue of the Warrants referred to below) constitutes related party transactions for the purposes of Rule 13 of the AIM Rules for Companies. As all of the Directors are participating in the Placing, there is no independent director for the purpose of the related party transaction as stipulated by the AIM Rules for Companies.\nThe Company's nominated adviser, SP Angel Corporate Finance LLP, considers that the Directors' participation in, and the terms of, the Placing is fair and reasonable in so far as CRISM's shareholders are concerned.\nWarrants\nThe Company will issue participants of the Placing with one Warrant for every two Placing Shares. As a result, 5,555,551 Warrants will be issued to the placees. Each Warrant will provide the holder with the right to one new ordinary share on its exercise. The Warrants will be exercisable at a price of 15 pence until 31 December 2026.\nAndrew Webb, Chris McConville and Gerry Beaney, have been issued with 458,333, 41,666 and 55,555 Warrants respectively, as a result of their participation in the Placing.\nAdmission and Total Voting Rights\nApplication has been made to the London Stock Exch",
          "content_length": 10532
        },
        "ingested_at": "2026-01-21T02:14:29.256918Z"
      },
      {
        "event_id": "RNS-27th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256932Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/holdings-in-company-kwrsef4hhyl4t9d.html",
          "rns_number": "RNS Number : 1800J",
          "full_content": "27 Nov 2025 07:00\nRNS Number : 1800J\nCRISM Therapeutics Corporation\n27 November 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nVGG042401262\nIssuer Name\nCRISM THERAPEUTICS CORPORATION\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nSpreadex LTD\nCity of registered office (if applicable)\nSt. Albans\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n19-Nov-2025\n6. Date on which Issuer notified\n26-Nov-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.940300\n0.000900\n2.941200\n1175374\nPosition of previous notification (if applicable)\n3.128000\n0.000900\n3.128900\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nVGG042401262\n1175000\n2.940300\nSub Total 8.A\n1175000\n2.940300%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nCFD/Spread Bet\n374\n0.000900\nSub Total 8.B1\n374\n0.000900%\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nLawson Roberts01727 895145Spreadex is an FCA regulated provider of spread betting and CFD trading. Founded in 1999, Spreadex gives both retail and professional traders the opportunity to trade over 10,000 global markets, including UK small caps. For more information see\nwww.spreadex.com/financials\n.\n12. Date of Completion\n26-Nov-2025\n13. Place Of Completion\nUnited Kingdom\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLEAFFKAFNSFAA",
          "content_length": 4181
        },
        "ingested_at": "2026-01-21T02:14:29.256944Z"
      },
      {
        "event_id": "RNS-30th Oct 2025-usorphan",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256957Z",
        "source": "LSE_RNS",
        "data": {
          "title": "US Orphan Drug Designation Application",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/us-orphan-drug-designation-application-i66ad8v6j9g09gh.html",
          "rns_number": "RNS Number : 4097F",
          "full_content": "30 Oct 2025 07:00\nRNS Number : 4097F\nCRISM Therapeutics Corporation\n30 October 2025\n30 October 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nSubmission of Orphan Drug Designation Application to the FDA for Irinotecan-ChemoSeed\u2122 in Glioblastoma\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that it has submitted an application to the US Food and Drug Administration (\"FDA\") seeking Orphan Drug Designation (\"ODD\") for its lead programme, irinotecan-ChemoSeed\u2122, for the treatment of glioblastoma.\nGlioblastoma is a rare and aggressive form of brain cancer with extremely limited treatment options and poor survival outcomes. The submission of this application marks another step in CRISM's strategy to advance irinotecan-ChemoSeed as a localised therapy for patients undergoing surgical resection of glioblastoma.\nThe FDA's Orphan Drug Designation programme is designed to encourage the development of medicines for rare diseases affecting fewer than 200,000 patients in the United States. If granted, ODD status would provide CRISM with potential benefits including: seven years of US market exclusivity following approval; tax credits for clinical research costs; waiver of FDA application fees; and enhanced regulatory support and guidance throughout development.\nCRISM has already been awarded an Innovation Passport for irinotecan-ChemoSeed under the UK's Innovative Licensing and Access Pathway (\"ILAP\"), recognising the therapy's potential to address the critical unmet need in glioblastoma. ILAP provides access to enhanced regulatory collaboration and accelerated assessment pathways in the UK. In addition, CRISM is exploring participation in Project Orbis, the international regulatory collaboration led by the FDA to speed up access to promising cancer treatments across major global markets.\nThe submission of the ODD application follows recent regulatory and ethical approvals in the UK for CRISM's registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in surgically resectable glioblastoma, which is expected to begin dosing of patients in Q1 2026.\nThe Company's ODD application forms a key part of its global regulatory strategy designed to unlock accelerated development and early market access opportunities in both the US and UK.\nProfessor Chris McConville\n,\nChief Scientific Officer of CRISM Therapeutics, commented:\n\"Submitting our Orphan Drug Designation application to the FDA represents another important step in CRISM's strategy. The US is the largest pharmaceutical market globally, and we believe this application will add further appeal to potential partners as we start to produce data from our Phase 2 clinical trial next year. Together with our Innovation Passport under ILAP and our potential alignment with Project Orbis, this application reflects a global regulatory strategy to bring ChemoSeed to patients faster, starting with glioblastoma.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its\nregistration-grade Phase 2 clinical trial\nof\nirinotecan-ChemoSeed\u2122\nin patients with\nsurgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commer",
          "content_length": 5172
        },
        "ingested_at": "2026-01-21T02:14:29.256973Z"
      },
      {
        "event_id": "RNS-14th Oct 2025-positive",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.256986Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Positive Preclinical Data in Prostate Cancer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/positive-preclinical-data-in-prostate-cancer-1s1x391ycumkffh.html",
          "rns_number": "RNS Number : 1888D",
          "full_content": "14 Oct 2025 07:00\nRNS Number : 1888D\nCRISM Therapeutics Corporation\n14 October 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n14 October 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nPositive Preclinical Data in Prostate Cancer and Prestigious Collaborative Doctoral Award\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, today is pleased to announce significant preclinical findings and a new research collaboration that mark key milestones in the development of its innovative ChemoSeed\u00ae platform in prostate cancer.\nProstate cancer, the most prevalent cancer in men, is the second programme in CRISM's pipeline of product opportunities using the implantable ChemoSeed drug delivery platform. The Company's most advanced programme, irinotecan-ChemoSeed in glioblastoma, remains on track for the first patients to be dosed in an open label Phase 2 clinical trial in early 2026.\nIn vitro studies conducted by CRISM Therapeutics have demonstrated that the sustained administration of docetaxel to prostate cancer cell lines is significantly more effective than the intermittent dosing schedules currently used in the standard of care.\nSustained administration killed 72% of the prostate cancer cells compared with 65% with intermittent dosing. Furthermore, the concentration of docetaxel needed to inhibit 50% (IC50) of prostate cancer cells from growing was 3.5nM for sustained administration compared with 9.8nM for intermittent dosing. The lower the IC50, the more potent the treatment. Finally, at lower doses sustained administration of docetaxel resulted in continued reduction of prostate cancer cells for 12 days, whereas with intermittent dosing there was less reduction in the prostate cancer cells and the cells started to regrow by day 9.\nThese findings strongly support the hypothesis that sustained, localised delivery of chemotherapy, enabled by CRISM's proprietary ChemoSeed drug delivery platform, could substantially enhance the efficacy of docetaxel, a generic chemotherapy drug, in the treatment of prostate cancer. Furthermore, with ChemoSeed this increase in efficacy could be achieved with lower amounts of docetaxel being given to the patient reducing the unwanted side effects typically seen with this drug.\nIn addition, CRISM has successfully formulated docetaxel within the ChemoSeed platform, achieving sustained drug release over a period of at least 28 days. This major technical milestone confirms the feasibility of using ChemoSeed for prolonged, controlled delivery of docetaxel directly into prostate tumours, addressing a major limitation of current systemic chemotherapy approaches.\nFurther strengthening its R&D capabilities, CRISM Therapeutics is proud to announce it has been awarded a prestigious Department for the Economy (\"DfE\") Collaborative Doctoral Partnership (\"CDP\") studentship in collaboration with Ulster University. This partnership will support the ongoing development of docetaxel-ChemoSeed and explore its application in the personalised treatment of prostate cancer, including potential patient-specific dosing strategies and tumour-targeting delivery models. The DfE will cover the university tuition fees and provide a maintenance stipend to support the doctoral candidate's living expenses.\nAndrew Webb\n,\nChief Executive Officer of CRISM Therapeutics, commented:\n\"These developments represent a major step forward in our mission to improve outcomes for prostate cancer patients by leveraging our ChemoSeed drug delivery platform. The data clearly suggest that delivering chemotherapy locally and continuously, rather than intermittently and systemically, could provide a much-needed improvement in therapeutic efficacy. Our partnership with Ulster University will further accelerate our progress and help bring this innovative treatment to patients faster. We welcome discussions with potential partners and collaborators as we build momentum towards first-in-human clinical trials.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead prod",
          "content_length": 6504
        },
        "ingested_at": "2026-01-21T02:14:29.257002Z"
      },
      {
        "event_id": "RNS-15th Sep 2025-halfyear",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257015Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half Year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/half-year-report-wm27bjbn2ir0zhe.html",
          "rns_number": "RNS Number : 3036Z",
          "full_content": "15 Sep 2025 07:00\nRNS Number : 3036Z\nCRISM Therapeutics Corporation\n15 September 2025\n15 September 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\", the \"Company\" or the \"Group\")\nHalf Year Report for the six month period ended 30 June 2025\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs,\ntoday announces its unaudited half-year results for the six months ended 30 June 2025 (the \"Period\").\nThe Company has made significant progress during the Period in advancing its proprietary ChemoSeed\u2122 drug delivery technology towards a Phase 2 clinical trial. ChemoSeed is an implantable, biodegradable technology designed for the localised and sustained delivery of chemotherapy directly into cancer tissue thereby improving clinical performance. ChemoSeed has an attractive risk profile owing to its use of pre-approved chemotherapy drugs such as irinotecan.\nCRISM's initial therapeutic focus is in brain tumour, owing to the very significant unmet need and attractive market size of an estimated \u00a31.7 billion. The Board believes ChemoSeed is a platform technology for other solid tumours, such as prostate, pancreatic and bladder, and the Company has already begun early work targeting prostate cancer, a major indication and the most prevalent cancer in men.\nHighlights in the year to date\n\u00b7\nSubmission of a Clinical Trial Application (\"CTA\") for the Company's open label, registration grade Phase 2 clinical trial of irinotecan-ChemoSeed in resectable glioblastoma to the Medicines & Healthcare product Regulatory Agency (\"MHRA\") on 30 June 2025\n\u00b7\nCTA approval received subsequently as announced on 1 September 2025\n\u00b7\nFavourable ethics committee approval also announced on 1 September 2025 from a UK Research Ethics Committee\nto approve the start of the Phase 2 trial, which is expected to commence in early Q1 2026\n\u00b7\nInitiated GMP (\"Good Manufacturing Practice\") manufacture of a clinical batch of irinotecan-ChemoSeed for the Company's Phase 2 clinical trial\n\u00b7\nEstablished Scientific Advisory Board to provide the Company with expert guidance on its clinical trial\n\u00b7\nCompany awarded an Innovate UK Launchpad grant of \u00a396,106 to support the formulation and preclinical development of ChemoSeed in prostate cancer with work commencing in May 2025\n\u00b7\nCompany raised \u00a3874,021 via a placing and retail offer in July 2025 (post period end)\n\u00b7\nNet cash at 12 September 2025 of \u00a3906,864\nCommenting on the Interim Results, CRISM CEO Andrew Webb said:\n\"We are very pleased with the progress made in the first six months of the financial year, and in progress since the half-year end. Our Clinical Trial Application has been approved, ethical approval granted and GMP manufacture of a clinical batch of irinotecan-ChemoSeed is underway. We are now focused on commencing set up of clinical trial centres in the UK so that patient recruitment in our open label, registration grade Phase 2 study in glioblastoma can begin. We continue to expect that the first patients will be dosed in Q1 2026.\n\"We have also made good progress in our early stage programme in prostate cancer, the most prevalent type of cancer in men. The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\n\"Key milestones in the remainder of the year include the selection and initiation of clinical trial sites ahead of patient recruitment early next year.\"\nPresentation via Investor Meet Company\nAndrew Webb, CEO of CRISM Therapeutics, will host a live presentation via Investor Meet Company on Tuesday 16 September 2025 at 12.00pm BST. The presentation will include Garth Cruickshank, Emeritus Professor of Neurosurgery at University of Birmingham and Queen Elizabeth Hospital Birmingham, and a member of CRISM's Scientific Advisory Board.\nThe Investor Meet Company presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST on 15 September 2025 or at any time during the live presentation.\nInvestors can sign up, free of charge, to Investor Meet Company and add to meet CRISM Therapeutics via:\nhttps://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor\nInvestors who already follow the Company on the Investor Meet Company platform will automatically be invited.\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into\nUK\nlaw by the\nEuropean Union\n(Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n-Ends\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO",
          "content_length": 30908
        },
        "ingested_at": "2026-01-21T02:14:29.257030Z"
      },
      {
        "event_id": "RNS-12th Sep 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257044Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Interim Results and IMC Presentation",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/notice-of-interim-results-and-imc-presentation-85i1mrt205fyouu.html",
          "rns_number": "RNS Number : 0414Z",
          "full_content": "12 Sep 2025 07:00\nRNS Number : 0414Z\nCRISM Therapeutics Corporation\n12 September 2025\n12 September 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nNotice of Interim Results and Presentation via Investor Meet Company\nCRISM Therapeutics Corporation (AIM: CRTX),\na UK clinical-stage drug delivery\ncompany focused on the localised and sustained delivery of chemotherapy drugs, will announce its Interim Results for the six months ended 30 June 2025 on Monday 15 September 2025.\nFollowing the results announcement, Andrew Webb, CEO of CRISM Therapeutics, will host a live presentation via Investor Meet Company on Tuesday 16 September 2025 at 12.00pm BST. The presentation will include Garth Cruickshank, Emeritus Professor of Neurosurgery at University of Birmingham and Queen Elizabeth Hospital Birmingham.\nProfessor Cruickshank, a member of CRISM's Scientific Advisory Board, will discuss the Company's upcoming Phase 2 trial of irinotecan-ChemoSeed in glioblastoma, including the early stage work leading up to the start of the Phase 2 trial.\nThe Investor Meet Company presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST on 15 September 2025 or at any time during the live presentation.\nInvestors can sign up, free of charge, to Investor Meet Company and add to meet CRISM Therapeutics via:\nhttps://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor\nInvestors who already follow the Company on the Investor Meet Company platform will automatically be invited.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local and sustained delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This ensures that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORQFLFFEKLEBBE",
          "content_length": 3755
        },
        "ingested_at": "2026-01-21T02:14:29.257056Z"
      },
      {
        "event_id": "RNS-1st Sep 2025-approval",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257069Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Approval for phase 2 clinical trial",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/approval-for-phase-2-clinical-trial-m8xtx2brsj40xv1.html",
          "rns_number": "RNS Number : 3434X",
          "full_content": "1 Sep 2025 07:00\nRNS Number : 3434X\nCRISM Therapeutics Corporation\n01 September 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n1 September 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nRegulatory and Ethical Approval for Registration-Grade Phase 2 Trial of irinotecan-ChemoSeed in Glioblastoma\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, today confirms that it has received both\nregulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA)\nand\nfavourable ethical opinion from a UK Research Ethics Committee (REC)\nto initiate its open label\nregistration-grade Phase 2 clinical trial\nof\nirinotecan-ChemoSeed\u2122\nin patients with\nsurgically resectable glioblastoma\n.\nThis dual approval marks a significant operational milestone and clears the Company to commence the trial across selected UK clinical sites in\nQ1 2026\n, as planned.\nThe approved study, titled\n\"An Open-label Phase 2 Safety and Efficacy Trial of Irinotecan ChemoSeed Administered Directly into the Resection Margin in Patients with Surgically Resectable Glioblastoma\"\n, is designed to assess the safety, tolerability, and efficacy of irinotecan-ChemoSeed, CRISM's proprietary, biodegradable implant technology delivering sustained-release irinotecan directly into the tumour resection margin following surgical removal of the glioblastoma tumour. The trial has been designed in alignment with regulatory expectations for\nfuture marketing authorisation submissions\n.\nKey Highlights:\n\u00b7\nRegulatory (MHRA) and Ethical (REC) approval received\n\u00b7\nTrial confirmed to initiate in Q1 2026 at leading UK neuro-oncology centres\n\u00b7\nOpen-label format\nsupports interim analysis, reporting of\nearly results\nand potential for expedited regulatory approval\n\u00b7\nChemoSeed platform targets local recurrence with sustained, localised chemotherapy\n\u00b7\nRegistration-grade Phase 2 design supports pathway to marketing authorisation and commercialisation.\nProfessor Chris McConville\n,\nChief Scientific Officer of CRISM Therapeutics, commented:\n\"We are delighted to have received both regulatory and ethical approval to begin our Phase 2 study. This is a critical inflection point for CRISM as we prepare to clinically validate our ChemoSeed platform in patients with glioblastoma, an area of immense unmet need. With these approvals secured, we are now in a position to move rapidly into trial activation and first patient dosing. We believe the data from this study could serve as a foundation for future regulatory submissions and commercial advancement.\"\nProfessor Garth Cruickshank, Emeritus Professor of Neurosurgery at the University of Birmingham, and scientific advisor to CRISM, added:\n\"\nThis is a very exciting development in the drive to treat one of the most complex cancers. The technical innovation of putting the tumour killing drug irinotecan into the tumour site at the time of the surgery offers the very best chance to hit the tumour when it is at its smallest. The release process at least covers the time until radiotherapy and or temozolomide are introduced providing a much more powerful sustained antitumour assault. The local deposition of drug already known to attack glioblastoma, avoids systemic side effects, so no additional problems for patients. This approach safely enables high antitumour concentrations without evidence of associated neurotoxicity. Furthermore, the spectrum of patients likely to respond is greater than for any gene targeted or existing immunotherapy. Patients and surgeons will surely welcome such a pragmatic and truly practical step forward in treatment for glioblastoma.\"\nCRISM is working with its CRO, Aixial Group, to activate the first site in the UK and start to enrol patients in Q1 of 2026. Further details of the trial are included in the\nSubmission of Clinical Trial Authorisation application to the MHRA\nannouncement on 01 July 2025.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin followi",
          "content_length": 6426
        },
        "ingested_at": "2026-01-21T02:14:29.257084Z"
      },
      {
        "event_id": "RNS-26th Aug 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257111Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/result-of-agm-6cyon9r2ckwp5cv.html",
          "rns_number": "RNS Number : 7323W",
          "full_content": "26 Aug 2025 16:03\nRNS Number : 7323W\nCRISM Therapeutics Corporation\n26 August 2025\n26 August 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nResult of AGM\nCRISM Therapeutics (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nis pleased to confirm that at the Company's Annual General Meeting held earlier today, all resolutions were duly passed. Full details of the resolutions are set out in the Notice of Annual General Meeting dated 4 August 2025 and available on the Company's website at:\nhttps://www.crismtherapeutics.com/documents-and-notices\nThe votes cast were as follows:\nResolution\nVotes for\nVotes for %\nVotes against\nVotes against %\nAbstentions\n1\n5,094,571\n100.00%\n-\n-\n62\n2\n5,094,049\n99.99%\n510\n0.01%\n74\n3\n5,094,571\n100.00%\n-\n-\n62\n4\n5,094,571\n100.00%\n-\n-\n62\n5\n5,094,571\n100.00%\n-\n-\n62\n6\n5,094,559\n100.00%\n-\n-\n74\n7\n5,094,571\n100.00%\n-\n-\n62\n8\n5,094,049\n99.99%\n572\n0.01%\n12\n9\n5,094,049\n99.99%\n572\n0.01%\n12\n10\n5,094,049\n99.99%\n572\n0.01%\n12\n11\n5,094,213\n99.99%\n346\n0.01%\n74\n12\n5,094,213\n99.99%\n408\n0.01%\n12\n13\n5,094,213\n99.99%\n408\n0.01%\n12\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGUNRVRVRUWUAR",
          "content_length": 3097
        },
        "ingested_at": "2026-01-21T02:14:29.257129Z"
      },
      {
        "event_id": "RNS-26th Aug 2025-agmstate",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257143Z",
        "source": "LSE_RNS",
        "data": {
          "title": "AGM Statement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/agm-statement-q2e1k2q8x579f0u.html",
          "rns_number": "RNS Number : 4927W",
          "full_content": "26 Aug 2025 07:00\nRNS Number : 4927W\nCRISM Therapeutics Corporation\n26 August 2025\n26 August 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nAGM Statement\nCRISM Therapeutics (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nis holding its Annual General Meeting (\"AGM\") today at 11am at the office of Fieldfisher LLP. At the meeting, CRISM's Non-Executive Chair, Dr Nermeen Varawalla will make the following statement:\n\"This meeting marks our first AGM since CRISM Therapeutics was admitted to AIM following the reverse takeover of Amur Minerals in May 2024. This transformative transaction has provided us with the platform to deliver the significant progress we have made since becoming a listed entity. Our strategy has delivered some key operational achievements during 2025.\n\"In June we successfully submitted our Clinical Trial Authorisation application to the MHRA for our registration grade Phase 2 study of irinotecan ChemoSeed in patients with resectable glioblastoma, a critical milestone in the technology's development. We recently announced the initiation of production of a clinical batch of ChemoSeed under Good Manufacturing Practice with ProMed Pharma. Our progress is being supported by a recent fundraise, raising \u00a3874,021 in June and I thank all shareholders for their continued support.\n\"The potential of ChemoSeed extends beyond a single application and was validated by a grant award from Innovate UK in March to support the pre-clinical development of ChemoSeed for prostate cancer, representing a second indication and significant market opportunity for our technology.\n\"In order to achieve our objectives, we must attract, retain and incentivise the best people. To that end, we have established an Enterprise Management Incentives Option Plan, to ensure our team is motivated and aligned with our long-term goals, which shareholders are voting on today.\n\"Going forward we are focused on gaining trial approval from the MHRA in glioblastoma and progressing towards dosing our first patients in early 2026. Additionally, we will continue to seek further validation for our novel delivery method and are confident that ChemoSeed has the potential to transform treatment for patients with solid-tumour cancers.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGMUUSSRVRUWUAR",
          "content_length": 4288
        },
        "ingested_at": "2026-01-21T02:14:29.257155Z"
      },
      {
        "event_id": "RNS-12th Aug 2025-gmpmanuf",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257168Z",
        "source": "LSE_RNS",
        "data": {
          "title": "GMP Manufacture of ChemoSeed",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/gmp-manufacture-of-chemoseed-4gzpbvei3gj1uwt.html",
          "rns_number": "RNS Number : 8754U",
          "full_content": "12 Aug 2025 07:00\nRNS Number : 8754U\nCRISM Therapeutics Corporation\n12 August 2025\n12 August 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nGMP Manufacture of ChemoSeed for Phase 2 Clinical Trial in Glioblastoma\nCRISM Therapeutics (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nannounces the initiation of production of a clinical batch of ChemoSeed, its proprietary sustained-release implant containing irinotecan, under Good Manufacturing Practice (GMP).\nThis clinical batch will be produced for the Company's upcoming open-label Phase 2 safety and efficacy trial evaluating ChemoSeed administered directly into the resection margin in patients with surgically resectable glioblastoma. US-based ProMed Pharma LLC, a Contract Development and Manufacturing Organisation (\"CDMO\"), will produce the clinical batch.\nThe start of production marks a critical step toward first patient dosing, expected in Q1 2026, and underscores CRISM's commitment to addressing the significant unmet need in glioblastoma, a highly aggressive brain cancer with poor prognosis and limited effective treatment options.\nThe Phase 2 study is designed to evaluate both safety and efficacy following direct administration of ChemoSeed into the tumour resection margin, with the goal of delivering a local high-dose of chemotherapy over a sustained period of time, while minimising systemic toxicity. This innovative approach builds on positive preclinical and early clinical data and has the potential to redefine the standard of care in post-surgical glioblastoma management.\nAndrew Webb, Chief Executive Officer of CRISM Therapeutics, commented:\n\"Initiating GMP manufacturing of ChemoSeed for our upcoming Phase 2 trial is an important step towards bringing a potentially transformative therapy to glioblastoma patients. This achievement reinforces CRISM's leading position in the localised and sustained delivery of chemotherapeutics and advances our mission to improve outcomes in some of the most challenging cancers.\"\nJim Arps, Director of Business Development at ProMed Pharma LLC, commented:\n\"We are proud to support CRISM Therapeutics in the GMP manufacture of ChemoSeed for their innovative glioblastoma program. Our team is committed to ensuring timely and compliant production of this novel treatment, which represents a promising new approach to post-surgical cancer treatment.\"\nThe Company will provide further updates on its Clinical Trial Application, clinical site activation and patient enrolment timelines in due course.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nVadim Alexandre\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nAbout ProMed Pharma\nProMed Pharma specializes in the molding and extrusion of drug-loaded silicones, thermoplastics, and bioresorbable materials, leveraging this expertise to manufacture long-term implants and combination devices under cGMP. Working with both established and early-stage companies, we utilize robust manufacturing processes for controlled release of APIs utilizing a variety of materials. From clinical trial materials to commercial products, ProMed supports pharmaceutical and medical device companies developing controlled release formulations including subcutaneous, orthopedic, cardiovascular, and ophthalmic implants, intravaginal rings, and steroid-eluting combination components. The company has facilities in Plymouth and Maple Grove, Minnesota.\nFor more information please visit:\nhttps://www.promedpharmallc.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may ",
          "content_length": 5408
        },
        "ingested_at": "2026-01-21T02:14:29.257182Z"
      },
      {
        "event_id": "RNS-4th Aug 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257195Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of AGM and EMI Option Plan",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/notice-of-agm-and-emi-option-plan-ixsss5lx9lkn4ep.html",
          "rns_number": "RNS Number : 9183T",
          "full_content": "4 Aug 2025 17:45\nRNS Number : 9183T\nCRISM Therapeutics Corporation\n04 August 2025\n4 August 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nNotice of AGM and EMI Option Plan\nCRISM Therapeutics Corporation (AIM:CRTX) confirms that the Annual General Meeting (\"AGM\") will take place at 11:00am on Tuesday 26 August 2025 at the offices of\nFieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT. Further details are set out in the Notice of AGM, which has been posted to shareholders today.\nA copy Notice of AGM can be accessed from the Company\u00b4s website at:\nhttps://www.crismtherapeutics.com/documents-and-notices\nEMI Option Plan\nIncluded within the Notice of AGM is a resolution for a proposed Enterprise Management Incentives Option Plan (the \"EMI Option Plan\"). The EMI Option Plan is intended to be used to help recruit, retain and incentivise key talent and align employee and shareholder interests by providing eligible employees with the opportunity to acquire ordinary shares in CRISM at a fixed price. There are also schedules to the EMI Option Plan which enable the Company to grant non-tax favoured unapproved options to certain people who are engaged by the Group, including advisors, consultants and non-executive directors, but who would not be eligible to receive tax-favoured EMI options under the EMI Option Plan.\nOptions under the EMI Option Plan would vest in three equal portions over a two-year period and be exercisable on the second anniversary of their vesting. The exercise price is expected to be the closing price of the underlying shares on the day prior to the grant, as may be agreed with HMRC from time to time. Options would lapse after 10 years. The total of options granted under the EMI Option Plan will be limited to a maximum of 10% of the Company's issued share capital.\nAll directors are eligible to receive options in the Company under the EMI Option Plan, which is considered a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. The Company's Nominated Adviser, SP Angel Corporate Finance LLP, considers the terms of the EMI Option Plan and director eligibility to receive options pursuant to the EMI Option Plan to be fair and reasonable insofar as CRISM's shareholders are concerned.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOAPKQBQABKDNFK",
          "content_length": 4234
        },
        "ingested_at": "2026-01-21T02:14:29.257207Z"
      },
      {
        "event_id": "RNS-10th Jul 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257220Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/holdings-in-company-5a5mqxf0k2zvyi2.html",
          "rns_number": "RNS Number : 6121Q",
          "full_content": "10 Jul 2025 15:04\nRNS Number : 6121Q\nCRISM Therapeutics Corporation\n10 July 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nVGG042401262\nIssuer Name\nCRISM THERAPEUTICS CORPORATION\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights; An acquisition or disposal of financial instruments\n3. Details of person subject to the notification obligation\nName\nSpreadex LTD\nCity of registered office (if applicable)\nSt. Albans\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n07-Jul-2025\n6. Date on which Issuer notified\n08-Jul-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n3.128000\n0.000900\n3.128900\n1250374\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nVGG042401262\n1250000\n3.128000\nSub Total 8.A\n1250000\n3.128000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nCFD/Spreadbet\n374\n0.000900\nSub Total 8.B1\n374\n0.000900%\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nLorenzo Dal Col01727 895144Spreadex is an FCA regulated provider of spread betting and CFD trading. Founded in 1999, Spreadex gives both retail and professional traders the opportunity to trade over 10,000 global markets, including UK small caps. For more information see\nwww.spreadex.com/financials\n.\n12. Date of Completion\n08-Jul-2025\n13. Place Of Completion\nUK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLEALXEFEASEFA",
          "content_length": 4191
        },
        "ingested_at": "2026-01-21T02:14:29.257233Z"
      },
      {
        "event_id": "RNS-3rd Jul 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257246Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of Retail Offer and Additional Placing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/result-of-retail-offer-and-additional-placing-lwqn2rt4bjdhhcc.html",
          "rns_number": "RNS Number : 5098P",
          "full_content": "3 Jul 2025 07:00\nRNS Number : 5098P\nCRISM Therapeutics Corporation\n03 July 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS INCORPORATED INTO UK\u00a0LAW BY THE\u00a0EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"UK MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\u00a0IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n3 July 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nResult of Retail Offer and Additional Placing\nFurther to the announcement by the Company in respect of the Retail Offer dated 30 June 2025, CRISM Therapeutics Corporation announces that, following the closing of the Retail Offer on the BookBuild platform on 2 July 2025, the Company has raised gross proceeds of \u00a354,021 (the \"\nRetail Offer\n\") by way of a subscription of 450,176 Retail Offer Shares at the Issue Price of 12 pence per share.\nIn parallel with the Retail Offer, the Company announces an additional placement of 166,666 new ordinary shares of no par value each in the Company (\"\nAdditional Placing Shares\n\") at the Issue Price to raise gross proceeds of \u00a320,000 (the \"\nAdditional Placing\n\"), to an existing shareholder who was unable to participate in the Retail Offer. The gross proceeds of the Placing, the Additional Placing and the Retail Offer raised, in aggregate, \u00a3874,021.\nThe proceeds of the Retail Offer and Additional Placing, together with the Placing announced on 30 June 2025 (together the \"\nProceeds\n\"), will enable the Company to continue to progress the development of ChemoSeed. Specifically, the Proceeds will fund CRISM for GMP manufacture of a clinical trial batch of ChemoSeed, through the MHRA's Clinical Trial Authorisation approval process and to first patients dosed in CRISM's registration grade Phase 2 clinical trial in early 2026.\nAdmission and Total Voting Rights\nApplication has been made to the London Stock Exchange for admission of the Retail Offer Shares and Additional Placing Shares (\"\nAdmission\n\"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 8 July 2025, or such later date as may be agreed between the Company and SP Angel. The Retail Offer Shares and Additional Placing Shares will rank\npari passu\nwith the Company's existing ordinary shares.\nFollowing Admission, the total issued share capital of the Company will consist of 39,961,822 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 39,961,822 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\nOther than where defined, capitalised terms used in this Announcement have the meanings given to them in the announcements of 30 June 2025.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison / Adam Cowl\nVadim Alexandre / Rob Rees\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lea",
          "content_length": 6317
        },
        "ingested_at": "2026-01-21T02:14:29.257260Z"
      },
      {
        "event_id": "RNS-1st Jul 2025-updatepr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257273Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update presentation on the IMC platform",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/CRTX/update-presentation-on-the-imc-platform-8bn6z25uyk2pjqi.html",
          "rns_number": "RNS Number : 2831P",
          "full_content": "1 Jul 2025 16:41\nRNS Number : 2831P\nCRISM Therapeutics Corporation\n01 July 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CRISM THERAPEUTICS CORPORATION). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION.\n1 July 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nUpdate presentation on the IMC platform\nCRISM Therapeutics Corporation is pleased to announce that Andrew Webb, the Company's CEO, has recorded an update for investors which is available to view on the Investor Meet Company (\"IMC\") platform via the below link:\nhttps://www.investormeetcompany.com/updates/9f497c5f-245a-4731-b298-45aaf49cbbc1\nThe update discusses the current funding round, including the retail offer announced yesterday, along with the Company's near-term plans.\nFurther details about the retail offer are included in the notification, Retail Offer, announced yesterday by the Company.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nFollow\nCRISM Therapeutics Corporation\non Investor Meet Company\nhttps://www.investormeetcompany.com/crism-therapeutics-corporation/register\nThe Company's LEI is 213800XFW6MKVCHHPW88.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFZGGNKMLGKZM",
          "content_length": 3970
        },
        "ingested_at": "2026-01-21T02:14:29.257285Z"
      },
      {
        "event_id": "RNS-1st Jul 2025-submissi",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257298Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Submission of CTA Application",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/submission-of-cta-application-ax3cfq1mci1g13y.html",
          "rns_number": "RNS Number : 0868P",
          "full_content": "1 Jul 2025 07:00\nRNS Number : 0868P\nCRISM Therapeutics Corporation\n01 July 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n1 July 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nSubmission of Clinical Trial Authorisation application to the MHRA\nFirst-in-human clinical trial of a novel treatment for brain tumours\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\ntoday confirms the submission of a Clinical Trial Authorisation (\"CTA\") application on 30 June 2025 to the UK Medicines and Healthcare products Regulatory Agency (\"MHRA\") for the Company's Phase 2 registration grade clinical study\nof irinotecan ChemoSeed in resectable glioblastoma.\nThe study, titled\nOpen-label Phase 2 Safety and Efficacy Trial of Irinotecan ChemoSeed Administered Directly into the Resection Margin in Patients with Surgically Resectable Glioblastoma\n, is designed to evaluate the safety, tolerability, and efficacy of ChemoSeed, CRISM's proprietary biodegradable implant technology, delivering irinotecan directly into the resection margin following surgical removal of glioblastoma tumours.\nThe Phase 2 trial will enrol patients with both recurrent and newly diagnosed, surgically resectable glioblastoma and aims to assess whether localised, sustained delivery of irinotecan immediately after tumour resection can improve outcomes compared with conventional systemic chemotherapy by targeting residual tumour cells at the site of highest risk of recurrence, when they are at their lowest volume and most vulnerable to chemotherapy.\nThe trial, which is open label, has been designed in two parts. The first part is a dose escalation study in recurrent glioblastoma using an increasing number of irinotecan ChemoSeeds in a total of 12 patients. Pending regulatory approval from the MHRA, the first patient is expected to be dosed in Q1 2026 and this part of the trial is expected to report in Q1 2027.\nThe second part of the trial will use the optimum dosage from part one of the trial and will include newly diagnosed and recurrent glioblastoma patients divided across two arms, a control arm and a treatment arm. It is expected that a total of 135 patients will be treated in this part of the trial at multiple specialist neuro-oncology centres across the UK, with 90 patients in the treatment arm and 45 in the control arm.\nThe second part of the trial is expected to start in H1 2027 and to report out approximately 2.5 years later.\nThe primary endpoint of the trial is progression free survival, and the secondary endpoint is median overall survival.\nProf. Chris McConville, Chief Scientific Officer at CRISM Therapeutics, commented:\n\"Submitting this CTA marks a significant milestone in the clinical development of ChemoSeed. By delivering irinotecan precisely where it is needed, in the resection margin, when the tumour is at its most vulnerable and treated over a sustained period of time, this study aims to provide a new therapeutic strategy for glioblastoma, a cancer with persistently poor prognosis despite standard-of-care interventions.\"\nAndrew Webb, CEO of CRISM Therapeutics, added:\n\"This first-in-human trial builds on compelling preclinical data and reflects our commitment to redefining solid tumour treatment through sustained localised therapy. We are hopeful that this Phase 2 study will demonstrate the clinical impact of our ChemoSeed drug delivery platform in one of the most urgent areas of need in neuro-oncology and bring a new treatment to patients affected by this devastating disease.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nFor more info",
          "content_length": 5836
        },
        "ingested_at": "2026-01-21T02:14:29.257312Z"
      },
      {
        "event_id": "RNS-30th Jun 2025-retailof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257324Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Retail Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/retail-offer-beyxf24zd05en97.html",
          "rns_number": "RNS Number : 8642O",
          "full_content": "30 Jun 2025 07:01\nRNS Number : 8642O\nCRISM Therapeutics Corporation\n30 June 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CRISM THERAPEUTICS CORPORATION). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION.\n30 June 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nRetail Offer\nto raise up to \u00a3100,000\nCRISM Therapeutics Corporation is pleased to announce a retail offer via BookBuild (the \"\nRetail Offer\n\") of new ordinary shares (\"\nOrdinary Shares\n\") of nil par value each in the Company (the \"\nRetail Offer Shares\n\") at an issue price of 12 pence per New Ordinary Share (as defined below) (the \"\nIssue Price\n\") to raise up to \u00a3100,000.\nIn addition to the Retail Offer, the Company is also conducting a placing of new ordinary shares at the Issue Price (the \"\nPlacing\n\" and together with the Retail Offer, the \"\nIssue\n\"). A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the Retail Offer is not part of the Placing.\nThe net proceeds of the Retail Offer and the Placing will enable the Company to continue to progress the development of ChemoSeed. Specifically, the Placing proceeds will fund CRISM for:\n\u00b7\nGMP manufacture, sterilization, batch qualification, packaging and distribution of a clinical batch of ChemoSeed for evaluation of safety and efficacy in glioblastoma patients in a Phase 2 registration grade clinical trial; and\n\u00b7\nClinical trial set up costs, including first patients dosed in early 2026.\nThe Retail Offer is conditional on the Retail Offer Shares being admitted to trading on the AIM market operated by the London Stock Exchange (\"\nAdmission\n\"). Admission of the Retail Offer Shares is expected to take place at 08/07/2025. Completion of the Retail Offer is conditional, inter alia, upon the completion of the Placing.\nExpected Timetable in relation to the Retail Offer\nRetail Offer opens\n30/06/2025, 07:05\nLatest time and date for commitments under the Retail Offer\n02/07/2025, 16:30\nResults of the Retail Offer announced\n03/07/2025, 07:00\nAdmission and dealings in Retail Offer Shares issuedpursuant to the Retail Offer commence\n08/07/2025\nAny changes to the expected timetable set out above will be notified by the Company through a Regulatory Information Service. References to times are to London times unless otherwise stated.\nDealing Codes\nTicker\nCRTX\nISIN for the Ordinary Shares\nVGG042401262\nSEDOL for the Ordinary Shares\nBS60QF6\nRetail Offer\nThe Company values its retail shareholder base. Given the support of retail shareholders, the Company believes that it is appropriate to provide its retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website:\nhttps://www.bookbuild.live/deals/J1Y6RQ/authorised-intermediaries\nSP Angel Corporate Finance LLP will be acting as retail offer coordinator in relation to this Retail Offer (the \"\nRetail Offer Coordinator\n\").\nExisting retail shareholders can contact their broker or wealth manager (\"\nIntermediary\n\") to participate in the Retail Offer. In order to participate in the Retail Offer, each intermediary must be on-boarded onto the BookBuild platform and agree to the final terms and the retail offer terms and conditions, which regulate, inter alia, the conduct of the Retail Offer on market standard terms and provide for the payment of commission to any intermediary that elects to receive a commission and/or fee (to the extent permitted by the FCA Handbook Rules) from the Retail Offer Coordinator (on behalf of the Company).\nAny expenses incurred by any intermediary are for its own account. Investors should con\ufb01rm separately with any intermediary whether there are any ",
          "content_length": 23571
        },
        "ingested_at": "2026-01-21T02:14:29.257341Z"
      },
      {
        "event_id": "RNS-30th Jun 2025-placing",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257353Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Placing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/placing-gzqlc528oob4ttn.html",
          "rns_number": "RNS Number : 8641O",
          "full_content": "30 Jun 2025 07:00\nRNS Number : 8641O\nCRISM Therapeutics Corporation\n30 June 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS INCORPORATED INTO UK\u00a0LAW BY THE\u00a0EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"UK MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nIN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n30 June 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nPlacing to raise approximately \u00a3800,000 (before expenses)\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs, is pleased to announce that it has successfully raised \u00a3800,000 (before expenses) by way of a placing of 6,666,668 new ordinary shares of no par value each in the Company (\"\nPlacing Shares\n\") at a price of 12 pence per share (the \"\nIssue Price\n\") (the \"\nPlacing\n\"). The Placing Shares each have an attaching grant of warrants (\"\nWarrants\n\") on a one for two basis, exercisable at a price of 24 pence per share, and expiring 24 months after the date of the admission to trading on AIM of the Placing Shares.\nThe Placing was undertaken by the Company's broker, SP Angel Corporate Finance LLP.\nThe Company values its retail shareholder base and believes that it is appropriate to provide existing retail shareholders the opportunity to purchase shares at the Issue Price. The Company intends to carry out a separate retail offer to raise further gross proceeds of up to \u00a3100,000 via the BookBuild Platform (the \"\nRetail Offer\n\"). A further announcement will be made shortly regarding the Retail Offer and its terms.\nHighlights of the Placing:\n- Completion of Placing raising \u00a3800,000 (before expenses) through the issue of 6,666,668 Placing Shares at 12 pence per share\n- The Company will use the net proceeds of the Placing for:\no\nThe GMP manufacture, sterilization, batch qualification, packaging and distribution of a clinical batch of ChemoSeed for evaluation of safety and efficacy in glioblastoma patients in a Phase 2 registration grade clinical trial\no\nClinical trial set up costs, including first patients dosed in early 2026\n- CRISM CEO, Andrew Webb, and Non-Executive Director, Gerry Beaney, both participated in the Placing\n- A separate retail offer to existing holders will be launched shortly\nCRISM CEO, Andrew Webb, said:\n\"The strong support from investors in this fundraising reflects the positive progress we have delivered since joining AIM last year. We are now at a very exciting stage in the development of the Company as we move closer to the start of our Phase 2 trial in glioblastoma using our novel drug delivery platform, ChemoSeed. We thank investors for their support and look forward to the launch of the retail offer, which will give existing shareholders an opportunity to participate in this funding round. With this funding we now have the opportunity to accelerate the approval and commercialisation of a new, much needed treatment for this devastating disease.\"\nRationale for the Placing\nThe Placing will enable the Company to continue to progress the development of ChemoSeed. Specifically, the Placing proceeds will fund CRISM for GMP manufacture of a clinical trial batch of ChemoSeed, through the MHRA's Clinical Trial Authorisation approval process and to first patients dosed in CRISM's registration grade Phase 2 clinical trial in early 2026.\nThe Company's Clinical Trial Authorisation application for regulatory approval to conduct its Phase 2 trial is expected to be submitted later today, and a further announcement will be made follow",
          "content_length": 11679
        },
        "ingested_at": "2026-01-21T02:14:29.257367Z"
      },
      {
        "event_id": "RNS-13th Jun 2025-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257380Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results for the year ended 31 December 2024",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/final-results-for-the-year-ended-31-december-2024-d08syda70ce0vgz.html",
          "rns_number": "RNS Number : 6833M",
          "full_content": "13 Jun 2025 07:00\nRNS Number : 6833M\nCRISM Therapeutics Corporation\n13 June 2025\nMarket Abuse Regulation (MAR) Disclosure:\nThis announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"MAR\"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.\n13 June 2025\nCRISM THERAPEUTICS CORPORATION\n(\"CRISM\", the \"Company\" or the \"Group\")\nFINAL RESULTS\nSignificant progress since joining AIM in May 2024\nCRISM Therapeutics Corporation (AIM: CRTX),\u00a0the innovative UK drug delivery\u00a0company focused on the localised delivery of chemotherapy drugs, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at\nwww.crismtherapeutics.com\nand copies will be mailed to shareholders shortly.\nHighlights:\n\u00b7\nJoined AIM on 31 May 2024 following the Reverse Takeover of Amur Minerals Corporation by Extruded Pharmaceuticals Ltd and a name change to CRISM Therapeutics Corporation\n\u00b7\nPrudent use of cash during the year - primarily for Good Laboratory Practice (\"GLP\") manufacturing of ChemoSeed, regulatory interactions and preparation for submission of clinical trial authorisation (\"CTA\")\n\u00b7\nAdditional revenues secured through service agreement contract win with imphatec limited for \u00a3230,000 in July 2024\n\u00b7\n\u00a325,000 grant funding secured from SPARK Midlands, recognising the unmet need CRISM is addressing in glioblastoma\n\u00b7\nIP position strengthened though the granting of EU patent for ChemoSeed in December 2024\n\u00b7\nSpecialist brain tumour contract research organisation (\"CRO\"), Aixial, appointed in December 2024 to progress Company's CTA application\n\u00b7\nNet cash at 31 December 2024 of \u00a31.28 million (31 May 2024: \u00a31.95 million)\nPost period end:\n\u00b7\nMarch 2025, CRISM received positive written scientific advice from the MHRA on the development of the clinical trial programme and market authorisation strategy for ChemoSeed in glioblastoma\n\u00b7\nMHRA confirmed that no further toxicology studies were needed, saving the Company \u00a3400,000\n\u00b7\nSuccessfully explored new indications for ChemoSeed, winning an Innovate UK grant for the development of ChemoSeed in prostate cancer treatment, to help fund the\nin vitro\ntests\n\u00b7\nEstablished Scientific Advisory Board to provide the Company with specific guidance on its upcoming registration grade Phase II clinical trial\n\u00b7\nInnovative potential of ChemoSeed recognised by the Controlled Release Society, receiving the Drug Delivery and Translational Research Journal Outstanding Paper Award\n\u00b7\nNet cash as at 31 May 2025 \u00a3550,000\nUpcoming Milestones & Outlook:\n\u00b7\nCTA authorisation to be submitted in H1 2025, with trial commencing in early 2026 subject to MHRA meeting regulatory review periods\n\u00b7\nInitiate GMP manufacturing of clinical trial batch of ChemoSeed\n\u00b7\nFirst patient dosed and early signal may indicate treatment tolerance in patient cohort\n\u00b7\nThe current financial year has started well, and in line with the Group's strategy, CRISM has successfully explored a further indication, in prostate cancer\n\u00b7\nThe progress made to date gives the Board confidence in the future prospects of the Group\nCRISM's CEO, Andrew Webb, said:\n\"We have achieved an incredible amount in our first year on AIM. The Company has made significant progress with its principal strategic goal which is\nto advance our lead programme in glioblastoma towards its CTA application. Having received positive feedback from the MHRA in March this year we are confident of progressing to patient recruitment for a phase II registration clinical study by the end of the year.\n\"In addition to the progress made in glioblastoma, the Group has successfully initiated another indication for ChemoSeed, prostate cancer, which represents a very significant market. Prostate cancer research and development in vitro costs will be funded by the successful award of a grant from Innovate UK which we won in March this year.\n\"CRISM is poised to submit its CTA application imminently and we are confident the phase II clinical trial will be approved by the MHRA which is a key strategic milestone which the Board views as a key value inflexion point. The progress made since joining AIM provides us with confidence in CRISM's prospects and we remain resolute in our mission to improve the clinical performance of existing drugs through our innovative delivery method.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments f",
          "content_length": 26478
        },
        "ingested_at": "2026-01-21T02:14:29.257396Z"
      },
      {
        "event_id": "RNS-9th Jun 2025-bestpape",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257409Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Best Paper Award",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/CRTX/best-paper-award-yhsr274ecli9cmf.html",
          "rns_number": "RNS Number : 8656L",
          "full_content": "9 Jun 2025 07:00\nRNS Number : 8656L\nCRISM Therapeutics Corporation\n09 June 2025\n9 June 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nBest Paper Award\nThird party validation for ChemoSeed\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nis pleased to announce it has been selected to receive the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society (\"CRS\") for its paper \"Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumour recurrence in a glioblastoma tumour model\".\nThe award, co-sponsored by CRS and Springer, recognises the most impactful and innovative original research article published in\nDrug Delivery and Translational Research\nduring the past year. CRISM's winning paper, presents foundational research and preclinical validation for ChemoSeed, CRISM's proprietary localised chemotherapy delivery technology designed to maximise on-target efficacy while minimising systemic toxicity. It highlights ChemoSeed's translational potential as a safe and effective treatment for glioblastoma.\nThe award was selected by a panel of internationally recognised scientists and will be formally presented at the upcoming CRS Annual Meeting, taking place in Philadelphia, PA in July 2025.\nProf. Chris McConville, Chief Scientific Officer at CRISM and lead author of the paper, commented:\n\"We are honoured to receive this recognition from CRS, a global authority in drug delivery science. This award not only reflects the quality of our research but provides strong third-party validation of the scientific underpinnings of ChemoSeed. It reinforces the promise of our platform to deliver targeted, sustained therapeutic action directly at the tumour site in glioblastoma patients. This accolade highlights the innovative potential of ChemoSeed and its ability to redefine treatment delivery for solid tumours. It is a testament to our team's commitment to advancing safer, more effective therapies.\"\nThe full article is available in the February 2024 issue of\nDrug Delivery and Translational Research\n, published by Springer and at the following link\nhttps://link.springer.com/article/10.1007/s13346-024-01524-x\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM is expects to submit a clinical trial application for ChemoSeed glioblastoma in H2 2025.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nFor more information on the Controlled Release Society, please visit:\nhttps://www.controlledreleasesociety.org/\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFLFFVRTIRIIE",
          "content_length": 4388
        },
        "ingested_at": "2026-01-21T02:14:29.257421Z"
      },
      {
        "event_id": "RNS-3rd Jun 2025-establis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257434Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Establishment of Scientific Advisory Board",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/establishment-of-scientific-advisory-board-ktsx9pii1ax48w7.html",
          "rns_number": "RNS Number : 1075L",
          "full_content": "3 Jun 2025 07:00\nRNS Number : 1075L\nCRISM Therapeutics Corporation\n03 June 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n3 June 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nEstablishment of Scientific Advisory Board\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nannounces that it has established a Scientific Advisory Board (\"SAB\") to provide the Company with expert guidance as it prepares to submit its Clinical Trial Application (\"CTA\") authorisation for ChemoSeed in glioblastoma.\nThe role of the SAB is to provide the Company with specific guidance on its upcoming registration grade Phase II clinical trial for irinotecan ChemoSeed in patients with glioblastoma. Furthermore, the Company can benefit from the external perspectives which the members of the SAB can bring to steer its future strategies. Details of the SAB members are as follows:\nGarth Cruickshank, PhD, MBBS, FRCS (Ed), FRCS (Eng), FRCS (SN)\nGarth Cruickshank is Emeritus Professor of Neurosurgery at the University of Birmingham. He has worked on hypoxic mechanisms in brain tumour behaviour using per-operative oxygen electrodes and was the first neurosurgeon to inject modified live oncolytic HSV1716 into human brain tumours. He has participated in several interventional glioma clinical trials including HSVtk, and TGFbeta infusion. He helped develop the NICE Improving Outcomes Guidance (2006) for Brain Tumours and was the Lead Clinician for 2018 NICE Brain Tumour current clinical guidelines. He has acted as an advisor for care provider, BSI Healthcare and a reviewer for the National Institute for Health and Care Research.\nDr. Vinton Cheng MBBS MRCP PGDip DPhil\nDr. Vinton Cheng is an Associate Clinical Professor and Honorary Consultant in Medical Oncology at the University of Birmingham with a clinical focus on the holistic management of adult patients with primary and metastatic brain tumours, including with the delivery of systemic therapies. Dr Cheng's research interests are in developing systemic therapy trials for brain tumour patients and studying the progression of cancer in the brain.\nCommenting on the establishment of the SAB, CRISM CEO Andrew Webb said:\n\"We believe that CRISM has established a strong scientific advisory board, with both Vinton and Garth highly experienced in the field of neuro-oncology. They have significant expertise in the field of running successful clinical trials, regulation and academia and we are fortunate to be able to draw on this as the Company prepares its CTA authorisation and subsequent phase II clinical trial for ChemoSeed in glioblastoma.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM is expects to submit a clinical trial application for ChemoSeed glioblastoma in H2 2025.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\n",
          "content_length": 5015
        },
        "ingested_at": "2026-01-21T02:14:29.257447Z"
      },
      {
        "event_id": "RNS-7th Apr 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257460Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director Dealing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/director-dealing-gapk5h6wiwworj5.html",
          "rns_number": "RNS Number : 9432D",
          "full_content": "7 Apr 2025 11:46\nRNS Number : 9432D\nCRISM Therapeutics Corporation\n07 April 2025\n7 April 2025\nCRISM Therapeutics Corporation\n(AIM:CRTX)\nDirector Dealing\nCRISM Therapeutics Corporation (\"CRISM\" or the \"Company\") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 20,182 ordinary shares of the Company at a price of 9.88 pence per share.\nFollowing this purchase, Mr Beaney holds 45,182 ordinary shares, which represents approximately 0.14% of the Company's total issued share capital of\n32,678,312.\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBuchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court mark.court@buchanancomms.co.uk\nJamie Hooper jamie.hooper@buchanancomms.co.uk\nvia Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nDealings by Persons Discharging Managerial Responsibilities\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nGerald Beaney\n2\nReason for the notification\na)\nPosition/status\nNon-Executive Director\nb)\nInitial notification /Amendment\nInitial Notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nCRISM Therapeutics Corporation\nb)\nLEI\n213800XFW6MKVCHHPW88\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nOrdinary shares with no par value\nIdentification code\nISIN: VGG042401262\nb)\nNature of the transaction\nPurchase of shares\nc)\nPrice(s) and volume(s)\nDirector/PDMR\nPrice\nVolume\nGerald Beaney\n9.88\n20,182\nd)\nAggregated information\n- Aggregated volume\n20,182\n- Price\n\u00a31,993.98\ne)\nDate of the transaction\n7 April 2025\nf)\nPlace of the transaction\nOutside a trading venue\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHFLFVISRIDIIE",
          "content_length": 2752
        },
        "ingested_at": "2026-01-21T02:14:29.257473Z"
      },
      {
        "event_id": "RNS-31st Mar 2025-clinical",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257486Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Clinical Trial Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/clinical-trial-update-zv9w458zd81xgwa.html",
          "rns_number": "RNS Number : 8631C",
          "full_content": "31 Mar 2025 07:00\nRNS Number : 8631C\nCRISM Therapeutics Corporation\n31 March 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n31 March 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nClinical Trial Update\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nprovides a positive update regarding its clinical trial authorisation (\"CTA\") application to evaluate irinotecan ChemoSeed (\"ChemoSeed\") in patients with high grade glioma.\nCRISM has been working with the Medicines and Healthcare products Regulatory Agency (\"MHRA\") to finalise the design of the first in-human trial of ChemoSeed and\nis pleased to confirm it has received positive\nwritten scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed.\nThe written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately \u00a3400,000 to conduct the toxicology studies.\nIn addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in H1 2025 and to begin clinical trials of ChemoSeed in Q4 2025, subject to MHRA and other external regulatory organisations meeting expected review times.\nThe Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify.\nCommenting on the MHRA guidance, CRISM CEO Andrew Webb said:\n\"\nWe are pleased that the MHRA has confirmed that our trial design is appropriate for a Phase 2 clinical trial\nin patients with high grade glioma\nwithout the need for further toxicology studies.\nThe MHRA confirmed the need for more drugs and methods of delivery in this disease where there remains a significant lack of treatment options. The written advice from the MHRA is well received, and we are working through the recommendations on ways to improve the trial design with our medical advisers and Aixial ahead of submitting our CTA. Additionally, we look forward to working with Ryan in order to secure grant funding for this trial.\"\nDr. Valentina Zhukova-Harrill, Chief Medical Officer at Aixial, added:\n\"We are proud to see Aixial's expertise playing a pivotal role in advancing the clinical strategy for ChemoSeed. This collaboration marks a critical step forward in addressing a significant unmet medical need, and we look forward to contributing to the upcoming Phase 2 study.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM is expects to submit a clinical trial application for ChemoSeed in high-grade glioma in H2 2025.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nFor more information about Aixial, p",
          "content_length": 5927
        },
        "ingested_at": "2026-01-21T02:14:29.257499Z"
      },
      {
        "event_id": "RNS-27th Mar 2025-innovate",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257512Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Innovate UK Grant Award",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/innovate-uk-grant-award-43ntsn53pjj2sry.html",
          "rns_number": "RNS Number : 3763C",
          "full_content": "27 Mar 2025 07:00\nRNS Number : 3763C\nCRISM Therapeutics Corporation\n27 March 2025\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n27 March 2025\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nInnovate UK Grant Award\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nis pleased to announce that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the \"Project\"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas.\nThe Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology (\"docetaxel ChemoSeed\") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment.\nDocetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect.\nThe Project, which will take about 12 months, is designed to deliver:\n\u00b7\nA functional prototype of the implantable device.\n\u00b7\nPre-clinical validation data demonstrating safety and efficacy.\n\u00b7\nIP protection through patents for core innovations.\n\u00b7\nScalable manufacturing protocols for commercialisation.\nThe outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy.\nThe total cost of the Project is \u00a3152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of \u00a396,106, which represents 63% of the total cost. The remaining \u00a356,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed.\nCommenting on the award Prof Suneil Jain, Professor of Clinical Oncology, and Co-director of The Prostate Cancer Centre of Excellence at Queens University Belfast and the clinical lead on the Project said:\n\"\nUnlike traditional chemotherapy, which often fails to reach the prostate due to its non-lipophilic nature, the docetaxel ChemoSeed is implanted directly into the prostate, delivering sustained, targeted chemotherapy to where it is needed most. This approach promises superior efficacy, minimal side-effects and improved patient outcomes compared to conventional systemic treatments.\"\nProstate cancer affects 50,000 men annually in the UK, and current treatments such as systemic chemotherapy and radiotherapy often cause severe side effects, reduced compliance, and limited efficacy. Docetaxel ChemoSeed is designed to overcome these issues by delivering sustained, controlled chemotherapy directly to the tumour site. This innovation reduces systemic toxicity, improves therapeutic outcomes, and aligns with the Launchpad competition's emphasis on advanced healthcare technologies that enhance patient care. Prostate cancer offers a high growth market opportunity as the global prostate cancer therapeutics market is valued at $13.4 billion in 2024, and projected to grow at a CAGR of 8.6%, reaching $22 billion by 2030*. This includes patients undergoing chemotherapy and those unsuitable for systemic treatments due to comorbidities.\nCommenting on the award, CRISM CSO and Professor of Biomedical Innovation, School of Biomedical Sciences at Ulster University, Chris McConville said:\n\"\nWe are pleased to have been awarded this Innovate UK grant which is a testimony to our innovative technology to treat solid tumours with the localised delivery of chemotherapy. Prostate cancer is a serious and growing condition, and we look forward to working with Queen's and Ulster Universities and Axis Bio to advance the study of using docetaxel in ChemoSeed as a treatment option.\n\"We believe that ChemoSeed has the potential to be transformational owing to its novel localised delivery mechanism and are excited to be adding another indication in a significant m",
          "content_length": 7385
        },
        "ingested_at": "2026-01-21T02:14:29.257525Z"
      },
      {
        "event_id": "RNS-20th Dec 2024-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257538Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Specialist Clinical CRO",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/appointment-of-specialist-clinical-cro-1810yd1d6t40i6x.html",
          "rns_number": "RNS Number : 8363Q",
          "full_content": "20 Dec 2024 07:00\nRNS Number : 8363Q\nCRISM Therapeutics Corporation\n20 December 2024\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n20 December 2024\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nAppointment of Specialist Clinical CRO\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nannounces that it has\nappointed Aixial Group (\"Aixial\"), a specialist clinical\ncontract research organisation\n(\"CRO\") to progress the Company's Clinical Trial Authorisation (\"CTA\") application.\nCRISM appointed Aixial, an international CRO, to progress and finalise the Company's CTA application for the Company's open label Phase 2 study of ChemoSeed in patients with glioblastoma.\nGlioblastoma, a rare disease, is the most aggressive form of brain tumour with a median overall survival of just 14.6 months, making it an area of major unmet medical need.\nAixial has significant experience of rare diseases and brain tumour trials, both in the UK and internationally, and has delivered more than 300 oncology studies across multiple jurisdictions including the UK, EU, USA and Asia Pacific. The Board considers that Aixial is best suited to serve CRISM's requirements for an accelerated CTA application and approval and they are currently in discussions with the Medicines and Healthcare products Regulatory Agency (\"MHRA\") to obtain scientific advice prior to the submission of the Company's Clinical Trial Application for the Phase 2 study, scheduled for early 2025.\nThe appointment of Aixial also brings the potential for study centres outside of the UK to be included in the Phase 2 study, which would be of great value in assisting patient recruitment and in the subsequent commercial pathway should the study be successful.\nThe Company continues to work closely with the University of Birmingham and the Tessa Jowell BRAIN MATRIX scientific advisory committee is supportive of the clinical evaluation of ChemoSeed in patients with primary brain cancer and will promote the clinical trial to patients via their network.\nCommenting on the appointment of Aixial, CRISM CEO Andrew Webb said:\n\"We are delighted to be working with a well-established CRO like Aixial on our CTA application. Operating across multiple jurisdictions and with expertise in rare diseases such as glioblastoma we believe that Aixial is the ideal strategic partner for CRISM. We would like to thank the University of Birmingham for its support and look forward to continuing collaborating with the Tessa Jowell BRAIN MATRIX\n.\n\"\nCommenting on the agreement, Aixial Managing Director, Jonas M\u00f6ller\u00a0said: \"\nAixial Group take great pride in our extensive glioblastoma experience.\u00a0Our partnership with CRISM Therapeutics is a testament of our commitment to advancing oncology research and our ability to support innovative and impactful treatments such as ChemoSeed.\n\"Leveraging the expertise of our operations teams and glioblastoma subject matter experts, including Dr. Valentina Zhukova-Harrill, Chief Medical Officer, we ensure every trial is grounded in robust medical, operational, and regulatory excellence. Aixial's deep understanding of complex oncology studies strengthens our ability to deliver high-quality solutions for our partners and, most importantly, for patients.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout Aixial Group\nAixial Group is a Contract Research Organization (CRO) with over 25 years of experience, dedicated to delivering high-quality clinical research solutions globally. We provide comprehensive support for clinical trials, with specialized expertise in Oncology, Rare Diseases, and Central Nervous System (CNS) disorders.\nFor more information please visit:\nhttps://www.aixialgroup.com/\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed\u00ae, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypas",
          "content_length": 6074
        },
        "ingested_at": "2026-01-21T02:14:29.257553Z"
      },
      {
        "event_id": "RNS-18th Dec 2024-european",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257565Z",
        "source": "LSE_RNS",
        "data": {
          "title": "European Patent Grant",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/european-patent-grant-eu2k9lxq5njg53p.html",
          "rns_number": "RNS Number : 4653Q",
          "full_content": "18 Dec 2024 07:00\nRNS Number : 4653Q\nCRISM Therapeutics Corporation\n18 December 2024\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n18 December 2024\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nEuropean Patent Grant\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\nis pleased to announce that it has been granted a European patent (EP4072552) by the European Patent Office.\nThe patent relates to the Company's lead product, ChemoSeed\u00ae, for chemotherapeutic drug implants and more, particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan. ChemoSeed was invented by Professor Chris McConville, CRISM's Chief Scientific Officer.\nThe patent covers the manufacturing processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours such as high grade glioma. The Company believes that local delivery of irinotecan directly to the brain tumour resection site could improve therapeutic outcomes by allowing for the delivery of larger doses directly to the tumour site, while reducing systemic concentrations and thus alleviating the traditional side-effects.\nThe Company has patents submitted in other key jurisdictions and will update the market as to their progress accordingly.\nCommenting on the patent grant, CRISM CEO Andrew Webb said:\n\"\nThe granting of this patent by the European patent office is a key milestone for CRISM and further validates the novelty of ChemoSeed. Additionally, this provides CRISM IP protection in one of our key markets whilst enhancing ChemoSeed's appeal to potential commercial partners. The Board believes that ChemoSeed could improve therapeutic outcomes for brain tumour patients and we look forward to demonstrating this as we prepare for a clinical trial in 2025.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM plans to submit a clinical trial application for ChemoSeed\u00ae in high-grade glioma\n.\nBased on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nREAEAKAXFDELFFA",
          "content_length": 4435
        },
        "ingested_at": "2026-01-21T02:14:29.257578Z"
      },
      {
        "event_id": "RNS-19th Sep 2024-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257590Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/interim-results-slsj3hj0d4nwk1a.html",
          "rns_number": "RNS Number : 7649E",
          "full_content": "19 Sep 2024 07:00\nRNS Number : 7649E\nCRISM Therapeutics Corporation\n19 September 2024\n19 September 2024\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\" or the \"Group\")\nHalf Year Report\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs,\ntoday announces its Interim Results for the six months ended 30 June 2024 (the \"Period\").\nHighlights & Background\n\u00b7\nAdmitted to AIM on 31 May 2024, following the Reverse Takeover of Amur Minerals Corporation by Extruded Pharmaceuticals Limited (the \"Reverse Takeover\"), changing name to CRISM Therapeutics Corporation\n\u00b7\nReverse Takeover providing funds of approximately \u00a31.95 million (after transaction costs), as of 30 June 2024 the Company held \u00a31,862,000 in cash\n\u00b7\nFunds will be utilised for the preparation of a Phase 2 clinical trial, with clinical trial authorisation (\"CTA\") submission on course for H2 2024 and trial commencement in Q4 2025\n\u00b7\nNew Board appointed on Admission comprising a combination of expertise in R&D, commercialisation in healthcare and public markets\n\u00b7\nCRISM has developed an innovative drug delivery technology, ChemoSeed\u00ae\n\u00b7\nChemoSeed is an implantable biodegradable drug delivery technology designed for the sustained delivery of chemotherapy directly into cancer tissue improving clinical performance\n\u00b7\nInitial therapeutic focus is in high grade glioma (brain tumour) owing to the very significant unmet need and attractive market, valued at \u00a31.7 billion\n\u00b7\nChemoSeed has an attractive risk profile owing to using pre-approved chemotherapy drugs such as irinotecan\n\u00b7\nAssuming no need for further toxicology studies, conditional marketing authorisation would be expedited and reduce costs of development by \u00a3400,000\n\u00b7\nBased on preclinical data, the Tessa Jowell BRAIN MATRIX SAB has approved ChemoSeed in a Phase 2 platform (open label) clinical trial, providing an efficient and cost-effective clinical development opportunity\n\u00b7\nThe Company intends to demonstrate ChemoSeed's potential as a platform for other cancers such as pancreatic, bladder and prostate.\nPost Period End Highlights\n\u00b7\nCRISM's drug formulation expertise was validated on 30 July 2024, by the signing of a service agreement with UK biotech company imphatec Limited (\"imphatec\") for approximately \u00a3230,000, providing the Company with additional revenue\n\u00b7\nIn September 2024, CRSIM was awarded an Innovation Passport from the MHRA as part of the Innovative Licensing and Access Pathway Programme (\"ILAP\"), which recognises ChemoSeed as an innovative technology in an area of unmet medical need and will enable the Company to benefit from expedited and increased access to medical, regulatory and scientific stakeholders\n\u00b7\nReceived \u00a325,000 in Grant Funding from SPARK the Midlands (supported by Innovate UK and the West Midlands Combined Authority), recognising the unmet medical need that CRISM is addressing\n\u00b7\nCRISM's drug delivery approach to administer irinotecan locally into the resection margin was validated on 3 September 2024 with the publication of a peer reviewed research article in journal, Cancers.\nhttps://www.mdpi.com/2072-6694/16/17/3008\nCommenting on the Interim Results, CRISM CEO Andrew Webb said:\n\"\nWe were pleased to complete the Reverse Takeover of Amur Minerals and since CRISM has become a listed entity, the Company has made good progress across its strategic goals. We remain on track with our principal short term strategic goal which is to submit a clinical trial authorisation for ChemoSeed in high grade glioma by the end of this year.\n\"Since the period end, the Company was awarded an Innovation Passport from the MHRA which we believe to be a significant developmental milestone and validates ChemoSeed to potentially enhance the lives of brain tumour patients as well as provide a quicker route to market.\nIn addition, and as part of our stated strategy, the Company signed a service agreement with imphatec which will provide welcome near-term revenue. Generating near term revenues by utilising our drug formulation expertise remains an important part of our strategy and CRISM Therapeutics remains in discussion with other biotech companies to utilise our formulation expertise.\n\"We are optimistic about CRISM's prospects, and believe our proposition is attractive owing to our favourable risk profile by using pre-approved drugs such as irinotecan as well our support from organisations such as the MHRA and Tessa Jowell BRAIN MATRIX. Finally, I would like to thank shareholders for their support, and we look forward to keeping the market up to date with our progress.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeu",
          "content_length": 36591
        },
        "ingested_at": "2026-01-21T02:14:29.257604Z"
      },
      {
        "event_id": "RNS-9th Sep 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257617Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Interim Results & IMC Presentation",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/notice-of-interim-results-imc-presentation-6p55q7i8utgwj27.html",
          "rns_number": "RNS Number : 2974D",
          "full_content": "9 Sep 2024 07:00\nRNS Number : 2974D\nCRISM Therapeutics Corporation\n09 September 2024\n9 September 2024\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nNotice of Interim Results and Presentation via Investor Meet Company\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs, will announce its Interim Results for the six months ended 30 June 2024 on Thursday, 19 September 2024.\nAndrew Webb, CEO of CRISM Therapeutics, will provide a live presentation via Investor Meet Company on 19 September 2024 at 12.00pm BST.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 18 September 2024, 9.00am BST, or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet CRISM Therapeutics via:\nhttps://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor\nInvestors who already follow the Company on the Investor Meet Company platform will automatically be invited.\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed\u00ae in high-grade glioma\n.\nBased on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORQKABDQBKDACK",
          "content_length": 3374
        },
        "ingested_at": "2026-01-21T02:14:29.257629Z"
      },
      {
        "event_id": "RNS-2nd Sep 2024-innovati",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257642Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Innovation Passport Award",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/innovation-passport-award-1hga39ipj3ea0z4.html",
          "rns_number": "RNS Number : 4536C",
          "full_content": "2 Sep 2024 07:00\nRNS Number : 4536C\nCRISM Therapeutics Corporation\n02 September 2024\n2 September 2024\nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nInnovation Passport Award\nCRISM Therapeutics Corporation (AIM: CRTX),\nthe innovative UK drug delivery\ncompany focused on the localised delivery of chemotherapy drugs\n,\nis pleased to announce that the Company has been awarded an Innovation Passport from the UK\nMedicine and Healthcare products Regulatory Agency (MHRA) for its lead programme, ChemoSeed\u00ae in high grade gliomas.\nAward of an Innovation Passport is the first step in the MHRA's Innovative Licensing and Access Pathway (ILAP) programme, which aims to accelerate the development of innovative technologies in areas of unmet medical need by providing access to a broad range of support throughout the product design, development and approvals process.\nCRISM Therapeutics' Innovation Passport award recognises ChemoSeed for high grade gliomas as a promising innovative technology in an area of unmet medical need and will enable CRISM to benefit from expedited and increased access to medical, regulatory and scientific stakeholders. The next stage in the ILAP programme for ChemoSeed is the creation of a Target Development Profile (TDP), which will establish the optimal approach for the clinical development of ChemoSeed.\nThe TDP is supported by the TDP toolkit, which seeks to bring clinically important and promising medicines to patients faster and more efficiently. Further details of the TDP toolkit are available at this link:\nhttps://www.gov.uk/guidance/the-target-development-profile-toolkit\nSeparately, the Company is pleased to announce it has received \u00a325,000 in Grant Funding (the \"Grant\") from SPARK The Midlands, a network which aims to bridge the gap between medical research discoveries of novel therapeutics, medical devices and diagnostics and real-world clinical use. SPARK The Midlands is the first UK branch of the globally recognised SPARK Stanford programme found in over sixty locations globally. SPARK awarded the project funding and support as part of its first cohort seeing the clear unmet clinical need that CRISM is seeking to address. SPARK The Midlands is supported by Innovate UK and the West Midlands Combined Authority.\nCommenting on the Innovation Passport award and Grant, CRISM Therapeutics CEO Andrew Webb said:\n\"The award of this Innovation Passport for ChemoSeed in high grade gliomas and access to the Innovative Licensing and Access Pathway represents a significant milestone in the development of ChemoSeed and this award alongside the grant funding from SPARK is an important endorsement for CRISM Therapeutics. The award validates the potential of our lead product to change the treatment landscape for brain tumours and will assist CRISM in potentially providing ChemoSeed to patients on a faster timescale compared with traditional routes.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court / Jamie Hooper\nCRISM@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed\u00ae in high-grade glioma\n.\nBased on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.\nFor more information please visit:\nhttps://www.crismtherapeutics.com/\nAbout The Innovative Licensing and Access Pathway\nThe Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications and repurposed medicines.\nThe\u00a0ILAP\u00a0is open to both commercial and non-commercial developers of medicines (UK based and or global). It comprises an Innovation Passport designation, a target development profile (TDP) and provides applicants with access to a toolkit to support the design, development and approvals process.\nFor more information:\nhttps://www.gov.",
          "content_length": 5950
        },
        "ingested_at": "2026-01-21T02:14:29.257655Z"
      },
      {
        "event_id": "RNS-30th Jul 2024-crismsig",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257668Z",
        "source": "LSE_RNS",
        "data": {
          "title": "CRISM Signs Service Agreement Contract",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/crism-signs-service-agreement-contract-3zbs0xy3lro33m8.html",
          "rns_number": "RNS Number : 2928Y",
          "full_content": "30 Jul 2024 07:00\nRNS Number : 2928Y\nCrism Therapeutics Corporation\n30 July 2024\n30 July 2024\nCRISM Therapeutics Corporation\n(\"CRISM\" or the \"Company)\nCRISM Signs Service Agreement Contract\nFurther to the Company's announcement on 3 July 2024, CRISM Therapeutics Corporation (AIM: CRTX),\nan innovative UK drug delivery\ncompany focused on the targeted delivery of chemotherapy drugs,\nconfirms that it has signed a service agreement with a total value of approximately \u00a3230,000 excluding VAT (the \"Agreement\") with imphatec Limited (\"imphatec\"), a privately held UK biotech company.\nThis Agreement is in line with CRISM's strategy to leverage its drug formulation expertise by winning service contracts to generate near term revenues. The Company remains on track with its principal goal, which is to submit a clinical trial application during H2 2024 for the use of ChemoSeed\u00ae in high grade glioma.\nUnder the Agreement, CRISM Therapeutics Limited, a wholly owned subsidiary of CRISM, will formulate\nsynthetic hormones into a novel customisable dose ethylene vinyl acetate implant so that the implant can deliver a specific, customised dose per day for up to a year.\nSynthetic hormones are used to treat hormone deficiency illnesses, which affect millions of patients per year in the UK alone, with many millions more across the world.\nThe total value of the Agreement is approximately \u00a3230,000 excluding VAT with approximately \u00a3105,000 payable on signature of the contract; approximately \u00a362,000 payable on entering\nin vivo\npharmacokinetic studies; and a final amount of approximately \u00a362,000 payable on completion of the final report. All of the work under the Agreement is expected to be completed by the end of 2025. Following this Agreement, there is potential for continued collaboration with imphatec, in areas such as technology transfer, GLP toxicity batches and GMP manufacturing, which may generate further revenues.\nCommenting on the Agreement, CRISM's Chief Executive Officer, Andrew Webb, said:\n\"We are pleased to announce that we have signed this service agreement with imphatec which will provide the Company with near term revenue and demonstrates the attractiveness of our drug formulation expertise. We look forward to working with imphatec to help improve the delivery of synthetic hormones in the treatment of hormone deficiency illnesses.\n\"As part of our strategy, we remain in discussions with other biotech companies to utilise our drug formulation expertise. Additionally, we are encouraged by the progress we are making with our clinical trial application for ChemoSeed in high grade glioma and further announcements will be made in due course.\"\nDr Hassan Morad, Chief Scientific Officer at imphatec, said:\n\"We are delighted to have signed a service agreement with CRISM to accelerate the pre-clinical development of our novel customisable-dose implant platform. CRISM has an excellent track record in both\nin vitro\nformulation and\nin vivo\nstudies using\nethylene vinyl acetate-based devices. This 18-month schedule of work will result in a full optimisation and controlled testing of the implant functionality and successful completion will allow imphatec to enter the GLP/GMP manufacturing stage, before proceeding into human clinical trials. Hormone deficiency illnesses affect the lives of millions of people in the UK alone each year, and many more across the world. We are excited to be working with CRISM to further the development of our novel implant to treat patients of such debilitating illnesses.\"\n-Ends-\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBurson Buchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court mark.court@buchanancomms.co.uk\nJamie Hooper jamie.hooper@buchanancomms.co.uk\nvia Burson Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nAbout CRISM Therapeutics Corporation\nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.\nCRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed\u00ae in high-grade glioma\n.\nBased on preclinical data, the Tessa Jowell BRAIN MATRIX Scienticfic Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.\nFor more information please visit:\nhttps://www.crismtherap",
          "content_length": 6627
        },
        "ingested_at": "2026-01-21T02:14:29.257681Z"
      },
      {
        "event_id": "RNS-3rd Jul 2024-response",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257695Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Response to Movement in Share Price",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/response-to-movement-in-share-price-h0x0mv4ybw08h0a.html",
          "rns_number": "RNS Number : 0420V",
          "full_content": "3 Jul 2024 16:18\nRNS Number : 0420V\nCrism Therapeutics Corporation\n03 July 2024\nThe information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK\u00a0law by the\u00a0European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n03 July 2024\nCRISM Therapeutics Corporation\n(AIM:CRTX)\nResponse to Movement in Share Price\nCRISM Therapeutics Corporation (\"CRISM\" or the \"Company\") notes the increase in the Company's share price today and confirms that it is not aware of any specific reason for the increase. The Company's share price has fallen since admission to AIM (Admission) on 31 May 2024, and today's price reversal reflects the Board's underlying view of the value of the business. The Company continues to work on its stated strategy of submitting a Clinical Trial Application in the second half of 2024 for its lead product, ChemoSeed. The Company is also at contract stage to provide services with an early stage UK SME who are seeking to utilise CRISM's drug formulation expertise. The value of that contract would be approximately \u00a3230k + VAT. A further announcement will be made in due course.\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBuchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court mark.court@buchanancomms.co.uk\nJamie Hooper jamie.hooper@buchanancomms.co.uk\nvia Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nSPMSSMFIDELSEFW",
          "content_length": 2415
        },
        "ingested_at": "2026-01-21T02:14:29.257707Z"
      },
      {
        "event_id": "RNS-3rd Jun 2024-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257719Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director Dealing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/director-dealing-r968sty73c9ee5a.html",
          "rns_number": "RNS Number : 9176Q",
          "full_content": "3 Jun 2024 15:25\nRNS Number : 9176Q\nCrism Therapeutics Corporation\n03 June 2024\n3 June 2024\nCRISM Therapeutics Corporation\n(AIM:CRTX)\nDirector Dealing\nCRISM Therapeutics Corporation (\"CRISM\" or the \"Company\") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 25,000 ordinary shares of the Company at a price of 9.265 pence per share.\nFollowing this purchase, Mr Beaney holds 25,000 ordinary shares, which represents approximately 0.08% of the Company's total issued share capital of\n32,678,312.\nEnquiries:\nCompany\nNomad and Broker\nFinancial PR\nCRISM Therapeutics Corporation\nS.P. Angel Corporate Finance LLP\nBuchanan\nAndrew Webb, CEO\nChris McConville, CSO\nRichard Morrison\nAdam Cowl\nMark Court mark.court@buchanancomms.co.uk\nJamie Hooper jamie.hooper@buchanancomms.co.uk\nvia Buchanan\n+44 (0) 20 3470 0470\n+44 (0) 20 7466 5000\nDealings by Persons Discharging Managerial Responsibilities\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nGerald Beaney\n2\nReason for the notification\na)\nPosition/status\nNon-Executive Director\nb)\nInitial notification /Amendment\nInitial Notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nCRISM Therapeutics Corporation\nb)\nLEI\n213800XFW6MKVCHHPW88\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nOrdinary shares with no par value\nIdentification code\nISIN: VGG042401262\nb)\nNature of the transaction\nPurchase of shares\nc)\nPrice(s) and volume(s)\nDirector/PDMR\nPrice\nVolume\nGerald Beaney\n9.265\n25,000\nd)\nAggregated information\n- Aggregated volume\n25,000\n- Price\n\u00a32,316.25\ne)\nDate of the transaction\n3 June 2024\nf)\nPlace of the transaction\nOutside a trading venue\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHFLFFSRSIVIIS",
          "content_length": 2751
        },
        "ingested_at": "2026-01-21T02:14:29.257732Z"
      },
      {
        "event_id": "RNS-31st May 2024-admissio",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:14:29.257745Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Admission to Trading and First Day of Dealings",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/CRTX/admission-to-trading-and-first-day-of-dealings-2nrfk2wejplpln1.html",
          "rns_number": "RNS Number : 5522Q",
          "full_content": "31 May 2024 07:00\nRNS Number : 5522Q\nCrism Therapeutics Corporation\n31 May 2024\n31 May 2024\nCRISM Therapeutics Corporation\n(AIM:CRTX)\nAdmission to Trading and First Day of Dealings\nCRISM Therapeutics Corporation (\"CRISM\" or the \"Company\"), previously called Amur Minerals Corporation, is pleased to announce that, in conjunction and simultaneously with the completion of the acquisition of the entire issued share capital and other securities of Extruded Pharmaceuticals Limited at 8:00 a.m. today, its ordinary shares will commence trading on AIM under the ticker CRTX, with ISIN\nVGG042401262\nand SEDOL number\nBS60QF6\n.\nCRISM Therapeutics Corporation is\na UK-based pharmaceutical company which has developed an innovative drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy.\nChemoSeed\nis a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and\ncan be implanted directly into a tumour or the resection margin following the removal of a tumour. ChemoSeed will initially be used to treat high grade gliomas, a brain tumour with no satisfactory treatment.\nMore information on CRISM Therapeutics Corporation and the Admission Document can be found here:\nwww.crismtherapeutics.com\n.\nThe Directors of CRISM consider key strengths to include:\n\u00b7\nPotential for rapid progression to clinical trials, assuming no need for further toxicology trials, which would reduce time to conditional marketing authorisation by six to nine months and direct costs of development by \u00a3400,000\n\u00b7\nBased on available animal data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved the inclusion of ChemoSeed in its Phase II platform clinical trial, which represents an efficient and cost-effective opportunity for clinical development\n\u00b7\nUtilising pre-approved drug, irinotecan, reduces risk profile in clinical trials\n\u00b7\nAttractive end market with the high grade glioma market valued at circa \u00a31.7 billion\n\u00b7\nTarget market has orphan disease designation, meaning that ChemoSeed could receive conditional marketing authorisation for high grade glioma in the UK following positive Phase II clinical trials\n\u00b7\nCRISM expects to begin its first clinical trial in late 2025. Should the trial generate positive results, given the unmet need for new treatments, this may enable CRISM to commercialise the product for both sales of ChemoSeed and licensing of the platform technology\n\u00b7\nIf ChemoSeed works well in clinical trials, the Board anticipates ChemoSeed may get approval for compassionate use for other solid tumours where surgical resection takes place or there is ease of access to the tumour, such as pancreatic cancer\n\u00b7\nAll the necessary intellectual property for ChemoSeed has been assigned to CRISM, which has submitted patent applications in relevant jurisdictions\nBoard of Directors\nCRISM has a strong Board with a combination of expertise in R&D, commercialisation in healthcare and public markets. Biographies of the Board of Directors are below.\nCRISM Therapeutics CEO, Andrew Webb commented:\n\"We are delighted to have completed this reverse takeover and to begin CRISM Therapeutics' journey as an AIM quoted company. We believe CRISM has an attractive risk profile owing to using an existing pre-approved drug, irinotecan, and\nwe have a clear strategy for progressing ChemoSeed through development and to commercialisation with support of organisations such as the Tessa Jowell BRAIN MATRIX.\n\"Brain tumours remain the biggest cancer killer of children and adults under 40, and there remains a significant lack of cancer research funding in this indication. We hope to change the lives of patients with this condition and believe that ChemoSeed has the potential to become transformational, owing to its novel delivery mechanism, in which we hope to prevent any tumour regrowth.\n\"CRISM operates in attractive markets, with the high grade glioma market valued at circa \u00a31.7 billion, and other indications with solid tumours providing further potential upside. We are very excited to progress into phase II clinical trials and will keep shareholders up to date with our development.\nI'd like to thank our shareholders, for their support in this process and we look forward to repaying their faith as we deliver on our objectives look to create value in the process.\n\"\nShares in issue and Total Voting Rights\nAs disclosed in the Company's Admission Document published on 13 May 2024, the Company expected to have 32,678,150 shares in issue at readmission. As a result of the share consolidation and fractional entitlements, the Company has issued a further 162 shares, application for which will be made to be to the London Stock Exchange to be admitted to trading on AIM on or around 7 June 2024 (\"Admission\"). Following Admission, the total issued share capital of the Company will consist of 32,678,312 Ordinary Shares each with voting rights.",
          "content_length": 12934
        },
        "ingested_at": "2026-01-21T02:14:29.257759Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251541-bigbeast-46581233",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.898986",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigbeasty",
          "content": "In layman terms it means you will be able to buy here sub 10p tomorrow. \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "462",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-22T21:35:27.909649+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20250811-Diesel20--3343041",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.898580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "In layman\u2019s terms. I would suggest you read the RNS properly , see what they have said and are going to do! I keep saying everything they have said they will do , it\u2019s done. Yesterday about the raise ! Today clinical trial!! Well done.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-22T21:35:27.909630+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20250909-Geng--2221767",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.898153",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Ok so on current burn rate they have circa \u00a3400k the raise will get them \u00a3900k, less expenses = \u00a31.2M  is less than a year at current burn. They don't say what the expenses are which is suspicious, will be at least 10%. Most of this will be gone before the trial even starts in Q1 2026 and they will need another raise or two or three before it ends in 2030! \"the first patient is expected to be dosed in Q1 2026\" \"The second part of the trial is expected to start in H1 2027 and to report out approximately 2.5 years later.\" This will be diluted into oblivion before it starts generating any meaningful cash. There may be a good trading opportunity as their 'investor' dumps the 6.6M placing shares onto the market, above 12p.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-22T21:35:27.909612+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20250914-ThisShar--5626937",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.897715",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Yesterday they anounced 6,666,668 new shares added. Even today with a more positive RNS there have been 8 trades totalling 42,000. This just does not have the exposure right now to shift and the market has just been flooded by more shares. Its  a long rd ahead before this will get any momentum, hence this will drift back. Its a buy for me when this is lower, which it will be soon. That placing yesterday with such a discount has now hurt the SP from seeing 20s for while. Will keep an eye on this over the coming days for a new entry level.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Why this will drift back to below 10p.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3DCD78FB-8C55-4A37-91FF-088C5C5EB5DF"
        },
        "ingested_at": "2026-01-22T21:35:27.909594+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251714-Geng-39571084",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.897289",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "To shift those 6.6 Million shares from institutional to retail!",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-22T21:35:27.909576+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251017-Countach--7553884",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.896867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is a seed in more ways than in name. You plant a seed, you water it and it grows. People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game. This will grow and patience will reward.",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "11.50",
          "thread_title": "RE: New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-22T21:35:27.909558+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251210-ThisShar--1025857",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.896449",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Thats the problem with a seed, most want the fruit now, if not they will find a new tree where they can eat! Hence with currnet low volumes... we are talking 4 trades today, then this will fall back signifcantly from here, now matter how many fluffy RNS's they put out.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Countach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=081DCE8A-1B39-471A-B065-D74727F51A96"
        },
        "ingested_at": "2026-01-22T21:35:27.909540+00:00"
      },
      {
        "event_id": "SOCIAL-10Jul20251819-Diesel20--2991280",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.896028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Can someone explain what the latest RNS means? Thanks",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.25",
          "thread_title": "Understanding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=668A365C-4662-4CCC-82EB-0231EC5AAF9E"
        },
        "ingested_at": "2026-01-22T21:35:27.909522+00:00"
      },
      {
        "event_id": "SOCIAL-12Aug20250910-Diesel20-18599489",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.895615",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Great news. Should see a good raise on this news",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-22T21:35:27.909504+00:00"
      },
      {
        "event_id": "SOCIAL-1Sep20250735-capri--2801639",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.895199",
        "source": "LSE_CHAT",
        "data": {
          "author": "capri",
          "content": "Things are going very well here! New trials starting soon",
          "sentiment": 0.0,
          "engagement": "102",
          "price_at_post": "10.50",
          "thread_title": "RE: Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-22T21:35:27.909487+00:00"
      },
      {
        "event_id": "SOCIAL-2Sep20251231-Diesel20-89311965",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.894785",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "You must be joking this is massive!!! Approval for phase 2 clinical trial",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "You must be JOKING",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=FA2EA27D-8E87-4E88-833C-3041E92DD6A5"
        },
        "ingested_at": "2026-01-22T21:35:27.909469+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20250759-Theodoro--3207225",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.894370",
        "source": "LSE_CHAT",
        "data": {
          "author": "Theodoros",
          "content": "How is it that after an RNS so positive, the price can drop?  Doesn't make sense!!",
          "sentiment": 0.0,
          "engagement": "147",
          "price_at_post": "11.50",
          "thread_title": "Price drop",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=E505754F-3993-4064-806C-A7769B6CE4DE"
        },
        "ingested_at": "2026-01-22T21:35:27.909451+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252049-Diesel20--1037163",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.893947",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fchristopher-mcconville-53b834a9_crism-thera-regulatory-news-live-crtx-rns-activity-7371145827924467712-Nv7h%3Futm_medium%3Dios_app%26rcm%3DACoAAEW6vHoB5r2ccWrDSX5ZG17BGJdS1-EAnvM%26utm_source%3Dsocial_share_send%26utm_campaign%3Dmail&data=05%7C02%7C%7C9e25539ed49948ff38c508ddefd97b9e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638930439538637327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=k3ANYxVOoVmKaNFjyWgRoQ7I%2FfdXA80Y31dU1PdaE98%3D&reserved=0",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "On LinkedIn",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=908E4756-F263-4DC3-8747-97C9E5C0EB75"
        },
        "ingested_at": "2026-01-22T21:35:27.909433+00:00"
      },
      {
        "event_id": "SOCIAL-12Sep20251308-Diesel20--5876342",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.893536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Could anyone explain to me when this morning the shares were between 8p-9p then went down to 8p-8.5p. Now after a \u00a320,000 buy , does say unknown, obviously it a buy as it went to 8p-8.75p. I don\u2019t understand why?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "8.375",
          "thread_title": "Why no Raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=982F8279-E12F-4026-B35A-8A00F576BFE7"
        },
        "ingested_at": "2026-01-22T21:35:27.909415+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250718-JOHNO77-72565882",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.893117",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Nice update",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "11.00",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-22T21:35:27.909398+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250815-tbcx--2212926",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.892694",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is unbelievable stuff to have delivered the science that looks to be more effective at killing prostate cancer than existing methods. Huge credit to them and a massive commercial opportunity.",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "11.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-22T21:35:27.909380+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252158-bunsenbu-81997353",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.892279",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Article in the Daily Telegraph today: lammy:%20Labour%20%E2%80%98up%20for%20the%20fight%E2%80%99%20on%20prostate%20cancer",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "11.00",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-22T21:35:27.909362+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20251914-HideInPl-26210745",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.891848",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Just taken a new position recently as I build out my medtech/biotech portfolio. Usual industry funding risk, but my research came up good and feels like a top risk/reward balance for me. Gla HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "11.00",
          "thread_title": "Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-22T21:35:27.909344+00:00"
      },
      {
        "event_id": "SOCIAL-16Oct20250536-bunsenbu-90735587",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.891430",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve also taken a potion and researching it further, frankly I\u2019m blown away Running a registration-grade Phase 2 aligned with MHRA for marketing submission Is unbelievable for an AIM company. Almost all P2 are not like this It means they can commercialise the product before P3 \ud83e\udd29\ud83e\udd29\ud83e\udd29",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "11.00",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-22T21:35:27.909326+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251951-oldrig-79734518",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.890982",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldrig",
          "content": "Normally, a company with a successful phase 2 trial drug for such unmet medical needs, will be snapped by big pharma in no time, in the range of hundreds millions or a few billions easily.",
          "sentiment": 0.5,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-22T21:35:27.909307+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250934-Magic-or--5482993",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.890565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Have you not learnt how the pharma market works yet, they are only interested in drugs that keep you as a customer for life, nothing about making people better sooner.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-22T21:35:27.909289+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251400-HideInPl-66909972",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.890149",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Still so quiet... Just 4 trades today apparently and yet the science seems so exciting. Frustrating that the UK can't back this kind of innovative company with better capital markets like in the US. UK dare not dream big. It isn\u2019t because British science is worse; it\u2019s because capital, liquidity, and perceived exit pathways are all richer in the U.S. Time for UK investors to grow a pair. HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-22T21:35:27.909272+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251615-HideInPl-38091731",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.889705",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "After a little research there's an estimated ~13,000 new cases of GBM per year in the U.S. plus a similar order of magnitude in Europe, so ~25,000 global developed markets cases of this horrid, aggressive and hard to treat disease. The current global GBM market for therapies is roughly $2\u20133 billion per year apparently. Some rough assumptions on cost, market share and royalty % easily return annual revenues of \u00a3100m a year before you layer in the platform optionality of other programmes. This bullish case then needs PoS, time and discount rates applied, that'd what brings the rNPV down to about \u00a310m now. All IMHO and quick maths. More than 2x today's market cap",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-22T21:35:27.909254+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251619-HideInPl-92069995",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.889266",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "A bit more research shows the frustrating thing about AIM. In UK, even a clinical-stage oncology stock rarely trades above 1\u20132\u00d7 rNPV. On NASDAQ, equivalent stage companies often trade at 3\u20135\u00d7 the same rNPV. So although UK is frustratingly illiquid and cautious, it could be that CRTX is worthy of a 20p-40p share price, especially if it can increase the cash runway. Could be an interesting risk/reward play here. HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-22T21:35:27.909236+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251742-Magic-or-71314820",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:27.888803",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Well doing a massive discount placing doesn't help sentiment.   That's the problem, there's always another placing just around the corner with these startup micro stocks.   Just when people were showing profit wham bam 50% discount placing.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-22T21:35:27.909218+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251939-HideInPl--2546294",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.152290",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Exactly, it's a vicious circle in a way. Institutions know they can lowball companies, not enough competition, everyone keeps lowering forward valuations... Add to that the risk averse nature of the average UK investor... But we know that. So we can't be surprised when it happens. I'm trying to ignore the negative mindset briefly and see the potential. HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-22T21:35:27.909200+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250911-bunsenbu-91806317",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.151860",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Potentially the highest reward share on the mkt \u00a34m cap about to start in human trials P2, all the top accreditation secured. #CRTX. I think it\u2019s a 10x mover within 6 months. DYOR",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "11.75",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-22T21:35:27.909182+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20251121-sajy-23718482",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.151439",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A bit of info on the phase 2 trial starting Q1 26 for anyone new here. The trial will be split into two parts, the first part of the trial will cost \u00a31M and as it is an open label trial the company will be providing regular updates on safety and efficacy.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "11.75",
          "thread_title": "Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-22T21:35:27.909164+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252210-sajy--8623181",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.151016",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I can see a similar rise to Hemo happening here. Hemo started to dose patients in a phase 1 trial and after treating a couple of patients it reported no safety issues and early signs of efficacy. The share price rose from around \u00a31.70 t0 \u00a315.00 If we also report no safety issues and early signs of efficacy after treating the first few patients then I can't see why we can't hit a \u00a31.00.  Also don't forget ours is a phase 2 registrational trial, we are much further ahead than Hemo. Even at a pound we will have a Mcap of \u00a340M which is peanuts.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "11.75",
          "thread_title": "RE: Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-22T21:35:27.909146+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252008-gwm121-26871503",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.150597",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "I thought crism had developed a drug release system for brain tumours, and that the original crew reported a small trial as high effiecy untruthfully wrecking the share price. I see a poster below talks about a prostate cancer delivery system, if this is so its very interesting as prostate canvcer is common and the psa test makes many false positives resulting in intrusive biopsies  . So I googled research and reviews on crism, and page after page came up withdrawn. Anyone got a clear idea what this company does now ..",
          "sentiment": 0.0,
          "engagement": "736",
          "price_at_post": "12.00",
          "thread_title": "What does crism do!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DDF20205-8A1B-4AAE-B0BE-C02260650174"
        },
        "ingested_at": "2026-01-22T21:35:27.909128+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250751-sajy-64089704",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.150169",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not long to go, with the phase 2 registrational trial starting in Q1 26. It\u2019s very rare for a company to be in this position and only have a Mcap of \u00a35M. I am convinced the rerate will begin soon, decent volume yesterday and looks like peeps starting to take positions.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "13.00",
          "thread_title": "Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.909107+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251008-Magic-or-18588593",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.149749",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "With about \u00a3800k in the bank the market knows another discount placing is on it's way.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.909079+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251014-sajy--4381771",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.149340",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not necessarily, they only need \u00a31M for the first part of the trial. I am hoping they treat the first few patients and report positive safety and efficacy data and then raise the small amount they need at a much higher share price.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.909061+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251147-bunsenbu-44809638",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.148911",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If you read the RNSs you\u2019ll see they\u2019re expecting grants too Grants from the NHS I might add",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.909043+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251424-Magic-or--7339545",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.148484",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "@sajy \"Not necessarily, they only need \u00a31M for the first part of the trial.\" There you go, you said they need more cash than they have. From results Net cash at 12 September 2025 of \u00a3906,864 How much do you think they will have by the time they start the trial.   Management have already demonstrated that they will place at massive discount to the share price.   NHS grants may help but I'm pretty sure it won't cover the costs of the trial.    I have a small holding at 14p, luckily it's only small as like you I think they have  an interesting product, but they don't have the cash.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.909025+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251432-bunsenbu-61410221",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.148047",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read the RNSs - They\u2019re expecting grants!",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.909007+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251445-Magic-or--1021303",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.147627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\" Great but seeking and securing are two different things.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908988+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251549-Techtoni-19314810",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.147211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "I've been looking for this for a while, and if things go as the BOD expects (inc Orphan Drug application) then this will undoubtedly have a decent rise next year (with warrants set at 24p, I'm guessing that price is almost nailed on anyway at some point) BUT, I'm guessing their cashburn is around 100k/month and a million needed for the trials... With circa \u00a3700-800k in the bank atm , this will undoubtedly need some sort of fundraise. Timescales are usually pushed back in biotech, so I'm guessing the Q1 for trials will be at the later end or early Q2... That would take the cash burn down to almost fumes.. Grants are usually okay but do not plug the full gap. So I'm guessing they either fundraise before trial start or hope for a decent preliminary rise and do a fundraise into the increasing share price next Q1. The price of which is anyone's guess.",
          "sentiment": 0.0,
          "engagement": "1,410",
          "price_at_post": "12.00",
          "thread_title": "Fundraise or Grants ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6DEA5666-F205-4C50-8110-C82C87B82C9C"
        },
        "ingested_at": "2026-01-22T21:35:27.908969+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy--6416234",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.146773",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908935+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni--9002804",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.146366",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,410",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908903+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach-80917548",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.145936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908870+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu--2105351",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.145520",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908833+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or-25438645",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.144987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908796+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu-17200537",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.144574",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908763+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu-72203069",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.144142",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908730+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy--79648248",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.143714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,286",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908695+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy--4559289",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.143298",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908662+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng-25423214",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.142869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908633+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu--8941535",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.142294",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908616+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or--7251901",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:23.141838",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908598+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy--5479650",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.599388",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-01-22T21:35:27.908580+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR--2888396",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.598970",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-22T21:35:27.908563+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or--4579783",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.598563",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-22T21:35:27.908545+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77--8665904",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.598154",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-22T21:35:27.908526+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan--7878861",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.597730",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,438",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-22T21:35:27.908508+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy--5313546",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.597323",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-22T21:35:27.908490+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu--3040162",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.596904",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-22T21:35:27.908472+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or-56224430",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.596486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-22T21:35:27.908454+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or--3325942",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.596065",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-22T21:35:27.908436+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor-12175893",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.595657",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-22T21:35:27.908418+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy-34876509",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.595247",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-22T21:35:27.908400+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor-64937878",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.594820",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-22T21:35:27.908382+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu--1999415",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.594415",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-22T21:35:27.908364+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20-79732842",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.593977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-22T21:35:27.908343+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu--7236999",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.593556",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-22T21:35:27.908325+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh--2415680",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.593143",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-22T21:35:27.908307+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh--3849993",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.592715",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-22T21:35:27.908289+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh-58958316",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.592301",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-22T21:35:27.908272+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy--2661449",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.591873",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-22T21:35:27.908253+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh--8331759",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.591460",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-22T21:35:27.908235+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or--7514494",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.591038",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,157",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-22T21:35:27.908217+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72-12653272",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.590625",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-22T21:35:27.908198+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy-59881332",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.590215",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-22T21:35:27.908180+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72-64283109",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.589784",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-22T21:35:27.908160+00:00"
      },
      {
        "event_id": "SOCIAL-Today1854-KitKatCh-69102716",
        "event_type": "social_post",
        "date": "2026-01-22T21:35:18.589357",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Chatter here and over on Twitter re CRTX is slowly building\u2026! Looks like a few starting to load up.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-22T21:35:27.908134+00:00"
      },
      {
        "event_id": "SOCIAL-2May20250956-fyeburnm-78376197",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.112458",
        "source": "LSE_CHAT",
        "data": {
          "author": "fyeburnmouth",
          "content": "Asking 26 now...memories of how amur used to move many moons ago with big possibilities and relatively small market cap.",
          "sentiment": 0.0,
          "engagement": "29",
          "price_at_post": "25.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.127126+00:00"
      },
      {
        "event_id": "SOCIAL-2May20250958-Growmore-56864625",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.112041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "\ud83d\udca5No stopping this, by the looks of L2",
          "sentiment": 0.0,
          "engagement": "5,123",
          "price_at_post": "25.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.127088+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251000-spideram-90416816",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.111637",
        "source": "LSE_CHAT",
        "data": {
          "author": "spiderama",
          "content": "Year high smashed!!!!!!!",
          "sentiment": 0.0,
          "engagement": "2,870",
          "price_at_post": "25.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.127070+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251000-Ilovesus-14828885",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.111225",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Boooooom",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.127052+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251001-Ilovesus-26906017",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.110810",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Up 75%",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.127034+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251002-Growmore--5696811",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.110402",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "Bought some...L2 looking good \ud83d\udcc8",
          "sentiment": 0.0,
          "engagement": "5,123",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.127016+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251003-Growmore-67355208",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.109989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "Going to do 100% today, by the looks of it",
          "sentiment": 0.0,
          "engagement": "5,123",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126999+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251005-Growmore-55404173",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.109584",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "ONLY 32m shares here, so this can move very very fast",
          "sentiment": 0.0,
          "engagement": "5,123",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126981+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251006-Ilovesus--6448082",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.109178",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Up 78% gosh",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126963+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251011-Growmore-33025890",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.108762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "' Crism is pleased to announce that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the \"Project\")' From recent RNS",
          "sentiment": 0.0,
          "engagement": "5,123",
          "price_at_post": "26.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126945+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251012-Growmore--6800987",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.108349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "About to go into the 30s \ud83d\udcc8",
          "sentiment": 0.0,
          "engagement": "5,123",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126928+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251023-spideram--4794190",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.107926",
        "source": "LSE_CHAT",
        "data": {
          "author": "spiderama",
          "content": "Cant be many shares availlable 63.8% of shares not in public hands",
          "sentiment": 0.0,
          "engagement": "2,870",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126910+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251025-Rick123-28542271",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.107522",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rick123",
          "content": "Why the sudden rise today though?",
          "sentiment": 0.0,
          "engagement": "13,659",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126892+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251029-Growmore--8075110",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.107117",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "Come to think of it, there was just one person ramping it on various boards",
          "sentiment": 0.0,
          "engagement": "5,123",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126874+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251029-Rick123--3903202",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.106699",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rick123",
          "content": "Innovate UK Grant: In March 2025, Crism received a grant from Innovate UK, supporting the development of its drug delivery technology.  \ufffc \u2022\tEuropean Patent: In December 2024, the company was granted a European patent for its ChemoSeed technology, enhancing its intellectual property portfolio.  \ufffc \u2022\tInnovation Passport: In September 2024, Crism was awarded an Innovation Passport, potentially facilitating accelerated regulatory approval processes.",
          "sentiment": 0.5,
          "engagement": "13,659",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T21:57:07.126856+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251030-Geng--2692932",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.106278",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Get real \u00a350 Mil Mcap, no revenue and a potential fund raise coming - good chance for any old AMC holders to dump!",
          "sentiment": -0.5,
          "engagement": "1,949",
          "price_at_post": "26.50",
          "thread_title": "Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T21:57:07.126838+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251054-Ilovesus-47387119",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.105851",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Hidden orders",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "26.50",
          "thread_title": "Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T21:57:07.126820+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251056-Ilovesus-86952353",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.105445",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "HIGHEST RISER",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "24.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T21:57:07.126802+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251058-Cheety23-11582537",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.105029",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheety23",
          "content": "...and day traders already leaving with 10% losses. Pumped n dumped. Hope I'm wrong for your sakes. I watched all morning , nearly bought at 24. Glad I didn't (although I may be proved wrong)",
          "sentiment": 0.0,
          "engagement": "588",
          "price_at_post": "23.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T21:57:07.126785+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251105-avocet12-60144681",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.104619",
        "source": "LSE_CHAT",
        "data": {
          "author": "avocet123",
          "content": "\"Get real \u00a350 Mil Mcap, no revenue and a potential fund raise coming - good chance for any old AMC holders to dump!\" Mcap is like \u00a38m?",
          "sentiment": 0.0,
          "engagement": "6,176",
          "price_at_post": "22.00",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T21:57:07.126767+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251153-richy--4565866",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.104207",
        "source": "LSE_CHAT",
        "data": {
          "author": "richy",
          "content": "NT to buy",
          "sentiment": 0.0,
          "engagement": "3,970",
          "price_at_post": "19.50",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T21:57:07.126749+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251156-Ilovesus--1823480",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.103784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Going back up. Looks like a big player or health provider wants a bit of this. Or and investor wants a stake for their portfolio. Could see delayed buys here. There were hidden buys here.",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "19.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T21:57:07.126731+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251200-richy-34795606",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.103374",
        "source": "LSE_CHAT",
        "data": {
          "author": "richy",
          "content": "Expecting RNS soon sushi?",
          "sentiment": 0.0,
          "engagement": "3,970",
          "price_at_post": "19.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T21:57:07.126713+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251233-Cheety23--8705602",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.102945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheety23",
          "content": "Spread just opened back up to 15%",
          "sentiment": 0.0,
          "engagement": "588",
          "price_at_post": "21.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T21:57:07.126695+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251236-Destitut--4520914",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:07.102505",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Hi GENG hope ye well, what\u2019s your thoughts on this: Deposit sold for $5m. \u00a35m paid to Shareholders & the Market Cap drops \u00a35m. So did the \u00a35m come from the sale proceeds or the Market Cap ? can\u2019t be both or can it ?.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "21.50",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T21:57:07.126676+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251344-Geng--2368747",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.023279",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Hi DB, Depends which way you look at it  you could say the Mcap dropped to reflect the payout, same as with dividends. I'm sure there will be a fund raise here soon, why else list?",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "20.50",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T21:57:07.126659+00:00"
      },
      {
        "event_id": "SOCIAL-2May20251423-Destitut--2957037",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.022846",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Hi Geng, yep that is the obvious answer but\u2026 as we now know the true value of the listing was 2p in old money & that was reflected in the graph for years, right back to Jan 2020. I guess the input value from PI\u2019s over the 16 years was around \u00a31bn. It just doesn\u2019t add up to me. Was the $5m figure known in Jan 2020 ?",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "20.00",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T21:57:07.126641+00:00"
      },
      {
        "event_id": "SOCIAL-6May20251138-ThisShar-87993284",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.022442",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "No reason for this to go up just yet, another pump and dump. Same old amc company!",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "16.50",
          "thread_title": "Should be back to 8p by the end of the week.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=28BCE0F8-3AD0-45F4-8834-74AE88AF5BEB"
        },
        "ingested_at": "2026-01-21T21:57:07.126623+00:00"
      },
      {
        "event_id": "SOCIAL-6May20251232-Countach--6759375",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.022017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "I can see every reason for it to have gone up. Lots of support wanting to get it tested and approved asap. Grants given. Requirement for toxicology tests eliminated. Medical use on live patient went well. Labour approved plans for speeding up all trials. Prostate use now under research on top of brain tumors. Further cancer types to be targeted. It is a very exciting and worthwhile project that could well attract additional grants. I could have sold Friday at +100% but I am in this one long term. I intend to add to my holding.",
          "sentiment": 0.0,
          "engagement": "774",
          "price_at_post": "16.50",
          "thread_title": "RE: Should be back to 8p by the end of the week.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=28BCE0F8-3AD0-45F4-8834-74AE88AF5BEB"
        },
        "ingested_at": "2026-01-21T21:57:07.126604+00:00"
      },
      {
        "event_id": "SOCIAL-6May20251355-Diesel20--1117419",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.021571",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "AMC HAS GONE. AMC no more finished!!! Any AMC  share holders left  please read the announcements they have kept to all there promises. I\u2019m also here for the long term and will also be adding.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "16.00",
          "thread_title": "RE: Should be back to 8p by the end of the week.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=28BCE0F8-3AD0-45F4-8834-74AE88AF5BEB"
        },
        "ingested_at": "2026-01-21T21:57:07.126586+00:00"
      },
      {
        "event_id": "SOCIAL-7May20250907-Ilovesus-73528882",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.021151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Moving up very very fast",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "15.50",
          "thread_title": "Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T21:57:07.126569+00:00"
      },
      {
        "event_id": "SOCIAL-7May20252125-Diesel20--1158115",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.020730",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Folks are realizing what a great project is going on here , and how refreshing it is to see transparency. I would like to know where that 55250 buy went last thing today?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "17.50",
          "thread_title": "RE: Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T21:57:07.126551+00:00"
      },
      {
        "event_id": "SOCIAL-8May20251025-Ilovesus-53237275",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.020320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "ACTION",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "20.00",
          "thread_title": "RE: Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T21:57:07.126533+00:00"
      },
      {
        "event_id": "SOCIAL-8May20251025-Ilovesus-33907365",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.019900",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "UP 25%",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "20.00",
          "thread_title": "RE: Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T21:57:07.126515+00:00"
      },
      {
        "event_id": "SOCIAL-12May20251854-Garrrree--3534318",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.019489",
        "source": "LSE_CHAT",
        "data": {
          "author": "Garrrreee",
          "content": "Been watching the buys over the last few weeks. I am in after a Disaster at Miri. Quietly moving up. Shhhh don't tell anyone",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "19.50",
          "thread_title": "Just watching the buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6918EFF7-2027-42DF-A9CF-4FAC81EBA31A"
        },
        "ingested_at": "2026-01-21T21:57:07.126497+00:00"
      },
      {
        "event_id": "SOCIAL-16May20251709-Diesel20--8671974",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.019073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This is going the right way but for what they are forecasting should be a lot ,lot higher . Some were even selling off , very strange. Read there announcements they are  going to human trials.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "18.50",
          "thread_title": "RE: Just watching the buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6918EFF7-2027-42DF-A9CF-4FAC81EBA31A"
        },
        "ingested_at": "2026-01-21T21:57:07.126479+00:00"
      },
      {
        "event_id": "SOCIAL-20May20251835-Camkite-60248531",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.018663",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "To buy in here. Slowly slowly, few free float in issue. Looks like golden.",
          "sentiment": 0.0,
          "engagement": "7,198",
          "price_at_post": "18.50",
          "thread_title": "Just started",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=64AB9319-02E9-4E0A-A603-8F7D8C434EA1"
        },
        "ingested_at": "2026-01-21T21:57:07.126461+00:00"
      },
      {
        "event_id": "SOCIAL-3Jun20251016-Diesel20-72183541",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.018253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "What a fantastic announcement and achievement to get these two professors on board. Obviously they can\u2019t be far from clinic. Well done the board .",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "19.00",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C5D81564-E830-4D67-AE1C-DC89443AF20A"
        },
        "ingested_at": "2026-01-21T21:57:07.126444+00:00"
      },
      {
        "event_id": "SOCIAL-9Jun20250743-Countach--7395968",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.017826",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "CRISM Therapeutics Corporation (\u201cCRISM\u201d, \u201cCRISM Therapeutics\u201d or the \u201cCompany\u201d) Best Paper Award Third party validation for ChemoSeed CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to announce it has been selected to receive the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society (\u201cCRS\u201d) for its paper \u201cLocal administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumour recurrence in a glioblastoma tumour model\u201d. The award, co-sponsored by CRS and Springer, recognises the most impactful and innovative original research article published in Drug Delivery and Translational Research during the past year. CRISM\u2019s winning paper, presents foundational research and preclinical validation for ChemoSeed, CRISM\u2019s proprietary localised chemotherapy delivery technology designed to maximise on-target efficacy while minimising systemic toxicity. It highlights ChemoSeed\u2019s translational potential as a safe and effective treatment for glioblastoma. The award was selected by a panel of internationally recognised scientists and will be formally presented at the upcoming CRS Annual Meeting, taking place in Philadelphia, PA in July 2025. Prof. Chris McConville, Chief Scientific Officer at CRISM and lead author of the paper, commented: \u201cWe are honoured to receive this recognition from CRS, a global authority in drug delivery science. This award not only reflects the quality of our research but provides strong third-party validation of the scientific underpinnings of ChemoSeed. It reinforces the promise of our platform to deliver targeted, sustained therapeutic action directly at the tumour site in glioblastoma patients. This accolade highlights the innovative potential of ChemoSeed and its ability to redefine treatment delivery for solid tumours. It is a testament to our team's commitment to advancing safer, more effective therapies.\u201d The full article is available in the February 2024 issue of Drug Delivery and Translational Research, published by Springer and at the following link https://link.springer.com/article/10.1007/s13346-024-01524-x -Ends-",
          "sentiment": 0.0,
          "engagement": "774",
          "price_at_post": "19.50",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C5D81564-E830-4D67-AE1C-DC89443AF20A"
        },
        "ingested_at": "2026-01-21T21:57:07.126426+00:00"
      },
      {
        "event_id": "SOCIAL-13Jun20251123-Geng--2416828",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.017368",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Got an RNS alert, so decided to have a look in - SP has increased surprisingly but that will be because the low float and friends and family purchases. \"Net cash at 31 December 2024 of \u00a31.28 million (31 May 2024: \u00a31.95 million)\" Allowing for the small amount of revenue (and no future increase expected), this is > \u00a3100k per month, so probably down to around \u00a3600k by now and \u00a30 by the end of the year. Anyone else feeling a fund raise coming along, why else would they have listed on AIM?",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "23.00",
          "thread_title": "Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T21:57:07.126408+00:00"
      },
      {
        "event_id": "SOCIAL-13Jun20251154-Hammer11--7009046",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.016932",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hammer11",
          "content": "Hi Geng, If you look a bit further down  - Net cash as at 31 May 2025 \u00a3550,000 - so you are almost spot on!",
          "sentiment": 0.0,
          "engagement": "129",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T21:57:07.126390+00:00"
      },
      {
        "event_id": "SOCIAL-13Jun20251505-Diesel20-54681284",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.016515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "The Board has done everything it has said it would do and we all know a raise is needed. Very refreshing to here what is promised is done.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "24.00",
          "thread_title": "Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T21:57:07.126372+00:00"
      },
      {
        "event_id": "SOCIAL-13Jun20251950-gwm121--7089439",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.016094",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "Hi Geng X amc.. HUGE loss. Im confused ... price has been going up,  and there have been some big percentage increases, but if only \u00a3550 k and burning 100k a month and raise likely... what is the risk reward profile. As the shares are worth so little now I dont mind holding as a punt if there is a possible huge upside, but how can this be if there is a raise in the offing. Id appreciate your overview,  overview not advice of course. (Other shares ive got have done better .. r royce 350pc up.)",
          "sentiment": 0.0,
          "engagement": "735",
          "price_at_post": "24.00",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T21:57:07.126354+00:00"
      },
      {
        "event_id": "SOCIAL-16Jun20251608-Geng-31226508",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.015661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Gwm, I'd be surprised if this comes good in the next year or two. Short term - leading up to the cash raise may be an opportunity as the free float is low and most of the insiders won't sell, so it will get pumped to get the best price. However following the raise will almost certainly see the price fall as the 'investors' sell off - remember Crede in the old AMC days. Only my views",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T21:57:07.126336+00:00"
      },
      {
        "event_id": "SOCIAL-16Jun20251629-Diesel20-41985529",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.015235",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "AMC is gone. NO LONGER TRADING. Geng have a look what this company has promised and now done. You\u2019re no fool obviously they need a raise it\u2019s the way this market works for some. I will keep adding.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T21:57:07.126318+00:00"
      },
      {
        "event_id": "SOCIAL-17Jun20251121-Geng-42214593",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.014797",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Diesel, You are correct about AMC no longer trading but a lot of CRISM shares are held by ex AMC'ers who are looking for the best point to exit.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T21:57:07.126300+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20250831-Ilovesus-71098527",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.014373",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Huge discount. The company bought in on the listing for one purpose and one purpose only. To raise funds. There was nothing so obvious as this placing. Its surprising so did not sell out prior to this.",
          "sentiment": 0.0,
          "engagement": "7,717",
          "price_at_post": "15.00",
          "thread_title": "RE: Really big discounted placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5ED0D1BB-16BC-460B-85E1-F717EF24F5C8"
        },
        "ingested_at": "2026-01-21T21:57:07.126282+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20251105-ThisShar--6905417",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.013938",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "\"OUCH\" Can see this falling further from here, poss 10.00 before the week end! I hold here, but just a bunch of old AMC shares, hoping for this to rocket at some point, if it does drop to 10p may have a top up.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "13.00",
          "thread_title": "Like ET said to Elliot....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C57C048D-E716-441C-9559-B2599295A3B3"
        },
        "ingested_at": "2026-01-21T21:57:07.126264+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20251312-BeardedD-91186648",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.013511",
        "source": "LSE_CHAT",
        "data": {
          "author": "BeardedDragon",
          "content": "But the placing price is very much lower than expected. Are you still refreshed?",
          "sentiment": 0.0,
          "engagement": "4,255",
          "price_at_post": "12.00",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T21:57:07.126245+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20251350-Diesel20-83288066",
        "event_type": "social_post",
        "date": "2026-01-21T21:57:03.013068",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Yes. Obviously there was always going to be a raise. This is more or less done. From what this company has done is always stuck to what they said they were going to do. So no not just refreshing but excited on the short to midterm with what they have said today.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "12.00",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T21:57:07.126227+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20251530-silkd01--6781736",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.115735",
        "source": "LSE_CHAT",
        "data": {
          "author": "silkd01",
          "content": "So as a current holder of shares with this company,  what does today's news mean in layman's terms?",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T21:57:07.126209+00:00"
      },
      {
        "event_id": "SOCIAL-30Jun20251541-bigbeast--1332706",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.115332",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigbeasty",
          "content": "In layman terms it means you will be able to buy here sub 10p tomorrow. \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "462",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T21:57:07.126191+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20250811-Diesel20--7223064",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.114911",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "In layman\u2019s terms. I would suggest you read the RNS properly , see what they have said and are going to do! I keep saying everything they have said they will do , it\u2019s done. Yesterday about the raise ! Today clinical trial!! Well done.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T21:57:07.126173+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20250909-Geng-81162038",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.114485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Ok so on current burn rate they have circa \u00a3400k the raise will get them \u00a3900k, less expenses = \u00a31.2M  is less than a year at current burn. They don't say what the expenses are which is suspicious, will be at least 10%. Most of this will be gone before the trial even starts in Q1 2026 and they will need another raise or two or three before it ends in 2030! \"the first patient is expected to be dosed in Q1 2026\" \"The second part of the trial is expected to start in H1 2027 and to report out approximately 2.5 years later.\" This will be diluted into oblivion before it starts generating any meaningful cash. There may be a good trading opportunity as their 'investor' dumps the 6.6M placing shares onto the market, above 12p.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T21:57:07.126155+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20250914-ThisShar-25900652",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.114044",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Yesterday they anounced 6,666,668 new shares added. Even today with a more positive RNS there have been 8 trades totalling 42,000. This just does not have the exposure right now to shift and the market has just been flooded by more shares. Its  a long rd ahead before this will get any momentum, hence this will drift back. Its a buy for me when this is lower, which it will be soon. That placing yesterday with such a discount has now hurt the SP from seeing 20s for while. Will keep an eye on this over the coming days for a new entry level.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Why this will drift back to below 10p.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3DCD78FB-8C55-4A37-91FF-088C5C5EB5DF"
        },
        "ingested_at": "2026-01-21T21:57:07.126137+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251714-Geng-28349719",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.113617",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "To shift those 6.6 Million shares from institutional to retail!",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-21T21:57:07.126118+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251017-Countach-19131014",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.113207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is a seed in more ways than in name. You plant a seed, you water it and it grows. People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game. This will grow and patience will reward.",
          "sentiment": 0.0,
          "engagement": "774",
          "price_at_post": "11.50",
          "thread_title": "RE: New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-21T21:57:07.126086+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251210-ThisShar-18868534",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.112779",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Thats the problem with a seed, most want the fruit now, if not they will find a new tree where they can eat! Hence with currnet low volumes... we are talking 4 trades today, then this will fall back signifcantly from here, now matter how many fluffy RNS's they put out.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Countach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=081DCE8A-1B39-471A-B065-D74727F51A96"
        },
        "ingested_at": "2026-01-21T21:57:07.126069+00:00"
      },
      {
        "event_id": "SOCIAL-10Jul20251819-Diesel20--7506338",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.112367",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Can someone explain what the latest RNS means? Thanks",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.25",
          "thread_title": "Understanding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=668A365C-4662-4CCC-82EB-0231EC5AAF9E"
        },
        "ingested_at": "2026-01-21T21:57:07.126051+00:00"
      },
      {
        "event_id": "SOCIAL-12Aug20250910-Diesel20-90713549",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.111942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Great news. Should see a good raise on this news",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-21T21:57:07.126033+00:00"
      },
      {
        "event_id": "SOCIAL-1Sep20250735-capri--5875680",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.111533",
        "source": "LSE_CHAT",
        "data": {
          "author": "capri",
          "content": "Things are going very well here! New trials starting soon",
          "sentiment": 0.0,
          "engagement": "102",
          "price_at_post": "10.50",
          "thread_title": "RE: Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-21T21:57:07.126015+00:00"
      },
      {
        "event_id": "SOCIAL-2Sep20251231-Diesel20--8968333",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.111125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "You must be joking this is massive!!! Approval for phase 2 clinical trial",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "You must be JOKING",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=FA2EA27D-8E87-4E88-833C-3041E92DD6A5"
        },
        "ingested_at": "2026-01-21T21:57:07.125997+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20250759-Theodoro-66534228",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.110707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Theodoros",
          "content": "How is it that after an RNS so positive, the price can drop?  Doesn't make sense!!",
          "sentiment": 0.0,
          "engagement": "147",
          "price_at_post": "11.50",
          "thread_title": "Price drop",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=E505754F-3993-4064-806C-A7769B6CE4DE"
        },
        "ingested_at": "2026-01-21T21:57:07.125979+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252049-Diesel20-50307402",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.110302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fchristopher-mcconville-53b834a9_crism-thera-regulatory-news-live-crtx-rns-activity-7371145827924467712-Nv7h%3Futm_medium%3Dios_app%26rcm%3DACoAAEW6vHoB5r2ccWrDSX5ZG17BGJdS1-EAnvM%26utm_source%3Dsocial_share_send%26utm_campaign%3Dmail&data=05%7C02%7C%7C9e25539ed49948ff38c508ddefd97b9e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638930439538637327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=k3ANYxVOoVmKaNFjyWgRoQ7I%2FfdXA80Y31dU1PdaE98%3D&reserved=0",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "On LinkedIn",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=908E4756-F263-4DC3-8747-97C9E5C0EB75"
        },
        "ingested_at": "2026-01-21T21:57:07.125961+00:00"
      },
      {
        "event_id": "SOCIAL-12Sep20251308-Diesel20-62755887",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.109880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Could anyone explain to me when this morning the shares were between 8p-9p then went down to 8p-8.5p. Now after a \u00a320,000 buy , does say unknown, obviously it a buy as it went to 8p-8.75p. I don\u2019t understand why?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "8.375",
          "thread_title": "Why no Raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=982F8279-E12F-4026-B35A-8A00F576BFE7"
        },
        "ingested_at": "2026-01-21T21:57:07.125942+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250718-JOHNO77-87868219",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.109466",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Nice update",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "11.00",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-21T21:57:07.125923+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250815-tbcx--4100824",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.109036",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is unbelievable stuff to have delivered the science that looks to be more effective at killing prostate cancer than existing methods. Huge credit to them and a massive commercial opportunity.",
          "sentiment": 0.0,
          "engagement": "748",
          "price_at_post": "11.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-21T21:57:07.125905+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252158-bunsenbu--7739458",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.108620",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Article in the Daily Telegraph today: lammy:%20Labour%20%E2%80%98up%20for%20the%20fight%E2%80%99%20on%20prostate%20cancer",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "11.00",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-21T21:57:07.125887+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20251914-HideInPl-84207643",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.108197",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Just taken a new position recently as I build out my medtech/biotech portfolio. Usual industry funding risk, but my research came up good and feels like a top risk/reward balance for me. Gla HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "11.00",
          "thread_title": "Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-21T21:57:07.125870+00:00"
      },
      {
        "event_id": "SOCIAL-16Oct20250536-bunsenbu--5316501",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.107770",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve also taken a potion and researching it further, frankly I\u2019m blown away Running a registration-grade Phase 2 aligned with MHRA for marketing submission Is unbelievable for an AIM company. Almost all P2 are not like this It means they can commercialise the product before P3 \ud83e\udd29\ud83e\udd29\ud83e\udd29",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "11.00",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-21T21:57:07.125852+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251951-oldrig--6100444",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.107336",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldrig",
          "content": "Normally, a company with a successful phase 2 trial drug for such unmet medical needs, will be snapped by big pharma in no time, in the range of hundreds millions or a few billions easily.",
          "sentiment": 0.5,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-21T21:57:07.125834+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250934-Magic-or-87706305",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.106912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Have you not learnt how the pharma market works yet, they are only interested in drugs that keep you as a customer for life, nothing about making people better sooner.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-21T21:57:07.125816+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251400-HideInPl-96413238",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.106495",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Still so quiet... Just 4 trades today apparently and yet the science seems so exciting. Frustrating that the UK can't back this kind of innovative company with better capital markets like in the US. UK dare not dream big. It isn\u2019t because British science is worse; it\u2019s because capital, liquidity, and perceived exit pathways are all richer in the U.S. Time for UK investors to grow a pair. HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-21T21:57:07.125798+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251615-HideInPl--1805431",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.106055",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "After a little research there's an estimated ~13,000 new cases of GBM per year in the U.S. plus a similar order of magnitude in Europe, so ~25,000 global developed markets cases of this horrid, aggressive and hard to treat disease. The current global GBM market for therapies is roughly $2\u20133 billion per year apparently. Some rough assumptions on cost, market share and royalty % easily return annual revenues of \u00a3100m a year before you layer in the platform optionality of other programmes. This bullish case then needs PoS, time and discount rates applied, that'd what brings the rNPV down to about \u00a310m now. All IMHO and quick maths. More than 2x today's market cap",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-21T21:57:07.125781+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251619-HideInPl-14505288",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:58.105599",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "A bit more research shows the frustrating thing about AIM. In UK, even a clinical-stage oncology stock rarely trades above 1\u20132\u00d7 rNPV. On NASDAQ, equivalent stage companies often trade at 3\u20135\u00d7 the same rNPV. So although UK is frustratingly illiquid and cautious, it could be that CRTX is worthy of a 20p-40p share price, especially if it can increase the cash runway. Could be an interesting risk/reward play here. HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-21T21:57:07.125763+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251742-Magic-or--3952597",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.684286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Well doing a massive discount placing doesn't help sentiment.   That's the problem, there's always another placing just around the corner with these startup micro stocks.   Just when people were showing profit wham bam 50% discount placing.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-21T21:57:07.125745+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251939-HideInPl--8711988",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.683870",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Exactly, it's a vicious circle in a way. Institutions know they can lowball companies, not enough competition, everyone keeps lowering forward valuations... Add to that the risk averse nature of the average UK investor... But we know that. So we can't be surprised when it happens. I'm trying to ignore the negative mindset briefly and see the potential. HIPS",
          "sentiment": 0.0,
          "engagement": "86",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-21T21:57:07.125726+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250911-bunsenbu-74996861",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.683459",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Potentially the highest reward share on the mkt \u00a34m cap about to start in human trials P2, all the top accreditation secured. #CRTX. I think it\u2019s a 10x mover within 6 months. DYOR",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "11.75",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-21T21:57:07.125708+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20251121-sajy-10455872",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.683030",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A bit of info on the phase 2 trial starting Q1 26 for anyone new here. The trial will be split into two parts, the first part of the trial will cost \u00a31M and as it is an open label trial the company will be providing regular updates on safety and efficacy.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "11.75",
          "thread_title": "Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-21T21:57:07.125690+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252210-sajy-86232828",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.682620",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I can see a similar rise to Hemo happening here. Hemo started to dose patients in a phase 1 trial and after treating a couple of patients it reported no safety issues and early signs of efficacy. The share price rose from around \u00a31.70 t0 \u00a315.00 If we also report no safety issues and early signs of efficacy after treating the first few patients then I can't see why we can't hit a \u00a31.00.  Also don't forget ours is a phase 2 registrational trial, we are much further ahead than Hemo. Even at a pound we will have a Mcap of \u00a340M which is peanuts.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "11.75",
          "thread_title": "RE: Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-21T21:57:07.125672+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252008-gwm121-43348910",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.682205",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "I thought crism had developed a drug release system for brain tumours, and that the original crew reported a small trial as high effiecy untruthfully wrecking the share price. I see a poster below talks about a prostate cancer delivery system, if this is so its very interesting as prostate canvcer is common and the psa test makes many false positives resulting in intrusive biopsies  . So I googled research and reviews on crism, and page after page came up withdrawn. Anyone got a clear idea what this company does now ..",
          "sentiment": 0.0,
          "engagement": "735",
          "price_at_post": "12.00",
          "thread_title": "What does crism do!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DDF20205-8A1B-4AAE-B0BE-C02260650174"
        },
        "ingested_at": "2026-01-21T21:57:07.125655+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250751-sajy-32594484",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.681773",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not long to go, with the phase 2 registrational trial starting in Q1 26. It\u2019s very rare for a company to be in this position and only have a Mcap of \u00a35M. I am convinced the rerate will begin soon, decent volume yesterday and looks like peeps starting to take positions.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "13.00",
          "thread_title": "Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125637+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251008-Magic-or--5147628",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.681369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "With about \u00a3800k in the bank the market knows another discount placing is on it's way.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125619+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251014-sajy-32910637",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.680947",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not necessarily, they only need \u00a31M for the first part of the trial. I am hoping they treat the first few patients and report positive safety and efficacy data and then raise the small amount they need at a much higher share price.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125600+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251147-bunsenbu--6395608",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.680542",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If you read the RNSs you\u2019ll see they\u2019re expecting grants too Grants from the NHS I might add",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125582+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251424-Magic-or-21057007",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.680115",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "@sajy \"Not necessarily, they only need \u00a31M for the first part of the trial.\" There you go, you said they need more cash than they have. From results Net cash at 12 September 2025 of \u00a3906,864 How much do you think they will have by the time they start the trial.   Management have already demonstrated that they will place at massive discount to the share price.   NHS grants may help but I'm pretty sure it won't cover the costs of the trial.    I have a small holding at 14p, luckily it's only small as like you I think they have  an interesting product, but they don't have the cash.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125564+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251432-bunsenbu-50403900",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.679681",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read the RNSs - They\u2019re expecting grants!",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125546+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251445-Magic-or-55022128",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.679266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\" Great but seeking and securing are two different things.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125527+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251549-Techtoni-36511170",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.678844",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "I've been looking for this for a while, and if things go as the BOD expects (inc Orphan Drug application) then this will undoubtedly have a decent rise next year (with warrants set at 24p, I'm guessing that price is almost nailed on anyway at some point) BUT, I'm guessing their cashburn is around 100k/month and a million needed for the trials... With circa \u00a3700-800k in the bank atm , this will undoubtedly need some sort of fundraise. Timescales are usually pushed back in biotech, so I'm guessing the Q1 for trials will be at the later end or early Q2... That would take the cash burn down to almost fumes.. Grants are usually okay but do not plug the full gap. So I'm guessing they either fundraise before trial start or hope for a decent preliminary rise and do a fundraise into the increasing share price next Q1. The price of which is anyone's guess.",
          "sentiment": 0.0,
          "engagement": "1,410",
          "price_at_post": "12.00",
          "thread_title": "Fundraise or Grants ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6DEA5666-F205-4C50-8110-C82C87B82C9C"
        },
        "ingested_at": "2026-01-21T21:57:07.125509+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy--5677247",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.678417",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125491+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni-77613649",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.677995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,410",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125473+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach-87651800",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.677582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "774",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125455+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu-34504132",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.677172",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125437+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or--7742458",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.676640",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125419+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu--8050220",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.676227",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125401+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu--1416540",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.675790",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125383+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy---2589959",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.675373",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,286",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125364+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy--4120865",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.674952",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125346+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng--8084025",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.674529",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125328+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu-88260379",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:55.674058",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125309+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or--1890683",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.007003",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125291+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy-84336110",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.006598",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-01-21T21:57:07.125273+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR--1095265",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.006188",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T21:57:07.125254+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or-76671456",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.005771",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T21:57:07.125236+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77--1614928",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.005366",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T21:57:07.125218+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan--5433142",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.004940",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,391",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T21:57:07.125199+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy--1330466",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.004531",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T21:57:07.125181+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu--1110395",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.004121",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T21:57:07.125162+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or--6669639",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.003695",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T21:57:07.125143+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or--2192125",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.003281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T21:57:07.125111+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor-85804617",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.002862",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "356",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T21:57:07.125080+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy-44959823",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.002456",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T21:57:07.125063+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor-81721582",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.002034",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "356",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T21:57:07.125045+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu--7255566",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.001630",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T21:57:07.125027+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20--3032477",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.001202",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T21:57:07.125009+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu--1478484",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.000773",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T21:57:07.124992+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh--8187536",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:53.000365",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T21:57:07.124974+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh-82868901",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.999941",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T21:57:07.124956+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh-35983178",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.999532",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T21:57:07.124939+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy-91073852",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.999114",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T21:57:07.124921+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh--1874871",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.998694",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T21:57:07.124903+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or-87913955",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.998277",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,148",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T21:57:07.124885+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72-71866843",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.997854",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T21:57:07.124867+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy--8583855",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.997437",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T21:57:07.124847+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72-64376520",
        "event_type": "social_post",
        "date": "2026-01-21T21:56:52.996999",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T21:57:07.124822+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy--5400527",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.858757",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.729014Z"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni-10573082",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.858345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,410",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728988Z"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach--2592092",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.857916",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "774",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728962Z"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu--4772981",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.857502",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728935Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or--1790417",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.856968",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728909Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu--7007394",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.856552",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728883Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu--3571203",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.856122",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728857Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy---9082742",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.855696",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,286",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728830Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy-67780644",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.855284",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728804Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng-45302321",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.854849",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728778Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu--5874785",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:37.854394",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728751Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or-73786671",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.814979",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728725Z"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy-55199200",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.814572",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-01-21T02:14:47.728699Z"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR--5593007",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.814162",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-21T02:14:47.728673Z"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or-85381601",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.813743",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T02:14:47.728647Z"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77--1661286",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.813335",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T02:14:47.728621Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan--6069052",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.812906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,338",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T02:14:47.728595Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy--6290355",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.812497",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T02:14:47.728568Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu--8746730",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.812077",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T02:14:47.728542Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or--4032270",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.811659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T02:14:47.728515Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or-58299960",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.811252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-21T02:14:47.728489Z"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor-18651419",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.810836",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "356",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T02:14:47.728463Z"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy-89433640",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.810428",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T02:14:47.728437Z"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor--1873472",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.810006",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "356",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T02:14:47.728410Z"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu-19532882",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.809596",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-21T02:14:47.728384Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20--8226720",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.809163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T02:14:47.728358Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu-16660909",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.808726",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T02:14:47.728331Z"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh-57903179",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.808307",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "20",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T02:14:47.728305Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh--7566622",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.807883",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "20",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T02:14:47.728278Z"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh--6152977",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.807466",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "20",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-21T02:14:47.728251Z"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy-69630977",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.807028",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T02:14:47.728224Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh--8728466",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.806584",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "20",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T02:14:47.728197Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or--6835432",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.806162",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,143",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T02:14:47.728170Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72-11124511",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.805734",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T02:14:47.728142Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy-77508207",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.805319",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "407",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T02:14:47.728094Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72--7930440",
        "event_type": "social_post",
        "date": "2026-01-21T02:14:32.804876",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-21T02:14:47.728063Z"
      },
      {
        "event_id": "SOCIAL-31Mar20250751-Diesel20--8708096",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.881190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Massive announcement. Going into clinical trials in Q4 of 2025 Biggest move in Brain Cancer Treatment for over 20 years. Well done Crism for sticking to your commitments in your admission document.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "Clinical Trials",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=51717DCA-0421-4543-A8A1-BD4550350B3B"
        },
        "ingested_at": "2026-01-21T02:14:47.731710Z"
      },
      {
        "event_id": "SOCIAL-31Mar20250819-Countach-42375598",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.880755",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Todays RNS states no new toxicology reports required reducing the trial costs by \u00a3400k plus some very supportive feedback. Looks like the various bodies involved are very keen to progress this as it is the only breakthrough in brain cancer treatment. Bodes well for other uses too \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "10.50",
          "thread_title": "RE: Clinical Trials",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=51717DCA-0421-4543-A8A1-BD4550350B3B"
        },
        "ingested_at": "2026-01-21T02:14:47.731683Z"
      },
      {
        "event_id": "SOCIAL-31Mar20252106-Diesel20--1121677",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.880327",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "What a crazy thing has happened today. The biggest thing to happen in Brain  Cancer Treatment for over 20 years and nothing happened. This will happen with or without you . Please read the admission document.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "9.50",
          "thread_title": "RE: Clinical Trials",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=51717DCA-0421-4543-A8A1-BD4550350B3B"
        },
        "ingested_at": "2026-01-21T02:14:47.731657Z"
      },
      {
        "event_id": "SOCIAL-1Apr20250910-Countach--6899339",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.879828",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "It is the spread on tiny listed companies that limit the trading. However, if you go by the end of day trading value they have done ok recently. Once the SP goes up which it will trading will increase. This is one for those who are looking at the future and will do very well I belive.",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "9.50",
          "thread_title": "RE: Clinical Trials",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=51717DCA-0421-4543-A8A1-BD4550350B3B"
        },
        "ingested_at": "2026-01-21T02:14:47.731631Z"
      },
      {
        "event_id": "SOCIAL-1Apr20250959-Diesel20-83512191",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.879405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Totally agree. Don\u2019t understand why this hasn\u2019t ticked up a lot more. Patent in place MHRA Approval Clinical Trials in place Funding for Prostate trials in place. Everything is just right for success. I understand if people are playing the market but the uptick is low. Strange but I will keep buying.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "9.50",
          "thread_title": "RE: Clinical Trials",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=51717DCA-0421-4543-A8A1-BD4550350B3B"
        },
        "ingested_at": "2026-01-21T02:14:47.731605Z"
      },
      {
        "event_id": "SOCIAL-8Apr20251353-Countach--6110273",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.878955",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is good news https://www.independent.co.uk/news/uk/politics/keir-starmer-prime-minister-nhs-britain-government-b2728895.html",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "9.50",
          "thread_title": "RE: Clinical Trials",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=51717DCA-0421-4543-A8A1-BD4550350B3B"
        },
        "ingested_at": "2026-01-21T02:14:47.731579Z"
      },
      {
        "event_id": "SOCIAL-28Apr20251529-Diesel20-37777965",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.878536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "At last we can hopefully see where this is now going. Good buys on Friday and today. This is positive and hopefully they can understand where this is going.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731553Z"
      },
      {
        "event_id": "SOCIAL-1May20251209-BeardedD-88604606",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.878113",
        "source": "LSE_CHAT",
        "data": {
          "author": "BeardedDragon",
          "content": "Looking to burst past 15p any time now. Onwards and upwards.",
          "sentiment": 0.0,
          "engagement": "4,243",
          "price_at_post": "14.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731527Z"
      },
      {
        "event_id": "SOCIAL-1May20251400-silkd01-25110445",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.877685",
        "source": "LSE_CHAT",
        "data": {
          "author": "silkd01",
          "content": "There's definitely interest being shown this week with the number of big buys. Long may it continue.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "14.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731500Z"
      },
      {
        "event_id": "SOCIAL-2May20250939-JurysOut-46904838",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.877268",
        "source": "LSE_CHAT",
        "data": {
          "author": "JurysOut",
          "content": "Big spike to 24p. Don't know what's causing this, hopefully will be revealed soon.",
          "sentiment": 0.0,
          "engagement": "144",
          "price_at_post": "18.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731474Z"
      },
      {
        "event_id": "SOCIAL-2May20250940-Growmore--8171043",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.876782",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "WOW \ud83d\udca5What a find !!  Been hidden away this one!",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "18.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731448Z"
      },
      {
        "event_id": "SOCIAL-2May20250956-fyeburnm-57579815",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.876369",
        "source": "LSE_CHAT",
        "data": {
          "author": "fyeburnmouth",
          "content": "Asking 26 now...memories of how amur used to move many moons ago with big possibilities and relatively small market cap.",
          "sentiment": 0.0,
          "engagement": "29",
          "price_at_post": "25.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731421Z"
      },
      {
        "event_id": "SOCIAL-2May20250958-Growmore-36923997",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.875934",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "\ud83d\udca5No stopping this, by the looks of L2",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "25.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731394Z"
      },
      {
        "event_id": "SOCIAL-2May20251000-spideram-16781403",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.875415",
        "source": "LSE_CHAT",
        "data": {
          "author": "spiderama",
          "content": "Year high smashed!!!!!!!",
          "sentiment": 0.0,
          "engagement": "2,868",
          "price_at_post": "25.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731368Z"
      },
      {
        "event_id": "SOCIAL-2May20251000-Ilovesus--3334302",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.874971",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Boooooom",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731341Z"
      },
      {
        "event_id": "SOCIAL-2May20251001-Ilovesus--7288763",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.874531",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Up 75%",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731315Z"
      },
      {
        "event_id": "SOCIAL-2May20251002-Growmore-98299654",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.874073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "Bought some...L2 looking good \ud83d\udcc8",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731288Z"
      },
      {
        "event_id": "SOCIAL-2May20251003-Growmore-40414907",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.873661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "Going to do 100% today, by the looks of it",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731262Z"
      },
      {
        "event_id": "SOCIAL-2May20251005-Growmore--4537717",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.873250",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "ONLY 32m shares here, so this can move very very fast",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731235Z"
      },
      {
        "event_id": "SOCIAL-2May20251006-Ilovesus--2987021",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.872827",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Up 78% gosh",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "24.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731208Z"
      },
      {
        "event_id": "SOCIAL-2May20251011-Growmore--3374755",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.872413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "' Crism is pleased to announce that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the \"Project\")' From recent RNS",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "26.50",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731182Z"
      },
      {
        "event_id": "SOCIAL-2May20251012-Growmore--6856537",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.871976",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "About to go into the 30s \ud83d\udcc8",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731155Z"
      },
      {
        "event_id": "SOCIAL-2May20251023-spideram-50845861",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.871553",
        "source": "LSE_CHAT",
        "data": {
          "author": "spiderama",
          "content": "Cant be many shares availlable 63.8% of shares not in public hands",
          "sentiment": 0.0,
          "engagement": "2,868",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731129Z"
      },
      {
        "event_id": "SOCIAL-2May20251025-Rick123--5102440",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.871132",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rick123",
          "content": "Why the sudden rise today though?",
          "sentiment": 0.0,
          "engagement": "13,459",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731092Z"
      },
      {
        "event_id": "SOCIAL-2May20251029-Growmore-50056426",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:24.870674",
        "source": "LSE_CHAT",
        "data": {
          "author": "Growmorecash",
          "content": "Come to think of it, there was just one person ramping it on various boards",
          "sentiment": 0.0,
          "engagement": "4,991",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731065Z"
      },
      {
        "event_id": "SOCIAL-2May20251029-Rick123-12582523",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.277702",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rick123",
          "content": "Innovate UK Grant: In March 2025, Crism received a grant from Innovate UK, supporting the development of its drug delivery technology.  \ufffc \u2022\tEuropean Patent: In December 2024, the company was granted a European patent for its ChemoSeed technology, enhancing its intellectual property portfolio.  \ufffc \u2022\tInnovation Passport: In September 2024, Crism was awarded an Innovation Passport, potentially facilitating accelerated regulatory approval processes.",
          "sentiment": 0.5,
          "engagement": "13,459",
          "price_at_post": "28.00",
          "thread_title": "RE: Great buy",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=87B450E4-50E8-4349-9B14-21C7B756DF03"
        },
        "ingested_at": "2026-01-21T02:14:47.731038Z"
      },
      {
        "event_id": "SOCIAL-2May20251030-Geng--5753416",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.277283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Get real \u00a350 Mil Mcap, no revenue and a potential fund raise coming - good chance for any old AMC holders to dump!",
          "sentiment": -0.5,
          "engagement": "1,949",
          "price_at_post": "26.50",
          "thread_title": "Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T02:14:47.731012Z"
      },
      {
        "event_id": "SOCIAL-2May20251054-Ilovesus-67760214",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.276859",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Hidden orders",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "26.50",
          "thread_title": "Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T02:14:47.730985Z"
      },
      {
        "event_id": "SOCIAL-2May20251056-Ilovesus-61200462",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.276459",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "HIGHEST RISER",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "24.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T02:14:47.730959Z"
      },
      {
        "event_id": "SOCIAL-2May20251058-Cheety23--4208904",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.276040",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheety23",
          "content": "...and day traders already leaving with 10% losses. Pumped n dumped. Hope I'm wrong for your sakes. I watched all morning , nearly bought at 24. Glad I didn't (although I may be proved wrong)",
          "sentiment": 0.0,
          "engagement": "569",
          "price_at_post": "23.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T02:14:47.730932Z"
      },
      {
        "event_id": "SOCIAL-2May20251105-avocet12--6431244",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.275630",
        "source": "LSE_CHAT",
        "data": {
          "author": "avocet123",
          "content": "\"Get real \u00a350 Mil Mcap, no revenue and a potential fund raise coming - good chance for any old AMC holders to dump!\" Mcap is like \u00a38m?",
          "sentiment": 0.0,
          "engagement": "6,117",
          "price_at_post": "22.00",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T02:14:47.730906Z"
      },
      {
        "event_id": "SOCIAL-2May20251153-richy--3211294",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.275213",
        "source": "LSE_CHAT",
        "data": {
          "author": "richy",
          "content": "NT to buy",
          "sentiment": 0.0,
          "engagement": "3,970",
          "price_at_post": "19.50",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T02:14:47.730879Z"
      },
      {
        "event_id": "SOCIAL-2May20251156-Ilovesus-17751333",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.274798",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Going back up. Looks like a big player or health provider wants a bit of this. Or and investor wants a stake for their portfolio. Could see delayed buys here. There were hidden buys here.",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "19.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T02:14:47.730853Z"
      },
      {
        "event_id": "SOCIAL-2May20251200-richy--4858458",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.274389",
        "source": "LSE_CHAT",
        "data": {
          "author": "richy",
          "content": "Expecting RNS soon sushi?",
          "sentiment": 0.0,
          "engagement": "3,970",
          "price_at_post": "19.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T02:14:47.730826Z"
      },
      {
        "event_id": "SOCIAL-2May20251233-Cheety23-26028243",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.273972",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cheety23",
          "content": "Spread just opened back up to 15%",
          "sentiment": 0.0,
          "engagement": "569",
          "price_at_post": "21.50",
          "thread_title": "RE: Crazy movement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B60873CF-FD2E-4404-BE7D-C03458E51941"
        },
        "ingested_at": "2026-01-21T02:14:47.730800Z"
      },
      {
        "event_id": "SOCIAL-2May20251236-Destitut-70602948",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.273566",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Hi GENG hope ye well, what\u2019s your thoughts on this: Deposit sold for $5m. \u00a35m paid to Shareholders & the Market Cap drops \u00a35m. So did the \u00a35m come from the sale proceeds or the Market Cap ? can\u2019t be both or can it ?.",
          "sentiment": 0.0,
          "engagement": "2,334",
          "price_at_post": "21.50",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T02:14:47.730773Z"
      },
      {
        "event_id": "SOCIAL-2May20251344-Geng--2542784",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.273144",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Hi DB, Depends which way you look at it  you could say the Mcap dropped to reflect the payout, same as with dividends. I'm sure there will be a fund raise here soon, why else list?",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "20.50",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T02:14:47.730746Z"
      },
      {
        "event_id": "SOCIAL-2May20251423-Destitut--6492843",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.272715",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Hi Geng, yep that is the obvious answer but\u2026 as we now know the true value of the listing was 2p in old money & that was reflected in the graph for years, right back to Jan 2020. I guess the input value from PI\u2019s over the 16 years was around \u00a31bn. It just doesn\u2019t add up to me. Was the $5m figure known in Jan 2020 ?",
          "sentiment": 0.0,
          "engagement": "2,334",
          "price_at_post": "20.00",
          "thread_title": "RE: Excellent chance for a few more AMC'ers to get out!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3207BED8-F607-4CD6-94C6-0B8A6F09D520"
        },
        "ingested_at": "2026-01-21T02:14:47.730720Z"
      },
      {
        "event_id": "SOCIAL-6May20251138-ThisShar-10203524",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.272302",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "No reason for this to go up just yet, another pump and dump. Same old amc company!",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "16.50",
          "thread_title": "Should be back to 8p by the end of the week.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=28BCE0F8-3AD0-45F4-8834-74AE88AF5BEB"
        },
        "ingested_at": "2026-01-21T02:14:47.730694Z"
      },
      {
        "event_id": "SOCIAL-6May20251232-Countach--1902631",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.271879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "I can see every reason for it to have gone up. Lots of support wanting to get it tested and approved asap. Grants given. Requirement for toxicology tests eliminated. Medical use on live patient went well. Labour approved plans for speeding up all trials. Prostate use now under research on top of brain tumors. Further cancer types to be targeted. It is a very exciting and worthwhile project that could well attract additional grants. I could have sold Friday at +100% but I am in this one long term. I intend to add to my holding.",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "16.50",
          "thread_title": "RE: Should be back to 8p by the end of the week.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=28BCE0F8-3AD0-45F4-8834-74AE88AF5BEB"
        },
        "ingested_at": "2026-01-21T02:14:47.730667Z"
      },
      {
        "event_id": "SOCIAL-6May20251355-Diesel20--8986861",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.271435",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "AMC HAS GONE. AMC no more finished!!! Any AMC  share holders left  please read the announcements they have kept to all there promises. I\u2019m also here for the long term and will also be adding.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "16.00",
          "thread_title": "RE: Should be back to 8p by the end of the week.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=28BCE0F8-3AD0-45F4-8834-74AE88AF5BEB"
        },
        "ingested_at": "2026-01-21T02:14:47.730641Z"
      },
      {
        "event_id": "SOCIAL-7May20250907-Ilovesus-58780462",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.271006",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Moving up very very fast",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "15.50",
          "thread_title": "Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T02:14:47.730615Z"
      },
      {
        "event_id": "SOCIAL-7May20252125-Diesel20--1551657",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.270599",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Folks are realizing what a great project is going on here , and how refreshing it is to see transparency. I would like to know where that 55250 buy went last thing today?",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "17.50",
          "thread_title": "RE: Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T02:14:47.730588Z"
      },
      {
        "event_id": "SOCIAL-8May20251025-Ilovesus-80911741",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.270179",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "ACTION",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "20.00",
          "thread_title": "RE: Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T02:14:47.730560Z"
      },
      {
        "event_id": "SOCIAL-8May20251025-Ilovesus--6292279",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.269756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "UP 25%",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "20.00",
          "thread_title": "RE: Moving back up",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4D94D459-8A73-435A-AA2D-DD5C33D5011D"
        },
        "ingested_at": "2026-01-21T02:14:47.730533Z"
      },
      {
        "event_id": "SOCIAL-12May20251854-Garrrree--8078992",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.269340",
        "source": "LSE_CHAT",
        "data": {
          "author": "Garrrreee",
          "content": "Been watching the buys over the last few weeks. I am in after a Disaster at Miri. Quietly moving up. Shhhh don't tell anyone",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "19.50",
          "thread_title": "Just watching the buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6918EFF7-2027-42DF-A9CF-4FAC81EBA31A"
        },
        "ingested_at": "2026-01-21T02:14:47.730506Z"
      },
      {
        "event_id": "SOCIAL-16May20251709-Diesel20--7354537",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.268782",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This is going the right way but for what they are forecasting should be a lot ,lot higher . Some were even selling off , very strange. Read there announcements they are  going to human trials.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "18.50",
          "thread_title": "RE: Just watching the buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6918EFF7-2027-42DF-A9CF-4FAC81EBA31A"
        },
        "ingested_at": "2026-01-21T02:14:47.730479Z"
      },
      {
        "event_id": "SOCIAL-20May20251835-Camkite--5577999",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.268362",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "To buy in here. Slowly slowly, few free float in issue. Looks like golden.",
          "sentiment": 0.0,
          "engagement": "7,198",
          "price_at_post": "18.50",
          "thread_title": "Just started",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=64AB9319-02E9-4E0A-A603-8F7D8C434EA1"
        },
        "ingested_at": "2026-01-21T02:14:47.730453Z"
      },
      {
        "event_id": "SOCIAL-3Jun20251016-Diesel20--6370181",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.267926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "What a fantastic announcement and achievement to get these two professors on board. Obviously they can\u2019t be far from clinic. Well done the board .",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "19.00",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C5D81564-E830-4D67-AE1C-DC89443AF20A"
        },
        "ingested_at": "2026-01-21T02:14:47.730426Z"
      },
      {
        "event_id": "SOCIAL-9Jun20250743-Countach--3122712",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:21.267482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "CRISM Therapeutics Corporation (\u201cCRISM\u201d, \u201cCRISM Therapeutics\u201d or the \u201cCompany\u201d) Best Paper Award Third party validation for ChemoSeed CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to announce it has been selected to receive the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society (\u201cCRS\u201d) for its paper \u201cLocal administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumour recurrence in a glioblastoma tumour model\u201d. The award, co-sponsored by CRS and Springer, recognises the most impactful and innovative original research article published in Drug Delivery and Translational Research during the past year. CRISM\u2019s winning paper, presents foundational research and preclinical validation for ChemoSeed, CRISM\u2019s proprietary localised chemotherapy delivery technology designed to maximise on-target efficacy while minimising systemic toxicity. It highlights ChemoSeed\u2019s translational potential as a safe and effective treatment for glioblastoma. The award was selected by a panel of internationally recognised scientists and will be formally presented at the upcoming CRS Annual Meeting, taking place in Philadelphia, PA in July 2025. Prof. Chris McConville, Chief Scientific Officer at CRISM and lead author of the paper, commented: \u201cWe are honoured to receive this recognition from CRS, a global authority in drug delivery science. This award not only reflects the quality of our research but provides strong third-party validation of the scientific underpinnings of ChemoSeed. It reinforces the promise of our platform to deliver targeted, sustained therapeutic action directly at the tumour site in glioblastoma patients. This accolade highlights the innovative potential of ChemoSeed and its ability to redefine treatment delivery for solid tumours. It is a testament to our team's commitment to advancing safer, more effective therapies.\u201d The full article is available in the February 2024 issue of Drug Delivery and Translational Research, published by Springer and at the following link https://link.springer.com/article/10.1007/s13346-024-01524-x -Ends-",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "19.50",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C5D81564-E830-4D67-AE1C-DC89443AF20A"
        },
        "ingested_at": "2026-01-21T02:14:47.730400Z"
      },
      {
        "event_id": "SOCIAL-13Jun20251123-Geng--7945875",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.638955",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Got an RNS alert, so decided to have a look in - SP has increased surprisingly but that will be because the low float and friends and family purchases. \"Net cash at 31 December 2024 of \u00a31.28 million (31 May 2024: \u00a31.95 million)\" Allowing for the small amount of revenue (and no future increase expected), this is > \u00a3100k per month, so probably down to around \u00a3600k by now and \u00a30 by the end of the year. Anyone else feeling a fund raise coming along, why else would they have listed on AIM?",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "23.00",
          "thread_title": "Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T02:14:47.730373Z"
      },
      {
        "event_id": "SOCIAL-13Jun20251154-Hammer11--2002790",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.638533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hammer11",
          "content": "Hi Geng, If you look a bit further down  - Net cash as at 31 May 2025 \u00a3550,000 - so you are almost spot on!",
          "sentiment": 0.0,
          "engagement": "129",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T02:14:47.730347Z"
      },
      {
        "event_id": "SOCIAL-13Jun20251505-Diesel20--6927513",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.638115",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "The Board has done everything it has said it would do and we all know a raise is needed. Very refreshing to here what is promised is done.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "24.00",
          "thread_title": "Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T02:14:47.730321Z"
      },
      {
        "event_id": "SOCIAL-13Jun20251950-gwm121-29803137",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.637698",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "Hi Geng X amc.. HUGE loss. Im confused ... price has been going up,  and there have been some big percentage increases, but if only \u00a3550 k and burning 100k a month and raise likely... what is the risk reward profile. As the shares are worth so little now I dont mind holding as a punt if there is a possible huge upside, but how can this be if there is a raise in the offing. Id appreciate your overview,  overview not advice of course. (Other shares ive got have done better .. r royce 350pc up.)",
          "sentiment": 0.0,
          "engagement": "734",
          "price_at_post": "24.00",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T02:14:47.730294Z"
      },
      {
        "event_id": "SOCIAL-16Jun20251608-Geng-62854737",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.637274",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Gwm, I'd be surprised if this comes good in the next year or two. Short term - leading up to the cash raise may be an opportunity as the free float is low and most of the insiders won't sell, so it will get pumped to get the best price. However following the raise will almost certainly see the price fall as the 'investors' sell off - remember Crede in the old AMC days. Only my views",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T02:14:47.730268Z"
      },
      {
        "event_id": "SOCIAL-16Jun20251629-Diesel20--2528706",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.636843",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "AMC is gone. NO LONGER TRADING. Geng have a look what this company has promised and now done. You\u2019re no fool obviously they need a raise it\u2019s the way this market works for some. I will keep adding.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T02:14:47.730242Z"
      },
      {
        "event_id": "SOCIAL-17Jun20251121-Geng--8238219",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.636418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Diesel, You are correct about AMC no longer trading but a lot of CRISM shares are held by ex AMC'ers who are looking for the best point to exit.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "23.50",
          "thread_title": "RE: Wow some serious Cash Burn!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=49EF3E31-909B-4F7D-8AD1-4ADF2112C265"
        },
        "ingested_at": "2026-01-21T02:14:47.730216Z"
      },
      {
        "event_id": "SOCIAL-30Jun20250831-Ilovesus--8094579",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.635995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ilovesushi",
          "content": "Huge discount. The company bought in on the listing for one purpose and one purpose only. To raise funds. There was nothing so obvious as this placing. Its surprising so did not sell out prior to this.",
          "sentiment": 0.0,
          "engagement": "7,708",
          "price_at_post": "15.00",
          "thread_title": "RE: Really big discounted placing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5ED0D1BB-16BC-460B-85E1-F717EF24F5C8"
        },
        "ingested_at": "2026-01-21T02:14:47.730189Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251105-ThisShar-24939408",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.635586",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "\"OUCH\" Can see this falling further from here, poss 10.00 before the week end! I hold here, but just a bunch of old AMC shares, hoping for this to rocket at some point, if it does drop to 10p may have a top up.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "13.00",
          "thread_title": "Like ET said to Elliot....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C57C048D-E716-441C-9559-B2599295A3B3"
        },
        "ingested_at": "2026-01-21T02:14:47.730163Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251312-BeardedD--2738738",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.635172",
        "source": "LSE_CHAT",
        "data": {
          "author": "BeardedDragon",
          "content": "But the placing price is very much lower than expected. Are you still refreshed?",
          "sentiment": 0.0,
          "engagement": "4,243",
          "price_at_post": "12.00",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T02:14:47.730136Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251350-Diesel20--3672574",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.634760",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Yes. Obviously there was always going to be a raise. This is more or less done. From what this company has done is always stuck to what they said they were going to do. So no not just refreshing but excited on the short to midterm with what they have said today.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "12.00",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T02:14:47.730107Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251530-silkd01-33407400",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.634339",
        "source": "LSE_CHAT",
        "data": {
          "author": "silkd01",
          "content": "So as a current holder of shares with this company,  what does today's news mean in layman's terms?",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T02:14:47.730071Z"
      },
      {
        "event_id": "SOCIAL-30Jun20251541-bigbeast--3953377",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.633926",
        "source": "LSE_CHAT",
        "data": {
          "author": "bigbeasty",
          "content": "In layman terms it means you will be able to buy here sub 10p tomorrow. \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T02:14:47.730045Z"
      },
      {
        "event_id": "SOCIAL-1Jul20250811-Diesel20-18845927",
        "event_type": "social_post",
        "date": "2026-01-10T03:45:17.633520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "In layman\u2019s terms. I would suggest you read the RNS properly , see what they have said and are going to do! I keep saying everything they have said they will do , it\u2019s done. Yesterday about the raise ! Today clinical trial!! Well done.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "11.50",
          "thread_title": "RE: Refreshing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DF57747F-A2CA-4387-8475-8CDC934C7D72"
        },
        "ingested_at": "2026-01-21T02:14:47.730017Z"
      },
      {
        "event_id": "SOCIAL-23Jan20261741-sajy--5165048",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.314749",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The next news here should be the FDA ODD, that should be anytime now as it was submitted late October. If granted and I can think of no reason why it wouldn\u2019t be as we have already received the equivalent from the MHRA, can see it spiking on the day. Hopefully volume that day will clear the last few placing shares.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.331873+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261712-KitKatCh-34633577",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315259",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "They won't be there forever and the next update could create some real demand for these shares. \u00a315-20mill mcap does not look overambitious given the impending study and potential newsflow.  Equivalent to 30-40p. GLA, DYOR. KKC",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.331897+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261418-Magic-or-88153962",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those 9p placing shares are a real drag at the moment.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.331916+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261854-KitKatCh-80438330",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316120",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Chatter here and over on Twitter re CRTX is slowly building\u2026! Looks like a few starting to load up.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.331934+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72--1959673",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316534",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.331953+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy-39849747",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316947",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.331971+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72--8304066",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317375",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.331990+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or--2085017",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.332008+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh--9176499",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318222",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.332026+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy--2899793",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318643",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-24T02:18:04.332044+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh-78623875",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319061",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-24T02:18:04.332062+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh--5330243",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319491",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-24T02:18:04.332085+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh-36786709",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319909",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-24T02:18:04.332136+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu-24020307",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320334",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-24T02:18:04.332161+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20-75588287",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-24T02:18:04.332180+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu--7082525",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321200",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-24T02:18:04.332198+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor--2295878",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321611",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-24T02:18:04.332217+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy-67300789",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322027",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-24T02:18:04.332239+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor--2456936",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322447",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-24T02:18:04.332258+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or-91412012",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-24T02:18:04.332277+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or-35244606",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-24T02:18:04.332296+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu-66566581",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323702",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-24T02:18:04.332315+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy-79937196",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324123",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-24T02:18:04.332333+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan-66336345",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-24T02:18:04.332357+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77-79058292",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324952",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-24T02:18:04.332389+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260902-bunsenbu--4021559",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:45.216448",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yup. Placing clearing. ODD imminent. \u00a35m cap is beyond insane",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.572963+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or--3320789",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.820595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-29T10:43:53.573006+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR-78162590",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821132",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573041+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy--7689708",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821670",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-01-29T10:43:53.573078+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or-45939803",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573130+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu--7945534",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822716",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573170+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng--3378199",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573195+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy-11289366",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823801",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573214+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy---9202628",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,290",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573235+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu--2425192",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824828",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573266+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu--1716473",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825359",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573286+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or--8982608",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573304+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu--6652198",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826563",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573337+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach--5385129",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826983",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573359+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni-85060252",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827427",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573378+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy--4210457",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827841",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573397+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251549-Techtoni-87717613",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828299",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "I've been looking for this for a while, and if things go as the BOD expects (inc Orphan Drug application) then this will undoubtedly have a decent rise next year (with warrants set at 24p, I'm guessing that price is almost nailed on anyway at some point) BUT, I'm guessing their cashburn is around 100k/month and a million needed for the trials... With circa \u00a3700-800k in the bank atm , this will undoubtedly need some sort of fundraise. Timescales are usually pushed back in biotech, so I'm guessing the Q1 for trials will be at the later end or early Q2... That would take the cash burn down to almost fumes.. Grants are usually okay but do not plug the full gap. So I'm guessing they either fundraise before trial start or hope for a decent preliminary rise and do a fundraise into the increasing share price next Q1. The price of which is anyone's guess.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "Fundraise or Grants ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6DEA5666-F205-4C50-8110-C82C87B82C9C"
        },
        "ingested_at": "2026-01-29T10:43:53.573416+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251445-Magic-or--7486259",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\" Great but seeking and securing are two different things.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573436+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251432-bunsenbu--6717314",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829182",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read the RNSs - They\u2019re expecting grants!",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573474+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251424-Magic-or--2558342",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "@sajy \"Not necessarily, they only need \u00a31M for the first part of the trial.\" There you go, you said they need more cash than they have. From results Net cash at 12 September 2025 of \u00a3906,864 How much do you think they will have by the time they start the trial.   Management have already demonstrated that they will place at massive discount to the share price.   NHS grants may help but I'm pretty sure it won't cover the costs of the trial.    I have a small holding at 14p, luckily it's only small as like you I think they have  an interesting product, but they don't have the cash.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573500+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251147-bunsenbu--5784267",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830276",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If you read the RNSs you\u2019ll see they\u2019re expecting grants too Grants from the NHS I might add",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573519+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251014-sajy-65927511",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830697",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not necessarily, they only need \u00a31M for the first part of the trial. I am hoping they treat the first few patients and report positive safety and efficacy data and then raise the small amount they need at a much higher share price.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573537+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251008-Magic-or--2832430",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "With about \u00a3800k in the bank the market knows another discount placing is on it's way.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573556+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250751-sajy-46220144",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831550",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not long to go, with the phase 2 registrational trial starting in Q1 26. It\u2019s very rare for a company to be in this position and only have a Mcap of \u00a35M. I am convinced the rerate will begin soon, decent volume yesterday and looks like peeps starting to take positions.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-29T10:43:53.573589+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252008-gwm121--6145984",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.832053",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "I thought crism had developed a drug release system for brain tumours, and that the original crew reported a small trial as high effiecy untruthfully wrecking the share price. I see a poster below talks about a prostate cancer delivery system, if this is so its very interesting as prostate canvcer is common and the psa test makes many false positives resulting in intrusive biopsies  . So I googled research and reviews on crism, and page after page came up withdrawn. Anyone got a clear idea what this company does now ..",
          "sentiment": 0.0,
          "engagement": "747",
          "price_at_post": "12.00",
          "thread_title": "What does crism do!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DDF20205-8A1B-4AAE-B0BE-C02260650174"
        },
        "ingested_at": "2026-01-29T10:43:53.573611+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252210-sajy--4565584",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.542248",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I can see a similar rise to Hemo happening here. Hemo started to dose patients in a phase 1 trial and after treating a couple of patients it reported no safety issues and early signs of efficacy. The share price rose from around \u00a31.70 t0 \u00a315.00 If we also report no safety issues and early signs of efficacy after treating the first few patients then I can't see why we can't hit a \u00a31.00.  Also don't forget ours is a phase 2 registrational trial, we are much further ahead than Hemo. Even at a pound we will have a Mcap of \u00a340M which is peanuts.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "RE: Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-29T10:43:53.573630+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20251121-sajy-23998969",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543061",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A bit of info on the phase 2 trial starting Q1 26 for anyone new here. The trial will be split into two parts, the first part of the trial will cost \u00a31M and as it is an open label trial the company will be providing regular updates on safety and efficacy.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-29T10:43:53.573648+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250911-bunsenbu-92078856",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543885",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Potentially the highest reward share on the mkt \u00a34m cap about to start in human trials P2, all the top accreditation secured. #CRTX. I think it\u2019s a 10x mover within 6 months. DYOR",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.75",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-29T10:43:53.573667+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251939-HideInPl--6821477",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.544692",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Exactly, it's a vicious circle in a way. Institutions know they can lowball companies, not enough competition, everyone keeps lowering forward valuations... Add to that the risk averse nature of the average UK investor... But we know that. So we can't be surprised when it happens. I'm trying to ignore the negative mindset briefly and see the potential. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-29T10:43:53.573687+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251742-Magic-or-70975558",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.545478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Well doing a massive discount placing doesn't help sentiment.   That's the problem, there's always another placing just around the corner with these startup micro stocks.   Just when people were showing profit wham bam 50% discount placing.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-29T10:43:53.573721+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251619-HideInPl-67124031",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.546308",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "A bit more research shows the frustrating thing about AIM. In UK, even a clinical-stage oncology stock rarely trades above 1\u20132\u00d7 rNPV. On NASDAQ, equivalent stage companies often trade at 3\u20135\u00d7 the same rNPV. So although UK is frustratingly illiquid and cautious, it could be that CRTX is worthy of a 20p-40p share price, especially if it can increase the cash runway. Could be an interesting risk/reward play here. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-29T10:43:53.573741+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251615-HideInPl--2575492",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547127",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "After a little research there's an estimated ~13,000 new cases of GBM per year in the U.S. plus a similar order of magnitude in Europe, so ~25,000 global developed markets cases of this horrid, aggressive and hard to treat disease. The current global GBM market for therapies is roughly $2\u20133 billion per year apparently. Some rough assumptions on cost, market share and royalty % easily return annual revenues of \u00a3100m a year before you layer in the platform optionality of other programmes. This bullish case then needs PoS, time and discount rates applied, that'd what brings the rNPV down to about \u00a310m now. All IMHO and quick maths. More than 2x today's market cap",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-29T10:43:53.573761+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251400-HideInPl--3475885",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547938",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Still so quiet... Just 4 trades today apparently and yet the science seems so exciting. Frustrating that the UK can't back this kind of innovative company with better capital markets like in the US. UK dare not dream big. It isn\u2019t because British science is worse; it\u2019s because capital, liquidity, and perceived exit pathways are all richer in the U.S. Time for UK investors to grow a pair. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-29T10:43:53.573780+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250934-Magic-or-55475386",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.548723",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Have you not learnt how the pharma market works yet, they are only interested in drugs that keep you as a customer for life, nothing about making people better sooner.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-29T10:43:53.573798+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251951-oldrig--4484930",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.549504",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldrig",
          "content": "Normally, a company with a successful phase 2 trial drug for such unmet medical needs, will be snapped by big pharma in no time, in the range of hundreds millions or a few billions easily.",
          "sentiment": 0.5,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-29T10:43:53.573826+00:00"
      },
      {
        "event_id": "SOCIAL-16Oct20250536-bunsenbu--8936307",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.550340",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve also taken a potion and researching it further, frankly I\u2019m blown away Running a registration-grade Phase 2 aligned with MHRA for marketing submission Is unbelievable for an AIM company. Almost all P2 are not like this It means they can commercialise the product before P3 \ud83e\udd29\ud83e\udd29\ud83e\udd29",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-29T10:43:53.573854+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20251914-HideInPl--7460075",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551115",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Just taken a new position recently as I build out my medtech/biotech portfolio. Usual industry funding risk, but my research came up good and feels like a top risk/reward balance for me. Gla HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "11.00",
          "thread_title": "Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-29T10:43:53.573873+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252158-bunsenbu-78799715",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551920",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Article in the Daily Telegraph today: lammy:%20Labour%20%E2%80%98up%20for%20the%20fight%E2%80%99%20on%20prostate%20cancer",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-29T10:43:53.573892+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250815-tbcx--3970856",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.552718",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is unbelievable stuff to have delivered the science that looks to be more effective at killing prostate cancer than existing methods. Huge credit to them and a massive commercial opportunity.",
          "sentiment": 0.0,
          "engagement": "768",
          "price_at_post": "11.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-29T10:43:53.573911+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250718-JOHNO77-45926194",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.553508",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Nice update",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "11.00",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-29T10:43:53.573930+00:00"
      },
      {
        "event_id": "SOCIAL-12Sep20251308-Diesel20-76780472",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.554282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Could anyone explain to me when this morning the shares were between 8p-9p then went down to 8p-8.5p. Now after a \u00a320,000 buy , does say unknown, obviously it a buy as it went to 8p-8.75p. I don\u2019t understand why?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "8.375",
          "thread_title": "Why no Raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=982F8279-E12F-4026-B35A-8A00F576BFE7"
        },
        "ingested_at": "2026-01-29T10:43:53.573968+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252049-Diesel20--4725394",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.555050",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fchristopher-mcconville-53b834a9_crism-thera-regulatory-news-live-crtx-rns-activity-7371145827924467712-Nv7h%3Futm_medium%3Dios_app%26rcm%3DACoAAEW6vHoB5r2ccWrDSX5ZG17BGJdS1-EAnvM%26utm_source%3Dsocial_share_send%26utm_campaign%3Dmail&data=05%7C02%7C%7C9e25539ed49948ff38c508ddefd97b9e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638930439538637327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=k3ANYxVOoVmKaNFjyWgRoQ7I%2FfdXA80Y31dU1PdaE98%3D&reserved=0",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "On LinkedIn",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=908E4756-F263-4DC3-8747-97C9E5C0EB75"
        },
        "ingested_at": "2026-01-29T10:43:53.573989+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20250759-Theodoro--1933910",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.556482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Theodoros",
          "content": "How is it that after an RNS so positive, the price can drop?  Doesn't make sense!!",
          "sentiment": 0.0,
          "engagement": "147",
          "price_at_post": "11.50",
          "thread_title": "Price drop",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=E505754F-3993-4064-806C-A7769B6CE4DE"
        },
        "ingested_at": "2026-01-29T10:43:53.574008+00:00"
      },
      {
        "event_id": "SOCIAL-2Sep20251231-Diesel20--8451416",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "You must be joking this is massive!!! Approval for phase 2 clinical trial",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "You must be JOKING",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=FA2EA27D-8E87-4E88-833C-3041E92DD6A5"
        },
        "ingested_at": "2026-01-29T10:43:53.574027+00:00"
      },
      {
        "event_id": "SOCIAL-1Sep20250735-capri--5592158",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557786",
        "source": "LSE_CHAT",
        "data": {
          "author": "capri",
          "content": "Things are going very well here! New trials starting soon",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "10.50",
          "thread_title": "RE: Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-29T10:43:53.574046+00:00"
      },
      {
        "event_id": "SOCIAL-12Aug20250910-Diesel20--8418803",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Great news. Should see a good raise on this news",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-29T10:43:53.574070+00:00"
      },
      {
        "event_id": "SOCIAL-10Jul20251819-Diesel20-69859564",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Can someone explain what the latest RNS means? Thanks",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.25",
          "thread_title": "Understanding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=668A365C-4662-4CCC-82EB-0231EC5AAF9E"
        },
        "ingested_at": "2026-01-29T10:43:53.574116+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251210-ThisShar--5751144",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559056",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Thats the problem with a seed, most want the fruit now, if not they will find a new tree where they can eat! Hence with currnet low volumes... we are talking 4 trades today, then this will fall back signifcantly from here, now matter how many fluffy RNS's they put out.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Countach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=081DCE8A-1B39-471A-B065-D74727F51A96"
        },
        "ingested_at": "2026-01-29T10:43:53.574139+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251017-Countach-69590542",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is a seed in more ways than in name. You plant a seed, you water it and it grows. People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game. This will grow and patience will reward.",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.50",
          "thread_title": "RE: New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-29T10:43:53.574158+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251714-Geng--7824279",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "To shift those 6.6 Million shares from institutional to retail!",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-29T10:43:53.574177+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261741-sajy--7879678",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.314749",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The next news here should be the FDA ODD, that should be anytime now as it was submitted late October. If granted and I can think of no reason why it wouldn\u2019t be as we have already received the equivalent from the MHRA, can see it spiking on the day. Hopefully volume that day will clear the last few placing shares.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574197+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261712-KitKatCh-79677356",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315259",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "They won't be there forever and the next update could create some real demand for these shares. \u00a315-20mill mcap does not look overambitious given the impending study and potential newsflow.  Equivalent to 30-40p. GLA, DYOR. KKC",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574234+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261418-Magic-or-71876523",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those 9p placing shares are a real drag at the moment.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574255+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261854-KitKatCh-13988439",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316120",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Chatter here and over on Twitter re CRTX is slowly building\u2026! Looks like a few starting to load up.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574274+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72-71814788",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316534",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574293+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy-35413991",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316947",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574312+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72--2378572",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317375",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574336+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or--7291921",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574367+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh--4446359",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318222",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574386+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy--4575290",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318643",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-29T10:43:53.574405+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh-41374955",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319061",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-29T10:43:53.574424+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh--4524798",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319491",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-29T10:43:53.574442+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh--1199045",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319909",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-29T10:43:53.574470+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu--6470813",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320334",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-29T10:43:53.574499+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20-65878666",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-29T10:43:53.574517+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu-40632119",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321200",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-29T10:43:53.574536+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor--7378639",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321611",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-29T10:43:53.574555+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy-14619013",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322027",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-29T10:43:53.574574+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor-21524521",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322447",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-29T10:43:53.574608+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or-60002224",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-29T10:43:53.574629+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or--5138088",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-29T10:43:53.574648+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu--3993389",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323702",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-29T10:43:53.574667+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy--6730878",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324123",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-29T10:43:53.574685+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan-84420505",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-29T10:43:53.574706+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77--7882223",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324952",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-29T10:43:53.574739+00:00"
      },
      {
        "event_id": "SOCIAL-Today1251-bunsenbu--1246325",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860161",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Just need to clear this overhang before ODD and grants etc land Everyday there are nice delayed buys Shouldn\u2019t bee too long, think HEMO just before it 10x\u2019d IMO",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-01-30T23:27:15.381024+00:00"
      },
      {
        "event_id": "SOCIAL-Today0938-bunsenbu-25399632",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860601",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Agreed This really could be one of the great stories of 2026",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-01-30T23:27:15.381059+00:00"
      },
      {
        "event_id": "SOCIAL-Today0920-Diesel20-63713656",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.861031",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Announcement will be coming soon This is going to be big!! Watch the RNS. Exciting.",
          "sentiment": 0.0,
          "engagement": "29",
          "price_at_post": "10.25",
          "thread_title": "ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-01-30T23:27:15.381078+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260902-bunsenbu--5509490",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:45.216448",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yup. Placing clearing. ODD imminent. \u00a35m cap is beyond insane",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.381114+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or--1869132",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.820595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-30T23:27:15.381137+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR--6156393",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821132",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381156+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy-54377218",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821670",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-01-30T23:27:15.381173+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or--8721876",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381192+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu-67154010",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822716",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381209+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng-44214657",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381227+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy--1851926",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823801",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381245+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy--21471025",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,290",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381263+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu-67719609",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824828",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381281+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu-68993549",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825359",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381299+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or--1701962",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381318+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu--4244277",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826563",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381336+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach--7090658",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826983",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381354+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni--8413705",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827427",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381372+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy-50473141",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827841",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381390+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251549-Techtoni-63233311",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828299",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "I've been looking for this for a while, and if things go as the BOD expects (inc Orphan Drug application) then this will undoubtedly have a decent rise next year (with warrants set at 24p, I'm guessing that price is almost nailed on anyway at some point) BUT, I'm guessing their cashburn is around 100k/month and a million needed for the trials... With circa \u00a3700-800k in the bank atm , this will undoubtedly need some sort of fundraise. Timescales are usually pushed back in biotech, so I'm guessing the Q1 for trials will be at the later end or early Q2... That would take the cash burn down to almost fumes.. Grants are usually okay but do not plug the full gap. So I'm guessing they either fundraise before trial start or hope for a decent preliminary rise and do a fundraise into the increasing share price next Q1. The price of which is anyone's guess.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "Fundraise or Grants ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6DEA5666-F205-4C50-8110-C82C87B82C9C"
        },
        "ingested_at": "2026-01-30T23:27:15.381408+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251445-Magic-or-19942552",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\" Great but seeking and securing are two different things.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381426+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251432-bunsenbu--6239882",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829182",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read the RNSs - They\u2019re expecting grants!",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381448+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251424-Magic-or-80162743",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "@sajy \"Not necessarily, they only need \u00a31M for the first part of the trial.\" There you go, you said they need more cash than they have. From results Net cash at 12 September 2025 of \u00a3906,864 How much do you think they will have by the time they start the trial.   Management have already demonstrated that they will place at massive discount to the share price.   NHS grants may help but I'm pretty sure it won't cover the costs of the trial.    I have a small holding at 14p, luckily it's only small as like you I think they have  an interesting product, but they don't have the cash.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381466+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251147-bunsenbu-52454284",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830276",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If you read the RNSs you\u2019ll see they\u2019re expecting grants too Grants from the NHS I might add",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381483+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251014-sajy-62939255",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830697",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not necessarily, they only need \u00a31M for the first part of the trial. I am hoping they treat the first few patients and report positive safety and efficacy data and then raise the small amount they need at a much higher share price.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381501+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251008-Magic-or-79892110",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "With about \u00a3800k in the bank the market knows another discount placing is on it's way.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381518+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250751-sajy--5954367",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831550",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not long to go, with the phase 2 registrational trial starting in Q1 26. It\u2019s very rare for a company to be in this position and only have a Mcap of \u00a35M. I am convinced the rerate will begin soon, decent volume yesterday and looks like peeps starting to take positions.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-01-30T23:27:15.381536+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252008-gwm121--9122745",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.832053",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "I thought crism had developed a drug release system for brain tumours, and that the original crew reported a small trial as high effiecy untruthfully wrecking the share price. I see a poster below talks about a prostate cancer delivery system, if this is so its very interesting as prostate canvcer is common and the psa test makes many false positives resulting in intrusive biopsies  . So I googled research and reviews on crism, and page after page came up withdrawn. Anyone got a clear idea what this company does now ..",
          "sentiment": 0.0,
          "engagement": "747",
          "price_at_post": "12.00",
          "thread_title": "What does crism do!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DDF20205-8A1B-4AAE-B0BE-C02260650174"
        },
        "ingested_at": "2026-01-30T23:27:15.381554+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252210-sajy--4485168",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.542248",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I can see a similar rise to Hemo happening here. Hemo started to dose patients in a phase 1 trial and after treating a couple of patients it reported no safety issues and early signs of efficacy. The share price rose from around \u00a31.70 t0 \u00a315.00 If we also report no safety issues and early signs of efficacy after treating the first few patients then I can't see why we can't hit a \u00a31.00.  Also don't forget ours is a phase 2 registrational trial, we are much further ahead than Hemo. Even at a pound we will have a Mcap of \u00a340M which is peanuts.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "RE: Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-30T23:27:15.381572+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20251121-sajy--6763088",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543061",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A bit of info on the phase 2 trial starting Q1 26 for anyone new here. The trial will be split into two parts, the first part of the trial will cost \u00a31M and as it is an open label trial the company will be providing regular updates on safety and efficacy.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-01-30T23:27:15.381590+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250911-bunsenbu-22075881",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543885",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Potentially the highest reward share on the mkt \u00a34m cap about to start in human trials P2, all the top accreditation secured. #CRTX. I think it\u2019s a 10x mover within 6 months. DYOR",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.75",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-30T23:27:15.381607+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251939-HideInPl--2881592",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.544692",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Exactly, it's a vicious circle in a way. Institutions know they can lowball companies, not enough competition, everyone keeps lowering forward valuations... Add to that the risk averse nature of the average UK investor... But we know that. So we can't be surprised when it happens. I'm trying to ignore the negative mindset briefly and see the potential. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-30T23:27:15.381625+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251742-Magic-or-58089941",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.545478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Well doing a massive discount placing doesn't help sentiment.   That's the problem, there's always another placing just around the corner with these startup micro stocks.   Just when people were showing profit wham bam 50% discount placing.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-30T23:27:15.381643+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251619-HideInPl--8156878",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.546308",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "A bit more research shows the frustrating thing about AIM. In UK, even a clinical-stage oncology stock rarely trades above 1\u20132\u00d7 rNPV. On NASDAQ, equivalent stage companies often trade at 3\u20135\u00d7 the same rNPV. So although UK is frustratingly illiquid and cautious, it could be that CRTX is worthy of a 20p-40p share price, especially if it can increase the cash runway. Could be an interesting risk/reward play here. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-30T23:27:15.381661+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251615-HideInPl--3427581",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547127",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "After a little research there's an estimated ~13,000 new cases of GBM per year in the U.S. plus a similar order of magnitude in Europe, so ~25,000 global developed markets cases of this horrid, aggressive and hard to treat disease. The current global GBM market for therapies is roughly $2\u20133 billion per year apparently. Some rough assumptions on cost, market share and royalty % easily return annual revenues of \u00a3100m a year before you layer in the platform optionality of other programmes. This bullish case then needs PoS, time and discount rates applied, that'd what brings the rNPV down to about \u00a310m now. All IMHO and quick maths. More than 2x today's market cap",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-01-30T23:27:15.381679+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251400-HideInPl-86967705",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547938",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Still so quiet... Just 4 trades today apparently and yet the science seems so exciting. Frustrating that the UK can't back this kind of innovative company with better capital markets like in the US. UK dare not dream big. It isn\u2019t because British science is worse; it\u2019s because capital, liquidity, and perceived exit pathways are all richer in the U.S. Time for UK investors to grow a pair. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-30T23:27:15.381697+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250934-Magic-or-50836966",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.548723",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Have you not learnt how the pharma market works yet, they are only interested in drugs that keep you as a customer for life, nothing about making people better sooner.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-30T23:27:15.381715+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251951-oldrig--1120521",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.549504",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldrig",
          "content": "Normally, a company with a successful phase 2 trial drug for such unmet medical needs, will be snapped by big pharma in no time, in the range of hundreds millions or a few billions easily.",
          "sentiment": 0.5,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-30T23:27:15.381733+00:00"
      },
      {
        "event_id": "SOCIAL-16Oct20250536-bunsenbu--7523188",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.550340",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve also taken a potion and researching it further, frankly I\u2019m blown away Running a registration-grade Phase 2 aligned with MHRA for marketing submission Is unbelievable for an AIM company. Almost all P2 are not like this It means they can commercialise the product before P3 \ud83e\udd29\ud83e\udd29\ud83e\udd29",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-30T23:27:15.381752+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20251914-HideInPl-56453483",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551115",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Just taken a new position recently as I build out my medtech/biotech portfolio. Usual industry funding risk, but my research came up good and feels like a top risk/reward balance for me. Gla HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "11.00",
          "thread_title": "Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-01-30T23:27:15.381769+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252158-bunsenbu--2952027",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551920",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Article in the Daily Telegraph today: lammy:%20Labour%20%E2%80%98up%20for%20the%20fight%E2%80%99%20on%20prostate%20cancer",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-30T23:27:15.381787+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250815-tbcx-86867087",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.552718",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is unbelievable stuff to have delivered the science that looks to be more effective at killing prostate cancer than existing methods. Huge credit to them and a massive commercial opportunity.",
          "sentiment": 0.0,
          "engagement": "768",
          "price_at_post": "11.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-30T23:27:15.381806+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250718-JOHNO77--9257341",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.553508",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Nice update",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "11.00",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-01-30T23:27:15.381825+00:00"
      },
      {
        "event_id": "SOCIAL-12Sep20251308-Diesel20--8194764",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.554282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Could anyone explain to me when this morning the shares were between 8p-9p then went down to 8p-8.5p. Now after a \u00a320,000 buy , does say unknown, obviously it a buy as it went to 8p-8.75p. I don\u2019t understand why?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "8.375",
          "thread_title": "Why no Raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=982F8279-E12F-4026-B35A-8A00F576BFE7"
        },
        "ingested_at": "2026-01-30T23:27:15.381843+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252049-Diesel20-87237661",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.555050",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fchristopher-mcconville-53b834a9_crism-thera-regulatory-news-live-crtx-rns-activity-7371145827924467712-Nv7h%3Futm_medium%3Dios_app%26rcm%3DACoAAEW6vHoB5r2ccWrDSX5ZG17BGJdS1-EAnvM%26utm_source%3Dsocial_share_send%26utm_campaign%3Dmail&data=05%7C02%7C%7C9e25539ed49948ff38c508ddefd97b9e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638930439538637327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=k3ANYxVOoVmKaNFjyWgRoQ7I%2FfdXA80Y31dU1PdaE98%3D&reserved=0",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "On LinkedIn",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=908E4756-F263-4DC3-8747-97C9E5C0EB75"
        },
        "ingested_at": "2026-01-30T23:27:15.381862+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20250759-Theodoro--3808105",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.556482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Theodoros",
          "content": "How is it that after an RNS so positive, the price can drop?  Doesn't make sense!!",
          "sentiment": 0.0,
          "engagement": "147",
          "price_at_post": "11.50",
          "thread_title": "Price drop",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=E505754F-3993-4064-806C-A7769B6CE4DE"
        },
        "ingested_at": "2026-01-30T23:27:15.381880+00:00"
      },
      {
        "event_id": "SOCIAL-2Sep20251231-Diesel20--3796001",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "You must be joking this is massive!!! Approval for phase 2 clinical trial",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "You must be JOKING",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=FA2EA27D-8E87-4E88-833C-3041E92DD6A5"
        },
        "ingested_at": "2026-01-30T23:27:15.381898+00:00"
      },
      {
        "event_id": "SOCIAL-1Sep20250735-capri--1408313",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557786",
        "source": "LSE_CHAT",
        "data": {
          "author": "capri",
          "content": "Things are going very well here! New trials starting soon",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "10.50",
          "thread_title": "RE: Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-30T23:27:15.381916+00:00"
      },
      {
        "event_id": "SOCIAL-12Aug20250910-Diesel20--2622733",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Great news. Should see a good raise on this news",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-01-30T23:27:15.381934+00:00"
      },
      {
        "event_id": "SOCIAL-10Jul20251819-Diesel20-78115369",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Can someone explain what the latest RNS means? Thanks",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.25",
          "thread_title": "Understanding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=668A365C-4662-4CCC-82EB-0231EC5AAF9E"
        },
        "ingested_at": "2026-01-30T23:27:15.381951+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251210-ThisShar--7633230",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559056",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Thats the problem with a seed, most want the fruit now, if not they will find a new tree where they can eat! Hence with currnet low volumes... we are talking 4 trades today, then this will fall back signifcantly from here, now matter how many fluffy RNS's they put out.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Countach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=081DCE8A-1B39-471A-B065-D74727F51A96"
        },
        "ingested_at": "2026-01-30T23:27:15.381970+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251017-Countach--2210351",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is a seed in more ways than in name. You plant a seed, you water it and it grows. People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game. This will grow and patience will reward.",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.50",
          "thread_title": "RE: New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-30T23:27:15.381988+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251714-Geng--6362227",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "To shift those 6.6 Million shares from institutional to retail!",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-01-30T23:27:15.382006+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261741-sajy-12460459",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.314749",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The next news here should be the FDA ODD, that should be anytime now as it was submitted late October. If granted and I can think of no reason why it wouldn\u2019t be as we have already received the equivalent from the MHRA, can see it spiking on the day. Hopefully volume that day will clear the last few placing shares.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382023+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261712-KitKatCh-31319316",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315259",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "They won't be there forever and the next update could create some real demand for these shares. \u00a315-20mill mcap does not look overambitious given the impending study and potential newsflow.  Equivalent to 30-40p. GLA, DYOR. KKC",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382042+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261418-Magic-or-25470963",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those 9p placing shares are a real drag at the moment.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382059+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261854-KitKatCh--5650228",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316120",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Chatter here and over on Twitter re CRTX is slowly building\u2026! Looks like a few starting to load up.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382077+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72-73711555",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316534",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382106+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy-51518894",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316947",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382134+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72--7186205",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317375",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382152+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or--5685280",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382170+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh--3676516",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318222",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382189+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy--2873312",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318643",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-01-30T23:27:15.382207+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh--3167867",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319061",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-30T23:27:15.382225+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh--8071481",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319491",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-30T23:27:15.382243+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh--4772335",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319909",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-30T23:27:15.382261+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu--6753364",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320334",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-30T23:27:15.382279+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20--6815558",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-01-30T23:27:15.382297+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu-72993805",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321200",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-30T23:27:15.382315+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor-16170159",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321611",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-30T23:27:15.382333+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy--1380483",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322027",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-30T23:27:15.382352+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor--6096496",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322447",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-01-30T23:27:15.382370+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or--3213905",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-30T23:27:15.382388+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or-14068817",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-30T23:27:15.382406+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu-56491079",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323702",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-30T23:27:15.382423+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy-34389797",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324123",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-30T23:27:15.382441+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan-68901678",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-30T23:27:15.382459+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77-16944285",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324952",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-01-30T23:27:15.382477+00:00"
      },
      {
        "event_id": "SOCIAL-Today1837-KitKatCh--5277994",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.352701",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Price looking very solid at this level.  The next leg up will surely come as we edge towards the trial. IMO DYOR KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707704+00:00"
      },
      {
        "event_id": "SOCIAL-Today1610-Sundayro--6597255",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.353155",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like its creeping up slowly",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707745+00:00"
      },
      {
        "event_id": "SOCIAL-Today0744-bunsenbu--4636735",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.353597",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s my view that significant players are buying in big here We\u2019ve seen so many large delayed buys, I think something big could really happen here GL all holders So much news in the coming days and weeks",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707783+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261720-bunsenbu-35478945",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354019",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "\u00a330k delayed buy from today Big money loading for sure",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707806+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261716-Diesel20-23806550",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354459",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Thank you magic-orb. I can see that now. The buys today have been massive but no real uplift. Still don\u2019t understand.",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707825+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261632-bunsenbu--6888400",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354872",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I wonder if I\u2019ll ever see a registration grade phase 2 in human cancer trial that\u2019s valued under \u00a310 million in my life time again",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707844+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261611-KitKatCh-83574569",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.355374",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice reversal, c'mon let's regain 13p",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707862+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261455-Magic-or-12402840",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.355782",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "The 157,951 and 78999 were probably sells first thing this morning.",
          "sentiment": 0.0,
          "engagement": "1,210",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707884+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261309-Traa-dy--78124615",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.356202",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Undoubtedly. but they are getting less and less.  Better to get rid of them before news flow.",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707902+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261052-kand72-13983922",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.356610",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I bet there are still placing shares at 9p out there",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707922+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261045-Diesel20-26013591",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357029",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Little bit confused. There are almost half million buyers this morning. Share prices have gone down a little. Why? Apart from this all looks pretty good!!",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707940+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261406-KitKatCh-22370466",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357485",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Very exciting to see that!  Thanks  Kand72 Still states start date of March 26 so all on track KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707958+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261357-bunsenbu-40243759",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357910",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Wow awesome \ud83e\udd29 This could be such a huge mover",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707975+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261343-kand72--5953553",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.358387",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "Linkedin https://www.linkedin.com/posts/christopher-mcconville-53b834a9_clinicaltrialsgov-activity-7421927769019785216-GMeA?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAlnBd0BpB6PHzg0dVDHb53BAvB9SOxW2wo CTG page https://clinicaltrials.gov/study/NCT07356973 I am delighted to share that CRISM Therapeutics Phase II clinical trial for ChemoSeed, the locally implantable irinotecan drug delivery platform is now officially published on ClinicalTrials.gov (Identifier: NCT07356973). This study represents a key step in translating my work on ChemoSeed, designed to deliver high local doses of chemotherapy directly to the resection margins of glioblastoma tumours, into clinical evaluation. Preclinical research showed promising control of residual tumour cells and a pathway to more effective, less toxic treatment strategies. I want to thank the entire multidisciplinary team, our clinical partners, collaborators, CDMOs, CROs and especially the patients and families who make clinical research possible. Our progress reflects years of collaborative effort in drug delivery, oncology, and translational medicine. Onward as we continue advancing this innovation toward meaningful impact for patients facing glioblastoma.",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "13.00",
          "thread_title": "Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-06T23:29:42.707994+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261140-bunsenbu-86868055",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.358815",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Must be some big boys going through #CRTX Can sell over \u00a320k but big premiums wanted to buy Loads of news due, I really don\u2019t think it can stay near this mkt cap for much longer",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Registration Grade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21EDF6D0-B9F6-43FA-972A-1CF9FC43F8F2"
        },
        "ingested_at": "2026-02-06T23:29:42.708012+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260755-bunsenbu-27293678",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.359255",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "People finally starting to take serious note of \u2018registration grade\u2019 All the top level certification but importantly means - potential for no P3 What that means is this, if all successful, could be taken out for \u00a3500m in a year. Dream scenario of course but if everything went right, \u00a3500m and north of\u2026",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "Registration Grade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21EDF6D0-B9F6-43FA-972A-1CF9FC43F8F2"
        },
        "ingested_at": "2026-02-06T23:29:42.708029+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262207-sajy-42266783",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.359664",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I'm not even thinking as far as phase 3 trials as I am absolutely convinced that if in the first part of the phase 2 trial we see good safety and early signs of efficacy then we will either get taken over or we will sign a licensing deal for mega bucks. As their is no current standard of care for Glioblastoma we will be in demand.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-06T23:29:42.708047+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262126-KitKatCh--4543660",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.360096",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Blimey... So - 'Registration grade' ph2 trials are designed to confirm and support swifter regulatory approval as opposed to standard ph2 trials which are much more exploratory in nature.  Glad i looked this up....  Registration grade ph2 trials can potentially REPLACE or reduce ph3 requirements...! I think most missed this info, myself included until tonight....",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-06T23:29:42.708065+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261903-makemore-78115058",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.360807",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Might see a blue day tomorrow",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-06T23:29:42.708083+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261811-KitKatCh--2977434",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.361538",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "\ud83d\ude33\ud83d\ude33 wow massive delayed buys there from yesterday!! KKC.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-06T23:29:42.708117+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261742-bunsenbu--2402468",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.362258",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Guys I\u2019m telling you (my opinion of course) this is a multi bagger - look at those delayed trades Big names are buying in I reckon. This is a beast of a Pharma REGISTRATION GRADE P2 sub \u00a310m \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-06T23:29:42.708139+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261738-makemore-79661922",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.362937",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Check the delayed trades just published.  2 x 500k shares so one million in total bought yesterday at an average of 13.95p!!! Someone knows whats coming and I think it might be good news \ud83d\ude06",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-06T23:29:42.708158+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261652-KitKatCh--5317528",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.363651",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Another blue day here, lovely jubbly....! KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-06T23:29:42.708177+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261504-bunsenbu-64166197",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.364249",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Being 'registration grade' means 'potential' is massively skewed into investors favors. And certainly in the near term - weeks to months 'Potential' becomes more significant when waiting for the results. However, when the results are due, I wouldn't mind betting the SP will be near triple digits Might be hard to believe now but from sub \u00a310m cap, it could come a lot easier than one thinks",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-06T23:29:42.708195+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261455-gilyard--7435236",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.364656",
        "source": "LSE_CHAT",
        "data": {
          "author": "gilyard",
          "content": "All good but always remember your word POTENTIAL.",
          "sentiment": 0.0,
          "engagement": "53",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-06T23:29:42.708214+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261224-makemore--6177057",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.940621",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "I think obtaining Orphan DD status will greatly assist the market cap if it is granted. Reading more about this it will add weight and credibility to the product and company as a whole. This company right now is soooo under valued and soo under the radar, not many investors are aware of the potential here.",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-06T23:29:42.708232+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261206-bunsenbu--3481870",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.941279",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "End of P3* sorry typo \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-06T23:29:42.708251+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261206-Sundayro-73422782",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.941880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Great volume again, those placing shares being churned nicely.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-06T23:29:42.708286+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261205-bunsenbu--2988119",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.942530",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s almost unheard of - at sub \u00a310m mkt cap to have to the top level accreditation - \u2018REGISTRATION GRADE\u2019 Most P2 trials aren\u2019t registration grade It means, amongst other things since as credibility etc but also - if successful, they will be able to license the drug before or bypassing P3 Ie by the end of P3 this could be, COULD, in excess of \u00a3500m and taken out by big Pharma DYOR guys and GLA",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-06T23:29:42.708307+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261054-KitKatCh--1823470",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.943149",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Excellent thanks.  I can now see the target is 90 days but sometimes it extends to 120days, none the less we are  very close.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-06T23:29:42.708326+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261046-makemore--4756686",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.943724",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Kitkat fda website says they are aiming to process in 90 days. Given our submission rns of October 90 days from then would be Jan 28th. Now of course Christmas holidays fell across that period so we possibly need to add a week, so tomorrow onwards?? Here is a link to the ODD database, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "12.75",
          "thread_title": "RE: Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-06T23:29:42.708344+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261035-KitKatCh--6626191",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.944301",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice chunky delayed buy from 1st thing. KKC.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-06T23:29:42.708363+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261028-KitKatCh--8190172",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.944874",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "To be honest this has huge potential even without the ODD, but with it, even better. You say 90 days since ODD submission,  what is the usual response time for ODD decisions?",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-06T23:29:42.708381+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260922-bunsenbu--7779417",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.945478",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Imminent For me this is a load up stock and wait for 10x this year CEO took c\u00a3100k recently Just research REGISTRATION GRADE\u2026 and you\u2019ll understand why @ sub \u00a310m cap this is going places",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-06T23:29:42.708399+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260907-makemore--2785816",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.946021",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "90 days have passed since the submission, news must be imminent, anyone heard any chatter about this?",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "12.50",
          "thread_title": "Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-06T23:29:42.708417+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260739-bunsenbu--1800373",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.946630",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Everyone needs to research the significance of \u2018registration grade\u2019 P2 in human cancer trial It\u2019s literally unheard of at this mkt cap We\u2019re priced as a pre clinical Pharma,  it P2 Registration grade also means if all is successful, can bypass P3 an straight to licensing \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708435+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262006-Traa-dy---2062470",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.947197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Decent day, but the placing overhang has some more to go.  Looking forward to news flow",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708454+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261712-Value4Mo--8727103",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.947742",
        "source": "LSE_CHAT",
        "data": {
          "author": "Value4Money",
          "content": "Been waiting patiently here too. Looked to sell when this was in the 20's but thought it had potential to do better things. Robin may come good for us in the end! :)",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708472+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261559-EIDR-49474979",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.948362",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Great move, I just left mine on the bottom drawer, they cost me nothing so I thought there was no hurry to sell. Let\u2019s keep our fingers crossed. Good luck.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708490+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261507-Sundayro--4533382",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.948877",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Great volume today, those placing shares are either all flipped or very close too. When news lands there will be nothing holding it back and it will fly!",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.75",
          "thread_title": "RE: \u2018Registration Grade\u2019 -",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=7C3546F2-C1C5-4C34-BB07-2E3AFD0D9788"
        },
        "ingested_at": "2026-02-06T23:29:42.708509+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261436-gilyard--3581211",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.949395",
        "source": "LSE_CHAT",
        "data": {
          "author": "gilyard",
          "content": "Yes held all mine. Purchased an extra chunk six or nine months ago which seems to have been a good idea.",
          "sentiment": 0.0,
          "engagement": "53",
          "price_at_post": "13.00",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708527+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261408-mike001--1971847",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.949873",
        "source": "LSE_CHAT",
        "data": {
          "author": "mike001",
          "content": "Yes me too.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "13.25",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-06T23:29:42.708546+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261353-EIDR-10193345",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.950385",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "It is very possible, there were only ever a small number of us there, except for the no vote. We may all be able to form a survivors reunion.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708566+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261350-EIDR--4125077",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.950869",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "We may get the last laugh after all. Fingers crossed.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-06T23:29:42.708584+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261345-bunsenbu--1272130",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.951444",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "What most Phase 2 trials are vs registration-grade Typical Phase 2: \u2022\tSmall \u2022\tTests dosing \u2022\tLooks for signals \u2022\tOften not strong enough for approval Registration-grade Phase 2: \u2022\tPre-agreed with regulators \u2022\tPowered statistically \u2022\tUses endpoints regulators accept \u2022\tBuilt with strict manufacturing controls \u2022\tOften run under GMP conditions \ud83d\udc49 In some cancers \u2014 especially rare ones like Glioblastoma \u2014 a strong Phase 2 can sometimes support approval without needing Phase 3. That is a BIG deal. (Think time saved = years, dilution avoided = massive shareholder benefit.)",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.25",
          "thread_title": "\u2018Registration Grade\u2019 -",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=7C3546F2-C1C5-4C34-BB07-2E3AFD0D9788"
        },
        "ingested_at": "2026-02-06T23:29:42.708602+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261327-Traa-dy--26026294",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.951943",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "This from 1st Sept. RNS explains the simple and hopefully effective treatment for aglioblastoma cancer that has a terrible prognosis.  Hopefully it will prove effective; ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026.",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "13.50",
          "thread_title": "Simplicity , hopefully  genius",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=292B9D2D-A11E-4544-A51A-E6DB4CCC959F"
        },
        "ingested_at": "2026-02-06T23:29:42.708621+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261315-whooshba--3374833",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.952426",
        "source": "LSE_CHAT",
        "data": {
          "author": "whooshbang",
          "content": "Yup!",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-06T23:29:42.708639+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261310-OblastTi--3982483",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.952922",
        "source": "LSE_CHAT",
        "data": {
          "author": "OblastTigers",
          "content": "Still here",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-06T23:29:42.708657+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261259-cossy--4758042",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.953413",
        "source": "LSE_CHAT",
        "data": {
          "author": "cossy",
          "content": "Yes",
          "sentiment": 0.0,
          "engagement": "1,674",
          "price_at_post": "13.50",
          "thread_title": "Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-06T23:29:42.708675+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261140-Shaza-48379735",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.953904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shaza",
          "content": "Yes\ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708693+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261133-Hammer11-22005279",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.675635",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hammer11",
          "content": "I still own about \u00a33000 of these from back then. Didn`t I meet you at one of the shareholder meetings in London?",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708712+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261122-sajy--3638686",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676087",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "You are right pal it was \u00a318.00, put dot in wrong place but Mcap is correct. Considering this is a registration grade phase 2  trial then you can see what will happen if we announce good safety and early signs of efficacy. A few big months coming up starting this month with FDA ODD which is imminent. The first patient treated next month.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708730+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261110-EIDR--8437545",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676523",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Has anyone else from AMUR days held on to these, or am I the only one?",
          "sentiment": 0.5,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-06T23:29:42.708748+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261109-bunsenbu--4735511",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676953",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Wow. So even at \u00a3100m we would be unfairly valued, once we have first dosing confirmed HEMO nowhere near the stage or certification level of CRTX",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708767+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261109-Diesel20--4333384",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.677387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Sorry sajy. You will see it was \u00a318.00 per share, but \u00a31.80 would be good.",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708785+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261106-sajy-46237390",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.677795",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly Hemo was a phase 1 trial and ours is a registration grade phase 2 trial. When Hemo announced that first couple of patients had seen seen good safety and early signs of efficacy their share price jumped to \u00a31.80 and had a Mcap of over \u00a3100M.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708803+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261102-Sundayro-52776168",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.678226",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "So potentially upto a 1000% ?",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708820+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261054-bunsenbu--3327415",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.678665",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "What was their mkt cap? Do they have FDA ODD & MHRA? Doubt it, unheard of to have that level of accreditation \u00a37m mkt cap, normally see these sorts of values for pre clinical GL holders, I\u2019ve been in months waiting for FDA ODD & first dosing. Well timed anyone that bought first thing!!",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708839+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261047-Diesel20--4943012",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "HEMO went to 1800 per share on a Phase 1 trial. This is Phase 2 Who knows!!!",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708857+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261043-Sundayro--7074549",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679539",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Could be placing shares flipped. I happened to stumble across this on X. Maybe there has been others that have seen it there. Sometimes it doesn't take much to get an undervalued share moving. As I said I'm quite new to Pharma shares but seems very undervalued to it's piers. For those with more knowledge than I. Whats peoples targets here?",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708874+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261038-bunsenbu--6249861",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679963",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Tbf theres been regular delayed trades I felt as though the placing was clearing And it clearly has. FDA ODD any day now",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708892+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261036-Magic-or-91600111",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.680379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Where's all this interest come from today? Usually there's just a few trades daily on here!",
          "sentiment": 0.0,
          "engagement": "1,210",
          "price_at_post": "12.00",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708910+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261010-Sundayro--8530189",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.680921",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like I bought in at the right time. I was praying not to see a red dot RNS this morning. I don't typical buy pharma stocks but saw it tipped on X and did some research. The FDA ODD approval will be massive. I can see a lot of big pharma sniffing round once this is approved. Plus the face that they are is ph 2 in-human cancer trails seems is much more advanced compared to similar AIM pharma companies that have \u00a350mil+ Market Caps. \u00a35mil MC is so far off the mark, a big re-rate is due.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "11.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708928+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260930-bunsenbu-33096365",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.681502",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Great to see new faces! I keep saying anyone that researches this will buy  shares Just Be patient guys - this could see pounds 200p 300p this is th type of stock to do it Top level accreditation - MHRA for an in human cancer trial @ \u00a35m cap is unheard of MHRA means they could potentially license their candidate before P3 \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "11.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708946+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260907-KitKatCh--6690124",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.681928",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "It has all the ingredients for a potential big move in the near term should things go to plan. Agree Buncey, HEMO is a good example of what can happen from a tiny mcap.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "10.75",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708964+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260901-Sundayro-82426988",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.682450",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Bought in this morning after some research the weekend. Could see a huge rise here when news lands.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "10.75",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.708982+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261251-bunsenbu--2652369",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.682973",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Just need to clear this overhang before ODD and grants etc land Everyday there are nice delayed buys Shouldn\u2019t bee too long, think HEMO just before it 10x\u2019d IMO",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.709000+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260938-bunsenbu--8272751",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.683604",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Agreed This really could be one of the great stories of 2026",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.709018+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260920-Diesel20--8861713",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.684168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Announcement will be coming soon This is going to be big!! Watch the RNS. Exciting.",
          "sentiment": 0.0,
          "engagement": "33",
          "price_at_post": "10.25",
          "thread_title": "ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.709036+00:00"
      },
      {
        "event_id": "SOCIAL-Today1251-bunsenbu--2652369",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860161",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Just need to clear this overhang before ODD and grants etc land Everyday there are nice delayed buys Shouldn\u2019t bee too long, think HEMO just before it 10x\u2019d IMO",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.709056+00:00"
      },
      {
        "event_id": "SOCIAL-Today0938-bunsenbu--8272751",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860601",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Agreed This really could be one of the great stories of 2026",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.709074+00:00"
      },
      {
        "event_id": "SOCIAL-Today0920-Diesel20--8861713",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.861031",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Announcement will be coming soon This is going to be big!! Watch the RNS. Exciting.",
          "sentiment": 0.0,
          "engagement": "29",
          "price_at_post": "10.25",
          "thread_title": "ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-06T23:29:42.709092+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260902-bunsenbu--9020819",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:45.216448",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yup. Placing clearing. ODD imminent. \u00a35m cap is beyond insane",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.709126+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or--5655441",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.820595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-06T23:29:42.709144+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR-19309003",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821132",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709163+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy-36456593",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821670",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-02-06T23:29:42.709181+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or-66570580",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709355+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu-46119307",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822716",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709374+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng-17849868",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709392+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy--1305660",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823801",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709413+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy--76363772",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,290",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709432+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu--5322226",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824828",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709450+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu-54187724",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825359",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709469+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or--3842227",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709488+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu-63720437",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826563",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709506+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach-62945366",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826983",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709524+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni-79470804",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827427",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709543+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy-23046351",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827841",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709561+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251549-Techtoni--4173798",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828299",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "I've been looking for this for a while, and if things go as the BOD expects (inc Orphan Drug application) then this will undoubtedly have a decent rise next year (with warrants set at 24p, I'm guessing that price is almost nailed on anyway at some point) BUT, I'm guessing their cashburn is around 100k/month and a million needed for the trials... With circa \u00a3700-800k in the bank atm , this will undoubtedly need some sort of fundraise. Timescales are usually pushed back in biotech, so I'm guessing the Q1 for trials will be at the later end or early Q2... That would take the cash burn down to almost fumes.. Grants are usually okay but do not plug the full gap. So I'm guessing they either fundraise before trial start or hope for a decent preliminary rise and do a fundraise into the increasing share price next Q1. The price of which is anyone's guess.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "Fundraise or Grants ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6DEA5666-F205-4C50-8110-C82C87B82C9C"
        },
        "ingested_at": "2026-02-06T23:29:42.709579+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251445-Magic-or-89052098",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\" Great but seeking and securing are two different things.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709597+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251432-bunsenbu--2346994",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829182",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read the RNSs - They\u2019re expecting grants!",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709615+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251424-Magic-or-78679913",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "@sajy \"Not necessarily, they only need \u00a31M for the first part of the trial.\" There you go, you said they need more cash than they have. From results Net cash at 12 September 2025 of \u00a3906,864 How much do you think they will have by the time they start the trial.   Management have already demonstrated that they will place at massive discount to the share price.   NHS grants may help but I'm pretty sure it won't cover the costs of the trial.    I have a small holding at 14p, luckily it's only small as like you I think they have  an interesting product, but they don't have the cash.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709633+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251147-bunsenbu--8820787",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830276",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If you read the RNSs you\u2019ll see they\u2019re expecting grants too Grants from the NHS I might add",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709652+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251014-sajy-78729913",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830697",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not necessarily, they only need \u00a31M for the first part of the trial. I am hoping they treat the first few patients and report positive safety and efficacy data and then raise the small amount they need at a much higher share price.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709670+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251008-Magic-or--8210686",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "With about \u00a3800k in the bank the market knows another discount placing is on it's way.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709689+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250751-sajy-57900874",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831550",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not long to go, with the phase 2 registrational trial starting in Q1 26. It\u2019s very rare for a company to be in this position and only have a Mcap of \u00a35M. I am convinced the rerate will begin soon, decent volume yesterday and looks like peeps starting to take positions.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-06T23:29:42.709707+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252008-gwm121--5132630",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.832053",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "I thought crism had developed a drug release system for brain tumours, and that the original crew reported a small trial as high effiecy untruthfully wrecking the share price. I see a poster below talks about a prostate cancer delivery system, if this is so its very interesting as prostate canvcer is common and the psa test makes many false positives resulting in intrusive biopsies  . So I googled research and reviews on crism, and page after page came up withdrawn. Anyone got a clear idea what this company does now ..",
          "sentiment": 0.0,
          "engagement": "747",
          "price_at_post": "12.00",
          "thread_title": "What does crism do!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DDF20205-8A1B-4AAE-B0BE-C02260650174"
        },
        "ingested_at": "2026-02-06T23:29:42.709725+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252210-sajy--6687872",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.542248",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I can see a similar rise to Hemo happening here. Hemo started to dose patients in a phase 1 trial and after treating a couple of patients it reported no safety issues and early signs of efficacy. The share price rose from around \u00a31.70 t0 \u00a315.00 If we also report no safety issues and early signs of efficacy after treating the first few patients then I can't see why we can't hit a \u00a31.00.  Also don't forget ours is a phase 2 registrational trial, we are much further ahead than Hemo. Even at a pound we will have a Mcap of \u00a340M which is peanuts.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "RE: Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-02-06T23:29:42.709743+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20251121-sajy-58317719",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543061",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A bit of info on the phase 2 trial starting Q1 26 for anyone new here. The trial will be split into two parts, the first part of the trial will cost \u00a31M and as it is an open label trial the company will be providing regular updates on safety and efficacy.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-02-06T23:29:42.709761+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250911-bunsenbu-89689673",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543885",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Potentially the highest reward share on the mkt \u00a34m cap about to start in human trials P2, all the top accreditation secured. #CRTX. I think it\u2019s a 10x mover within 6 months. DYOR",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.75",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-06T23:29:42.709779+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251939-HideInPl--3996935",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.544692",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Exactly, it's a vicious circle in a way. Institutions know they can lowball companies, not enough competition, everyone keeps lowering forward valuations... Add to that the risk averse nature of the average UK investor... But we know that. So we can't be surprised when it happens. I'm trying to ignore the negative mindset briefly and see the potential. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-06T23:29:42.709798+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251742-Magic-or-89171006",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.545478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Well doing a massive discount placing doesn't help sentiment.   That's the problem, there's always another placing just around the corner with these startup micro stocks.   Just when people were showing profit wham bam 50% discount placing.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-06T23:29:42.709816+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251619-HideInPl-76405533",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.546308",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "A bit more research shows the frustrating thing about AIM. In UK, even a clinical-stage oncology stock rarely trades above 1\u20132\u00d7 rNPV. On NASDAQ, equivalent stage companies often trade at 3\u20135\u00d7 the same rNPV. So although UK is frustratingly illiquid and cautious, it could be that CRTX is worthy of a 20p-40p share price, especially if it can increase the cash runway. Could be an interesting risk/reward play here. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-06T23:29:42.709834+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251615-HideInPl-42591379",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547127",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "After a little research there's an estimated ~13,000 new cases of GBM per year in the U.S. plus a similar order of magnitude in Europe, so ~25,000 global developed markets cases of this horrid, aggressive and hard to treat disease. The current global GBM market for therapies is roughly $2\u20133 billion per year apparently. Some rough assumptions on cost, market share and royalty % easily return annual revenues of \u00a3100m a year before you layer in the platform optionality of other programmes. This bullish case then needs PoS, time and discount rates applied, that'd what brings the rNPV down to about \u00a310m now. All IMHO and quick maths. More than 2x today's market cap",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-06T23:29:42.709852+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251400-HideInPl-27702570",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547938",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Still so quiet... Just 4 trades today apparently and yet the science seems so exciting. Frustrating that the UK can't back this kind of innovative company with better capital markets like in the US. UK dare not dream big. It isn\u2019t because British science is worse; it\u2019s because capital, liquidity, and perceived exit pathways are all richer in the U.S. Time for UK investors to grow a pair. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-06T23:29:42.709871+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250934-Magic-or-55377107",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.548723",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Have you not learnt how the pharma market works yet, they are only interested in drugs that keep you as a customer for life, nothing about making people better sooner.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-06T23:29:42.709889+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251951-oldrig--1356272",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.549504",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldrig",
          "content": "Normally, a company with a successful phase 2 trial drug for such unmet medical needs, will be snapped by big pharma in no time, in the range of hundreds millions or a few billions easily.",
          "sentiment": 0.5,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-06T23:29:42.709906+00:00"
      },
      {
        "event_id": "SOCIAL-16Oct20250536-bunsenbu--6971345",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.550340",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve also taken a potion and researching it further, frankly I\u2019m blown away Running a registration-grade Phase 2 aligned with MHRA for marketing submission Is unbelievable for an AIM company. Almost all P2 are not like this It means they can commercialise the product before P3 \ud83e\udd29\ud83e\udd29\ud83e\udd29",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-06T23:29:42.709924+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20251914-HideInPl-54465657",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551115",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Just taken a new position recently as I build out my medtech/biotech portfolio. Usual industry funding risk, but my research came up good and feels like a top risk/reward balance for me. Gla HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "11.00",
          "thread_title": "Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-06T23:29:42.709942+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252158-bunsenbu-42662563",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551920",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Article in the Daily Telegraph today: lammy:%20Labour%20%E2%80%98up%20for%20the%20fight%E2%80%99%20on%20prostate%20cancer",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-06T23:29:42.709960+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250815-tbcx-73563678",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.552718",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is unbelievable stuff to have delivered the science that looks to be more effective at killing prostate cancer than existing methods. Huge credit to them and a massive commercial opportunity.",
          "sentiment": 0.0,
          "engagement": "768",
          "price_at_post": "11.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-06T23:29:42.709978+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250718-JOHNO77-23096006",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.553508",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Nice update",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "11.00",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-06T23:29:42.709996+00:00"
      },
      {
        "event_id": "SOCIAL-12Sep20251308-Diesel20-76881912",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.554282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Could anyone explain to me when this morning the shares were between 8p-9p then went down to 8p-8.5p. Now after a \u00a320,000 buy , does say unknown, obviously it a buy as it went to 8p-8.75p. I don\u2019t understand why?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "8.375",
          "thread_title": "Why no Raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=982F8279-E12F-4026-B35A-8A00F576BFE7"
        },
        "ingested_at": "2026-02-06T23:29:42.710014+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252049-Diesel20-23592392",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.555050",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fchristopher-mcconville-53b834a9_crism-thera-regulatory-news-live-crtx-rns-activity-7371145827924467712-Nv7h%3Futm_medium%3Dios_app%26rcm%3DACoAAEW6vHoB5r2ccWrDSX5ZG17BGJdS1-EAnvM%26utm_source%3Dsocial_share_send%26utm_campaign%3Dmail&data=05%7C02%7C%7C9e25539ed49948ff38c508ddefd97b9e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638930439538637327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=k3ANYxVOoVmKaNFjyWgRoQ7I%2FfdXA80Y31dU1PdaE98%3D&reserved=0",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "On LinkedIn",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=908E4756-F263-4DC3-8747-97C9E5C0EB75"
        },
        "ingested_at": "2026-02-06T23:29:42.710032+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20250759-Theodoro-46549830",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.556482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Theodoros",
          "content": "How is it that after an RNS so positive, the price can drop?  Doesn't make sense!!",
          "sentiment": 0.0,
          "engagement": "147",
          "price_at_post": "11.50",
          "thread_title": "Price drop",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=E505754F-3993-4064-806C-A7769B6CE4DE"
        },
        "ingested_at": "2026-02-06T23:29:42.710051+00:00"
      },
      {
        "event_id": "SOCIAL-2Sep20251231-Diesel20-44499274",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "You must be joking this is massive!!! Approval for phase 2 clinical trial",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "You must be JOKING",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=FA2EA27D-8E87-4E88-833C-3041E92DD6A5"
        },
        "ingested_at": "2026-02-06T23:29:42.710068+00:00"
      },
      {
        "event_id": "SOCIAL-1Sep20250735-capri--8360220",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557786",
        "source": "LSE_CHAT",
        "data": {
          "author": "capri",
          "content": "Things are going very well here! New trials starting soon",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "10.50",
          "thread_title": "RE: Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-02-06T23:29:42.710086+00:00"
      },
      {
        "event_id": "SOCIAL-12Aug20250910-Diesel20-11409717",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Great news. Should see a good raise on this news",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-02-06T23:29:42.710120+00:00"
      },
      {
        "event_id": "SOCIAL-10Jul20251819-Diesel20--4322888",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Can someone explain what the latest RNS means? Thanks",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.25",
          "thread_title": "Understanding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=668A365C-4662-4CCC-82EB-0231EC5AAF9E"
        },
        "ingested_at": "2026-02-06T23:29:42.710140+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251210-ThisShar-17467098",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559056",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Thats the problem with a seed, most want the fruit now, if not they will find a new tree where they can eat! Hence with currnet low volumes... we are talking 4 trades today, then this will fall back signifcantly from here, now matter how many fluffy RNS's they put out.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Countach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=081DCE8A-1B39-471A-B065-D74727F51A96"
        },
        "ingested_at": "2026-02-06T23:29:42.710158+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251017-Countach--2860019",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is a seed in more ways than in name. You plant a seed, you water it and it grows. People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game. This will grow and patience will reward.",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.50",
          "thread_title": "RE: New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-02-06T23:29:42.710177+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251714-Geng-79268115",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "To shift those 6.6 Million shares from institutional to retail!",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-02-06T23:29:42.710196+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261741-sajy--3729821",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.314749",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The next news here should be the FDA ODD, that should be anytime now as it was submitted late October. If granted and I can think of no reason why it wouldn\u2019t be as we have already received the equivalent from the MHRA, can see it spiking on the day. Hopefully volume that day will clear the last few placing shares.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710214+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261712-KitKatCh--5825709",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315259",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "They won't be there forever and the next update could create some real demand for these shares. \u00a315-20mill mcap does not look overambitious given the impending study and potential newsflow.  Equivalent to 30-40p. GLA, DYOR. KKC",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710232+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261418-Magic-or--7186366",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those 9p placing shares are a real drag at the moment.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710250+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261854-KitKatCh--5499715",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316120",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Chatter here and over on Twitter re CRTX is slowly building\u2026! Looks like a few starting to load up.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710268+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72-19658310",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316534",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710286+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy--8259231",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316947",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710305+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72-33867862",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317375",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710323+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or--2379771",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710341+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh-69940368",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318222",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710359+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy-25175241",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318643",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-06T23:29:42.710377+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh-64913395",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319061",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-06T23:29:42.710395+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh--5961823",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319491",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-06T23:29:42.710413+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh-36062708",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319909",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-06T23:29:42.710431+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu--8470135",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320334",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-06T23:29:42.710449+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20-47910684",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-06T23:29:42.710467+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu-89530750",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321200",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-06T23:29:42.710485+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor-13549453",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321611",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-06T23:29:42.710503+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy-76770504",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322027",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-06T23:29:42.710521+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor-55496401",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322447",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-06T23:29:42.710540+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or--4359064",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-06T23:29:42.710558+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or--3008218",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-06T23:29:42.710576+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu-68865344",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323702",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-06T23:29:42.710594+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy-19361508",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324123",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-06T23:29:42.710612+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan--5950360",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-06T23:29:42.710630+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77--5377392",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324952",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-06T23:29:42.710648+00:00"
      },
      {
        "event_id": "SOCIAL-Today2332-C0hen--5119664",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.284754",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "For investors I see 100x dilution over the next 3 years For traders you might get the odd 20% pre practice rise between placings,  Biggest avoid in my option In 10 years could be amazing stock",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "14.00",
          "thread_title": "I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-09T23:49:44.652595+00:00"
      },
      {
        "event_id": "SOCIAL-Today2152-bunsenbu--5440960",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.285256",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Another. Massive delayed buy. This is not normal for CRTX. Constant massive delayed buys. Amazing to see",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652638+00:00"
      },
      {
        "event_id": "SOCIAL-Today2104-cyberbub--9021991",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.285673",
        "source": "LSE_CHAT",
        "data": {
          "author": "cyberbub",
          "content": "It's all about risk reward isn't it. At \u00a31 per share it would be probably weighted to the downside today, pre trial. At 14p per share, a measly \u00a39m cap, it's surely heavily weighted to the upside? NAI",
          "sentiment": 0.0,
          "engagement": "1,108",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652671+00:00"
      },
      {
        "event_id": "SOCIAL-Today1825-KitKatCh-20341125",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.286089",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice day today. Pharmas that have been recently funded at this mcap level,  with upcoming trials on AIM, are a true gift.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652702+00:00"
      },
      {
        "event_id": "SOCIAL-Today1812-sajy-35711663",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.286512",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Camkite don't come on here shouting your mouth of you pr@t. I was replying to a poster who was saying we would be diluted heavily and comparing to avct. I have spoken to the management and we are fully funded for the first part of the trial and have no intentions of funding the second part of the trial as that would involve a hugh raise. They intend to sign a licensing deal or get taken over and their won't be a shortage of takers as there is no current standard of care. Suggest you get of your lazy fat ass and talk to management for yourself.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652735+00:00"
      },
      {
        "event_id": "SOCIAL-Today1649-bunsenbu-78204267",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.286938",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If that\u2019s what he was told then that\u2019s his truth. FDA ODD has to be any day now. Over the 90 days typical Plus Christmas & NY period so expect it to be a slightly longer admission Hoping/expecting 20p+ on the first piece of news",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652767+00:00"
      },
      {
        "event_id": "SOCIAL-Today1630-Camkite-28577596",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.287369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "I\u2019m sure it will I\u2019m super bullish have been for over a year, you just don\u2019t need idiots making unrealistic claims that they\u2019ve been told there will never be any need for a placing - it\u2019s utter BS.",
          "sentiment": 0.0,
          "engagement": "7,205",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652798+00:00"
      },
      {
        "event_id": "SOCIAL-Today1629-bunsenbu--3814639",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.287781",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Lol ok. Just promise me to check in when we sail through 20p?",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652831+00:00"
      },
      {
        "event_id": "SOCIAL-Today1627-Camkite-31272617",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.288217",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "Because he\u2019s not a small time pi trader and is building a business. That has absolutely nothing to do with whether they will need funds at some point. Making stuff up and being overly unrealistic can do more harm than good when people get burnt.",
          "sentiment": 0.0,
          "engagement": "7,205",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652860+00:00"
      },
      {
        "event_id": "SOCIAL-Today1552-bunsenbu-78212059",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.288630",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Why would the CEO take \u00a3100k in the recent placing? I fancy a huge move on the next bit of news",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652890+00:00"
      },
      {
        "event_id": "SOCIAL-Today1528-Camkite--6173286",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.289033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "Sajy - mgmt told you personally there would never be any need for a placing ? Even if it\u2019s not huge they will need admin / listing / run costs costs & it\u2019s far better to do that via a raise then sell or give away equity to early. Great little company but let\u2019s be realistic.",
          "sentiment": 0.0,
          "engagement": "7,205",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652921+00:00"
      },
      {
        "event_id": "SOCIAL-Today1147-sajy-19733557",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.289450",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "TRT is also very cheap having dropped from \u00a31.40 to 67p. I have bought some and also rumours about a contract announcement, not sure how true that is.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652952+00:00"
      },
      {
        "event_id": "SOCIAL-Today1132-sajy--5632014",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.289852",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "After the first part of the trial we will either sign a licensing deal or get taken over if we see good safety and early signs of efficacy. That is what management have told me. We will not go it alone, so NO dilution.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.652989+00:00"
      },
      {
        "event_id": "SOCIAL-Today1125-C0hen--1432669",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.290278",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "Look at the amount of placings avct has needed This is 3 years behind avct You\u2019ll be diluted to an oblivion here",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.653019+00:00"
      },
      {
        "event_id": "SOCIAL-Today1124-Sundayro-41846941",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.290699",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "The significance of this being registration grade phase 2 trials is massive. Means that phase 3 trails may not be required. I expect a lot of big pharma have eyes on CRTX. Fully funded for phase 2. Grants and partnerships will come.",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.653050+00:00"
      },
      {
        "event_id": "SOCIAL-Today1119-sajy--1917856",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.291129",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Fully funded for first part of trial. Kn @b",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.653081+00:00"
      },
      {
        "event_id": "SOCIAL-Today1114-Sundayro--2258251",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.291548",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "MM's walking this up on small volume. Re-rate behaviour, reached 29p may last year. When good news lands it could smash through that!",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "14.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653126+00:00"
      },
      {
        "event_id": "SOCIAL-Today1104-bunsenbu-61417285",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.291957",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read RNSs - grants likely",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.653157+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-C0hen-19413760",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.292371",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "This is going to be diluted and diluted surely",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "14.75",
          "thread_title": "Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-09T23:49:44.653187+00:00"
      },
      {
        "event_id": "SOCIAL-Today1014-Magic-or-86095209",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.292774",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Constant 50k delayed buys coming up.   This really isn't typical for a stock like this.",
          "sentiment": 0.0,
          "engagement": "1,211",
          "price_at_post": "14.50",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653218+00:00"
      },
      {
        "event_id": "SOCIAL-Today0921-Traa-dy---3954524",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.293255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Such a low m/c it  could really motor when last of placing is done and news starts arrving.",
          "sentiment": 0.0,
          "engagement": "1,299",
          "price_at_post": "13.25",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653247+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-Sundayro--8495180",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.293735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "On the move again, This will be 20p in no time.",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "13.00",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653276+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-bunsenbu-62747939",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.294355",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s going to be huge dude. I think some big players have been buying, yet to show their hand",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653306+00:00"
      },
      {
        "event_id": "SOCIAL-Today0656-Sundayro-49506282",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.295147",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Agreed, I think once they announce ph2 trails or FDA OOD confirmation then this will rocket. Its so undervalued compared to its piers.",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653336+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20262136-makemore--1068492",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.295922",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "This share is like a heap of petrol soaked wood, just needs one spark and its BOOOOM",
          "sentiment": 0.0,
          "engagement": "765",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653368+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261959-Sundayro-52159050",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.435158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "CRISM (CRTX) \u2013 \u00a36m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a36m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "12.75",
          "thread_title": "Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-09T23:49:44.653400+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261837-KitKatCh--9085188",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.435609",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Price looking very solid at this level.  The next leg up will surely come as we edge towards the trial. IMO DYOR KKC",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653432+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261610-Sundayro-47879698",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.436021",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like its creeping up slowly",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653463+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260744-bunsenbu-33405224",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.436483",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s my view that significant players are buying in big here We\u2019ve seen so many large delayed buys, I think something big could really happen here GL all holders So much news in the coming days and weeks",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653496+00:00"
      },
      {
        "event_id": "SOCIAL-Today1837-KitKatCh--9085188",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.352701",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Price looking very solid at this level.  The next leg up will surely come as we edge towards the trial. IMO DYOR KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653527+00:00"
      },
      {
        "event_id": "SOCIAL-Today1610-Sundayro-47879698",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.353155",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like its creeping up slowly",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653556+00:00"
      },
      {
        "event_id": "SOCIAL-Today0744-bunsenbu-33405224",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.353597",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s my view that significant players are buying in big here We\u2019ve seen so many large delayed buys, I think something big could really happen here GL all holders So much news in the coming days and weeks",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653586+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261720-bunsenbu-56583610",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354019",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "\u00a330k delayed buy from today Big money loading for sure",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653617+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261716-Diesel20--3723015",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354459",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Thank you magic-orb. I can see that now. The buys today have been massive but no real uplift. Still don\u2019t understand.",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653648+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261632-bunsenbu-53869669",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354872",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I wonder if I\u2019ll ever see a registration grade phase 2 in human cancer trial that\u2019s valued under \u00a310 million in my life time again",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653679+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261611-KitKatCh--8414550",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.355374",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice reversal, c'mon let's regain 13p",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653710+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261455-Magic-or-84878197",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.355782",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "The 157,951 and 78999 were probably sells first thing this morning.",
          "sentiment": 0.0,
          "engagement": "1,210",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653742+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261309-Traa-dy--62300496",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.356202",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Undoubtedly. but they are getting less and less.  Better to get rid of them before news flow.",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653773+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261052-kand72-19710369",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.356610",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I bet there are still placing shares at 9p out there",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653806+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261045-Diesel20--4412647",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357029",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Little bit confused. There are almost half million buyers this morning. Share prices have gone down a little. Why? Apart from this all looks pretty good!!",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653838+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261406-KitKatCh--6866260",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357485",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Very exciting to see that!  Thanks  Kand72 Still states start date of March 26 so all on track KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653870+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261357-bunsenbu--4257143",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357910",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Wow awesome \ud83e\udd29 This could be such a huge mover",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653902+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261343-kand72--6637330",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.358387",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "Linkedin https://www.linkedin.com/posts/christopher-mcconville-53b834a9_clinicaltrialsgov-activity-7421927769019785216-GMeA?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAlnBd0BpB6PHzg0dVDHb53BAvB9SOxW2wo CTG page https://clinicaltrials.gov/study/NCT07356973 I am delighted to share that CRISM Therapeutics Phase II clinical trial for ChemoSeed, the locally implantable irinotecan drug delivery platform is now officially published on ClinicalTrials.gov (Identifier: NCT07356973). This study represents a key step in translating my work on ChemoSeed, designed to deliver high local doses of chemotherapy directly to the resection margins of glioblastoma tumours, into clinical evaluation. Preclinical research showed promising control of residual tumour cells and a pathway to more effective, less toxic treatment strategies. I want to thank the entire multidisciplinary team, our clinical partners, collaborators, CDMOs, CROs and especially the patients and families who make clinical research possible. Our progress reflects years of collaborative effort in drug delivery, oncology, and translational medicine. Onward as we continue advancing this innovation toward meaningful impact for patients facing glioblastoma.",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "13.00",
          "thread_title": "Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-09T23:49:44.653933+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261140-bunsenbu-73391469",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.358815",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Must be some big boys going through #CRTX Can sell over \u00a320k but big premiums wanted to buy Loads of news due, I really don\u2019t think it can stay near this mkt cap for much longer",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Registration Grade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21EDF6D0-B9F6-43FA-972A-1CF9FC43F8F2"
        },
        "ingested_at": "2026-02-09T23:49:44.653965+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260755-bunsenbu-42748490",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.359255",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "People finally starting to take serious note of \u2018registration grade\u2019 All the top level certification but importantly means - potential for no P3 What that means is this, if all successful, could be taken out for \u00a3500m in a year. Dream scenario of course but if everything went right, \u00a3500m and north of\u2026",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "Registration Grade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21EDF6D0-B9F6-43FA-972A-1CF9FC43F8F2"
        },
        "ingested_at": "2026-02-09T23:49:44.653998+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262207-sajy-29946526",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.359664",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I'm not even thinking as far as phase 3 trials as I am absolutely convinced that if in the first part of the phase 2 trial we see good safety and early signs of efficacy then we will either get taken over or we will sign a licensing deal for mega bucks. As their is no current standard of care for Glioblastoma we will be in demand.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-09T23:49:44.654029+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262126-KitKatCh-81628953",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.360096",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Blimey... So - 'Registration grade' ph2 trials are designed to confirm and support swifter regulatory approval as opposed to standard ph2 trials which are much more exploratory in nature.  Glad i looked this up....  Registration grade ph2 trials can potentially REPLACE or reduce ph3 requirements...! I think most missed this info, myself included until tonight....",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-09T23:49:44.654060+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261903-makemore-92081511",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.360807",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Might see a blue day tomorrow",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-09T23:49:44.654091+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261811-KitKatCh--1186107",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.361538",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "\ud83d\ude33\ud83d\ude33 wow massive delayed buys there from yesterday!! KKC.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-09T23:49:44.654138+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261742-bunsenbu--1116164",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.362258",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Guys I\u2019m telling you (my opinion of course) this is a multi bagger - look at those delayed trades Big names are buying in I reckon. This is a beast of a Pharma REGISTRATION GRADE P2 sub \u00a310m \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-09T23:49:44.654170+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261738-makemore--8351990",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.362937",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Check the delayed trades just published.  2 x 500k shares so one million in total bought yesterday at an average of 13.95p!!! Someone knows whats coming and I think it might be good news \ud83d\ude06",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-09T23:49:44.654202+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261652-KitKatCh--9031288",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.363651",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Another blue day here, lovely jubbly....! KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-09T23:49:44.654234+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261504-bunsenbu--1604837",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.364249",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Being 'registration grade' means 'potential' is massively skewed into investors favors. And certainly in the near term - weeks to months 'Potential' becomes more significant when waiting for the results. However, when the results are due, I wouldn't mind betting the SP will be near triple digits Might be hard to believe now but from sub \u00a310m cap, it could come a lot easier than one thinks",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-09T23:49:44.654266+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261455-gilyard--6407480",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.364656",
        "source": "LSE_CHAT",
        "data": {
          "author": "gilyard",
          "content": "All good but always remember your word POTENTIAL.",
          "sentiment": 0.0,
          "engagement": "53",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-09T23:49:44.654298+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261224-makemore--8592515",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.940621",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "I think obtaining Orphan DD status will greatly assist the market cap if it is granted. Reading more about this it will add weight and credibility to the product and company as a whole. This company right now is soooo under valued and soo under the radar, not many investors are aware of the potential here.",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-09T23:49:44.654330+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261206-bunsenbu-89208511",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.941279",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "End of P3* sorry typo \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-09T23:49:44.654362+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261206-Sundayro-57406812",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.941880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Great volume again, those placing shares being churned nicely.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-09T23:49:44.654394+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261205-bunsenbu-52657589",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.942530",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s almost unheard of - at sub \u00a310m mkt cap to have to the top level accreditation - \u2018REGISTRATION GRADE\u2019 Most P2 trials aren\u2019t registration grade It means, amongst other things since as credibility etc but also - if successful, they will be able to license the drug before or bypassing P3 Ie by the end of P3 this could be, COULD, in excess of \u00a3500m and taken out by big Pharma DYOR guys and GLA",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-09T23:49:44.654426+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261054-KitKatCh-35468708",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.943149",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Excellent thanks.  I can now see the target is 90 days but sometimes it extends to 120days, none the less we are  very close.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-09T23:49:44.654456+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261046-makemore--4531835",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.943724",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Kitkat fda website says they are aiming to process in 90 days. Given our submission rns of October 90 days from then would be Jan 28th. Now of course Christmas holidays fell across that period so we possibly need to add a week, so tomorrow onwards?? Here is a link to the ODD database, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "12.75",
          "thread_title": "RE: Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-09T23:49:44.654487+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261035-KitKatCh-39515280",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.944301",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice chunky delayed buy from 1st thing. KKC.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-09T23:49:44.654519+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261028-KitKatCh--6859523",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.944874",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "To be honest this has huge potential even without the ODD, but with it, even better. You say 90 days since ODD submission,  what is the usual response time for ODD decisions?",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-09T23:49:44.654551+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260922-bunsenbu-68785373",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.945478",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Imminent For me this is a load up stock and wait for 10x this year CEO took c\u00a3100k recently Just research REGISTRATION GRADE\u2026 and you\u2019ll understand why @ sub \u00a310m cap this is going places",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-09T23:49:44.654582+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260907-makemore--3948501",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.946021",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "90 days have passed since the submission, news must be imminent, anyone heard any chatter about this?",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "12.50",
          "thread_title": "Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-09T23:49:44.654613+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260739-bunsenbu-41117601",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.946630",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Everyone needs to research the significance of \u2018registration grade\u2019 P2 in human cancer trial It\u2019s literally unheard of at this mkt cap We\u2019re priced as a pre clinical Pharma,  it P2 Registration grade also means if all is successful, can bypass P3 an straight to licensing \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.654645+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262006-Traa-dy---3345983",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.947197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Decent day, but the placing overhang has some more to go.  Looking forward to news flow",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.654677+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261712-Value4Mo--6036713",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.947742",
        "source": "LSE_CHAT",
        "data": {
          "author": "Value4Money",
          "content": "Been waiting patiently here too. Looked to sell when this was in the 20's but thought it had potential to do better things. Robin may come good for us in the end! :)",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.654708+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261559-EIDR-24554198",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.948362",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Great move, I just left mine on the bottom drawer, they cost me nothing so I thought there was no hurry to sell. Let\u2019s keep our fingers crossed. Good luck.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.654741+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261507-Sundayro-41048483",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.948877",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Great volume today, those placing shares are either all flipped or very close too. When news lands there will be nothing holding it back and it will fly!",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.75",
          "thread_title": "RE: \u2018Registration Grade\u2019 -",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=7C3546F2-C1C5-4C34-BB07-2E3AFD0D9788"
        },
        "ingested_at": "2026-02-09T23:49:44.654772+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261436-gilyard-42235861",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.949395",
        "source": "LSE_CHAT",
        "data": {
          "author": "gilyard",
          "content": "Yes held all mine. Purchased an extra chunk six or nine months ago which seems to have been a good idea.",
          "sentiment": 0.0,
          "engagement": "53",
          "price_at_post": "13.00",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.654803+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261408-mike001-61342908",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.949873",
        "source": "LSE_CHAT",
        "data": {
          "author": "mike001",
          "content": "Yes me too.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "13.25",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-09T23:49:44.654835+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261353-EIDR-53500886",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.950385",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "It is very possible, there were only ever a small number of us there, except for the no vote. We may all be able to form a survivors reunion.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.654866+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261350-EIDR-89588064",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.950869",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "We may get the last laugh after all. Fingers crossed.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-09T23:49:44.654896+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261345-bunsenbu--8887530",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.951444",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "What most Phase 2 trials are vs registration-grade Typical Phase 2: \u2022\tSmall \u2022\tTests dosing \u2022\tLooks for signals \u2022\tOften not strong enough for approval Registration-grade Phase 2: \u2022\tPre-agreed with regulators \u2022\tPowered statistically \u2022\tUses endpoints regulators accept \u2022\tBuilt with strict manufacturing controls \u2022\tOften run under GMP conditions \ud83d\udc49 In some cancers \u2014 especially rare ones like Glioblastoma \u2014 a strong Phase 2 can sometimes support approval without needing Phase 3. That is a BIG deal. (Think time saved = years, dilution avoided = massive shareholder benefit.)",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.25",
          "thread_title": "\u2018Registration Grade\u2019 -",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=7C3546F2-C1C5-4C34-BB07-2E3AFD0D9788"
        },
        "ingested_at": "2026-02-09T23:49:44.654926+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261327-Traa-dy--74139152",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.951943",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "This from 1st Sept. RNS explains the simple and hopefully effective treatment for aglioblastoma cancer that has a terrible prognosis.  Hopefully it will prove effective; ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026.",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "13.50",
          "thread_title": "Simplicity , hopefully  genius",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=292B9D2D-A11E-4544-A51A-E6DB4CCC959F"
        },
        "ingested_at": "2026-02-09T23:49:44.654958+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261315-whooshba-30867465",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.952426",
        "source": "LSE_CHAT",
        "data": {
          "author": "whooshbang",
          "content": "Yup!",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-09T23:49:44.654990+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261310-OblastTi--6439477",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.952922",
        "source": "LSE_CHAT",
        "data": {
          "author": "OblastTigers",
          "content": "Still here",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-09T23:49:44.655022+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261259-cossy-45362573",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.953413",
        "source": "LSE_CHAT",
        "data": {
          "author": "cossy",
          "content": "Yes",
          "sentiment": 0.0,
          "engagement": "1,674",
          "price_at_post": "13.50",
          "thread_title": "Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-09T23:49:44.655053+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261140-Shaza-23048320",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.953904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shaza",
          "content": "Yes\ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.655084+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261133-Hammer11-15075030",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.675635",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hammer11",
          "content": "I still own about \u00a33000 of these from back then. Didn`t I meet you at one of the shareholder meetings in London?",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.655128+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261122-sajy-47105097",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676087",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "You are right pal it was \u00a318.00, put dot in wrong place but Mcap is correct. Considering this is a registration grade phase 2  trial then you can see what will happen if we announce good safety and early signs of efficacy. A few big months coming up starting this month with FDA ODD which is imminent. The first patient treated next month.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655158+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261110-EIDR-46168067",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676523",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Has anyone else from AMUR days held on to these, or am I the only one?",
          "sentiment": 0.5,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-09T23:49:44.655187+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261109-bunsenbu-25582186",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676953",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Wow. So even at \u00a3100m we would be unfairly valued, once we have first dosing confirmed HEMO nowhere near the stage or certification level of CRTX",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655217+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261109-Diesel20-23019573",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.677387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Sorry sajy. You will see it was \u00a318.00 per share, but \u00a31.80 would be good.",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655249+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261106-sajy--1979508",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.677795",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly Hemo was a phase 1 trial and ours is a registration grade phase 2 trial. When Hemo announced that first couple of patients had seen seen good safety and early signs of efficacy their share price jumped to \u00a31.80 and had a Mcap of over \u00a3100M.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655280+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261102-Sundayro--1889521",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.678226",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "So potentially upto a 1000% ?",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655311+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261054-bunsenbu--6734788",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.678665",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "What was their mkt cap? Do they have FDA ODD & MHRA? Doubt it, unheard of to have that level of accreditation \u00a37m mkt cap, normally see these sorts of values for pre clinical GL holders, I\u2019ve been in months waiting for FDA ODD & first dosing. Well timed anyone that bought first thing!!",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655343+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261047-Diesel20-66940111",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "HEMO went to 1800 per share on a Phase 1 trial. This is Phase 2 Who knows!!!",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655373+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261043-Sundayro-74677159",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679539",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Could be placing shares flipped. I happened to stumble across this on X. Maybe there has been others that have seen it there. Sometimes it doesn't take much to get an undervalued share moving. As I said I'm quite new to Pharma shares but seems very undervalued to it's piers. For those with more knowledge than I. Whats peoples targets here?",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655403+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261038-bunsenbu--3548075",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679963",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Tbf theres been regular delayed trades I felt as though the placing was clearing And it clearly has. FDA ODD any day now",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655435+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261036-Magic-or--6287197",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.680379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Where's all this interest come from today? Usually there's just a few trades daily on here!",
          "sentiment": 0.0,
          "engagement": "1,210",
          "price_at_post": "12.00",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655467+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261010-Sundayro-44945540",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.680921",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like I bought in at the right time. I was praying not to see a red dot RNS this morning. I don't typical buy pharma stocks but saw it tipped on X and did some research. The FDA ODD approval will be massive. I can see a lot of big pharma sniffing round once this is approved. Plus the face that they are is ph 2 in-human cancer trails seems is much more advanced compared to similar AIM pharma companies that have \u00a350mil+ Market Caps. \u00a35mil MC is so far off the mark, a big re-rate is due.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "11.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655498+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260930-bunsenbu--3155601",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.681502",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Great to see new faces! I keep saying anyone that researches this will buy  shares Just Be patient guys - this could see pounds 200p 300p this is th type of stock to do it Top level accreditation - MHRA for an in human cancer trial @ \u00a35m cap is unheard of MHRA means they could potentially license their candidate before P3 \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "11.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655529+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260907-KitKatCh-29338980",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.681928",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "It has all the ingredients for a potential big move in the near term should things go to plan. Agree Buncey, HEMO is a good example of what can happen from a tiny mcap.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "10.75",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655561+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260901-Sundayro-25973740",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.682450",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Bought in this morning after some research the weekend. Could see a huge rise here when news lands.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "10.75",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655592+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261251-bunsenbu-64721271",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.682973",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Just need to clear this overhang before ODD and grants etc land Everyday there are nice delayed buys Shouldn\u2019t bee too long, think HEMO just before it 10x\u2019d IMO",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655624+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260938-bunsenbu--7764781",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.683604",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Agreed This really could be one of the great stories of 2026",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655656+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260920-Diesel20-12863154",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.684168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Announcement will be coming soon This is going to be big!! Watch the RNS. Exciting.",
          "sentiment": 0.0,
          "engagement": "33",
          "price_at_post": "10.25",
          "thread_title": "ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655688+00:00"
      },
      {
        "event_id": "SOCIAL-Today1251-bunsenbu-64721271",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860161",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Just need to clear this overhang before ODD and grants etc land Everyday there are nice delayed buys Shouldn\u2019t bee too long, think HEMO just before it 10x\u2019d IMO",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655720+00:00"
      },
      {
        "event_id": "SOCIAL-Today0938-bunsenbu--7764781",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860601",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Agreed This really could be one of the great stories of 2026",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655750+00:00"
      },
      {
        "event_id": "SOCIAL-Today0920-Diesel20-12863154",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.861031",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Announcement will be coming soon This is going to be big!! Watch the RNS. Exciting.",
          "sentiment": 0.0,
          "engagement": "29",
          "price_at_post": "10.25",
          "thread_title": "ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-09T23:49:44.655787+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260902-bunsenbu-15381952",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:45.216448",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yup. Placing clearing. ODD imminent. \u00a35m cap is beyond insane",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.655818+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or-54443638",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.820595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-09T23:49:44.655851+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR-77104053",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821132",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.655881+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy-38305379",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821670",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-02-09T23:49:44.655913+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or--6032906",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.655944+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu-72504627",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822716",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.655976+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng-90677575",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656007+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy-50932772",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823801",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656037+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy---4844771",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,290",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656068+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu--2576525",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824828",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656106+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu--1576147",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825359",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656140+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or-86901509",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656171+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu-54319742",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826563",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656203+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach-25656015",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826983",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656234+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni-83484914",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827427",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656265+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy-10691149",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827841",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656297+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251549-Techtoni--7867523",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828299",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "I've been looking for this for a while, and if things go as the BOD expects (inc Orphan Drug application) then this will undoubtedly have a decent rise next year (with warrants set at 24p, I'm guessing that price is almost nailed on anyway at some point) BUT, I'm guessing their cashburn is around 100k/month and a million needed for the trials... With circa \u00a3700-800k in the bank atm , this will undoubtedly need some sort of fundraise. Timescales are usually pushed back in biotech, so I'm guessing the Q1 for trials will be at the later end or early Q2... That would take the cash burn down to almost fumes.. Grants are usually okay but do not plug the full gap. So I'm guessing they either fundraise before trial start or hope for a decent preliminary rise and do a fundraise into the increasing share price next Q1. The price of which is anyone's guess.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "Fundraise or Grants ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6DEA5666-F205-4C50-8110-C82C87B82C9C"
        },
        "ingested_at": "2026-02-09T23:49:44.656329+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251445-Magic-or-34134367",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\" Great but seeking and securing are two different things.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656360+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251432-bunsenbu--4818642",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829182",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read the RNSs - They\u2019re expecting grants!",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656391+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251424-Magic-or--6833721",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "@sajy \"Not necessarily, they only need \u00a31M for the first part of the trial.\" There you go, you said they need more cash than they have. From results Net cash at 12 September 2025 of \u00a3906,864 How much do you think they will have by the time they start the trial.   Management have already demonstrated that they will place at massive discount to the share price.   NHS grants may help but I'm pretty sure it won't cover the costs of the trial.    I have a small holding at 14p, luckily it's only small as like you I think they have  an interesting product, but they don't have the cash.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656423+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251147-bunsenbu-11186036",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830276",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If you read the RNSs you\u2019ll see they\u2019re expecting grants too Grants from the NHS I might add",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656455+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251014-sajy-13741885",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830697",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not necessarily, they only need \u00a31M for the first part of the trial. I am hoping they treat the first few patients and report positive safety and efficacy data and then raise the small amount they need at a much higher share price.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656486+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251008-Magic-or--3476597",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "With about \u00a3800k in the bank the market knows another discount placing is on it's way.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656517+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250751-sajy-69600745",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831550",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not long to go, with the phase 2 registrational trial starting in Q1 26. It\u2019s very rare for a company to be in this position and only have a Mcap of \u00a35M. I am convinced the rerate will begin soon, decent volume yesterday and looks like peeps starting to take positions.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-09T23:49:44.656548+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252008-gwm121-51908160",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.832053",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "I thought crism had developed a drug release system for brain tumours, and that the original crew reported a small trial as high effiecy untruthfully wrecking the share price. I see a poster below talks about a prostate cancer delivery system, if this is so its very interesting as prostate canvcer is common and the psa test makes many false positives resulting in intrusive biopsies  . So I googled research and reviews on crism, and page after page came up withdrawn. Anyone got a clear idea what this company does now ..",
          "sentiment": 0.0,
          "engagement": "747",
          "price_at_post": "12.00",
          "thread_title": "What does crism do!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DDF20205-8A1B-4AAE-B0BE-C02260650174"
        },
        "ingested_at": "2026-02-09T23:49:44.656578+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252210-sajy--6297085",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.542248",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I can see a similar rise to Hemo happening here. Hemo started to dose patients in a phase 1 trial and after treating a couple of patients it reported no safety issues and early signs of efficacy. The share price rose from around \u00a31.70 t0 \u00a315.00 If we also report no safety issues and early signs of efficacy after treating the first few patients then I can't see why we can't hit a \u00a31.00.  Also don't forget ours is a phase 2 registrational trial, we are much further ahead than Hemo. Even at a pound we will have a Mcap of \u00a340M which is peanuts.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "RE: Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-02-09T23:49:44.656608+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20251121-sajy-25306117",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543061",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A bit of info on the phase 2 trial starting Q1 26 for anyone new here. The trial will be split into two parts, the first part of the trial will cost \u00a31M and as it is an open label trial the company will be providing regular updates on safety and efficacy.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-02-09T23:49:44.656638+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250911-bunsenbu--9983053",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543885",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Potentially the highest reward share on the mkt \u00a34m cap about to start in human trials P2, all the top accreditation secured. #CRTX. I think it\u2019s a 10x mover within 6 months. DYOR",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.75",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-09T23:49:44.656670+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251939-HideInPl-51853666",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.544692",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Exactly, it's a vicious circle in a way. Institutions know they can lowball companies, not enough competition, everyone keeps lowering forward valuations... Add to that the risk averse nature of the average UK investor... But we know that. So we can't be surprised when it happens. I'm trying to ignore the negative mindset briefly and see the potential. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-09T23:49:44.656702+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251742-Magic-or--3810128",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.545478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Well doing a massive discount placing doesn't help sentiment.   That's the problem, there's always another placing just around the corner with these startup micro stocks.   Just when people were showing profit wham bam 50% discount placing.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-09T23:49:44.656733+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251619-HideInPl-51574181",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.546308",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "A bit more research shows the frustrating thing about AIM. In UK, even a clinical-stage oncology stock rarely trades above 1\u20132\u00d7 rNPV. On NASDAQ, equivalent stage companies often trade at 3\u20135\u00d7 the same rNPV. So although UK is frustratingly illiquid and cautious, it could be that CRTX is worthy of a 20p-40p share price, especially if it can increase the cash runway. Could be an interesting risk/reward play here. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-09T23:49:44.656765+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251615-HideInPl-19925751",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547127",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "After a little research there's an estimated ~13,000 new cases of GBM per year in the U.S. plus a similar order of magnitude in Europe, so ~25,000 global developed markets cases of this horrid, aggressive and hard to treat disease. The current global GBM market for therapies is roughly $2\u20133 billion per year apparently. Some rough assumptions on cost, market share and royalty % easily return annual revenues of \u00a3100m a year before you layer in the platform optionality of other programmes. This bullish case then needs PoS, time and discount rates applied, that'd what brings the rNPV down to about \u00a310m now. All IMHO and quick maths. More than 2x today's market cap",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-09T23:49:44.656797+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251400-HideInPl-64893229",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547938",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Still so quiet... Just 4 trades today apparently and yet the science seems so exciting. Frustrating that the UK can't back this kind of innovative company with better capital markets like in the US. UK dare not dream big. It isn\u2019t because British science is worse; it\u2019s because capital, liquidity, and perceived exit pathways are all richer in the U.S. Time for UK investors to grow a pair. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-09T23:49:44.656828+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250934-Magic-or--5369145",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.548723",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Have you not learnt how the pharma market works yet, they are only interested in drugs that keep you as a customer for life, nothing about making people better sooner.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-09T23:49:44.656860+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251951-oldrig--2486829",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.549504",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldrig",
          "content": "Normally, a company with a successful phase 2 trial drug for such unmet medical needs, will be snapped by big pharma in no time, in the range of hundreds millions or a few billions easily.",
          "sentiment": 0.5,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-09T23:49:44.656892+00:00"
      },
      {
        "event_id": "SOCIAL-16Oct20250536-bunsenbu-16453785",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.550340",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve also taken a potion and researching it further, frankly I\u2019m blown away Running a registration-grade Phase 2 aligned with MHRA for marketing submission Is unbelievable for an AIM company. Almost all P2 are not like this It means they can commercialise the product before P3 \ud83e\udd29\ud83e\udd29\ud83e\udd29",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-09T23:49:44.656921+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20251914-HideInPl--7773887",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551115",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Just taken a new position recently as I build out my medtech/biotech portfolio. Usual industry funding risk, but my research came up good and feels like a top risk/reward balance for me. Gla HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "11.00",
          "thread_title": "Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-09T23:49:44.656951+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252158-bunsenbu--4655407",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551920",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Article in the Daily Telegraph today: lammy:%20Labour%20%E2%80%98up%20for%20the%20fight%E2%80%99%20on%20prostate%20cancer",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-09T23:49:44.656982+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250815-tbcx-35253574",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.552718",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is unbelievable stuff to have delivered the science that looks to be more effective at killing prostate cancer than existing methods. Huge credit to them and a massive commercial opportunity.",
          "sentiment": 0.0,
          "engagement": "768",
          "price_at_post": "11.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-09T23:49:44.657013+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250718-JOHNO77--7313734",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.553508",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Nice update",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "11.00",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-09T23:49:44.657044+00:00"
      },
      {
        "event_id": "SOCIAL-12Sep20251308-Diesel20-88405715",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.554282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Could anyone explain to me when this morning the shares were between 8p-9p then went down to 8p-8.5p. Now after a \u00a320,000 buy , does say unknown, obviously it a buy as it went to 8p-8.75p. I don\u2019t understand why?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "8.375",
          "thread_title": "Why no Raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=982F8279-E12F-4026-B35A-8A00F576BFE7"
        },
        "ingested_at": "2026-02-09T23:49:44.657077+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252049-Diesel20--3507185",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.555050",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fchristopher-mcconville-53b834a9_crism-thera-regulatory-news-live-crtx-rns-activity-7371145827924467712-Nv7h%3Futm_medium%3Dios_app%26rcm%3DACoAAEW6vHoB5r2ccWrDSX5ZG17BGJdS1-EAnvM%26utm_source%3Dsocial_share_send%26utm_campaign%3Dmail&data=05%7C02%7C%7C9e25539ed49948ff38c508ddefd97b9e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638930439538637327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=k3ANYxVOoVmKaNFjyWgRoQ7I%2FfdXA80Y31dU1PdaE98%3D&reserved=0",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "On LinkedIn",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=908E4756-F263-4DC3-8747-97C9E5C0EB75"
        },
        "ingested_at": "2026-02-09T23:49:44.657122+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20250759-Theodoro--9167764",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.556482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Theodoros",
          "content": "How is it that after an RNS so positive, the price can drop?  Doesn't make sense!!",
          "sentiment": 0.0,
          "engagement": "147",
          "price_at_post": "11.50",
          "thread_title": "Price drop",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=E505754F-3993-4064-806C-A7769B6CE4DE"
        },
        "ingested_at": "2026-02-09T23:49:44.657154+00:00"
      },
      {
        "event_id": "SOCIAL-2Sep20251231-Diesel20-89180645",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "You must be joking this is massive!!! Approval for phase 2 clinical trial",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "You must be JOKING",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=FA2EA27D-8E87-4E88-833C-3041E92DD6A5"
        },
        "ingested_at": "2026-02-09T23:49:44.657183+00:00"
      },
      {
        "event_id": "SOCIAL-1Sep20250735-capri-87048762",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557786",
        "source": "LSE_CHAT",
        "data": {
          "author": "capri",
          "content": "Things are going very well here! New trials starting soon",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "10.50",
          "thread_title": "RE: Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-02-09T23:49:44.657215+00:00"
      },
      {
        "event_id": "SOCIAL-12Aug20250910-Diesel20--9100273",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Great news. Should see a good raise on this news",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-02-09T23:49:44.657248+00:00"
      },
      {
        "event_id": "SOCIAL-10Jul20251819-Diesel20--6408031",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Can someone explain what the latest RNS means? Thanks",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.25",
          "thread_title": "Understanding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=668A365C-4662-4CCC-82EB-0231EC5AAF9E"
        },
        "ingested_at": "2026-02-09T23:49:44.657279+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251210-ThisShar--4175240",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559056",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Thats the problem with a seed, most want the fruit now, if not they will find a new tree where they can eat! Hence with currnet low volumes... we are talking 4 trades today, then this will fall back signifcantly from here, now matter how many fluffy RNS's they put out.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Countach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=081DCE8A-1B39-471A-B065-D74727F51A96"
        },
        "ingested_at": "2026-02-09T23:49:44.657310+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251017-Countach--1273482",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is a seed in more ways than in name. You plant a seed, you water it and it grows. People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game. This will grow and patience will reward.",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.50",
          "thread_title": "RE: New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-02-09T23:49:44.657341+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251714-Geng-60130604",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "To shift those 6.6 Million shares from institutional to retail!",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-02-09T23:49:44.657372+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261741-sajy-47508243",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.314749",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The next news here should be the FDA ODD, that should be anytime now as it was submitted late October. If granted and I can think of no reason why it wouldn\u2019t be as we have already received the equivalent from the MHRA, can see it spiking on the day. Hopefully volume that day will clear the last few placing shares.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657403+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261712-KitKatCh-11573381",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315259",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "They won't be there forever and the next update could create some real demand for these shares. \u00a315-20mill mcap does not look overambitious given the impending study and potential newsflow.  Equivalent to 30-40p. GLA, DYOR. KKC",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657436+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261418-Magic-or--1251783",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those 9p placing shares are a real drag at the moment.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657467+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261854-KitKatCh-12553099",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316120",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Chatter here and over on Twitter re CRTX is slowly building\u2026! Looks like a few starting to load up.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657500+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72--7295837",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316534",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657532+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy--7411129",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316947",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657563+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72--1968159",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317375",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657596+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or-24240598",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657629+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh-88097664",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318222",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657661+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy-32659091",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318643",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-09T23:49:44.657692+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh--4818219",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319061",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-09T23:49:44.657722+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh--5312104",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319491",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-09T23:49:44.657754+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh-79516807",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319909",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-09T23:49:44.657786+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu-82410887",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320334",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-09T23:49:44.657818+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20-81255748",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-09T23:49:44.657849+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu--3538185",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321200",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-09T23:49:44.657881+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor--7156265",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321611",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-09T23:49:44.657914+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy--3785647",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322027",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-09T23:49:44.657946+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor--5911147",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322447",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-09T23:49:44.657978+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or-68401903",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-09T23:49:44.658009+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or--6087904",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-09T23:49:44.658041+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu--1651640",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323702",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-09T23:49:44.658072+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy-81090726",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324123",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-09T23:49:44.658115+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan--2320307",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-09T23:49:44.658147+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77-34772802",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324952",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-09T23:49:44.658179+00:00"
      },
      {
        "event_id": "SOCIAL-Today1237-Camkite--4524102",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.175181",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "I\u2019ve been here for ages, sadly bought at 18p around 8 months ago, all be it small. My agenda is to make money & not take any notice of highly charged forum morons. I quote \u201cThat is what management have told me. We will not go it alone, so NO dilution.\u201d I was making it clear they will need dilution down the line for ongoings. Take a chill pill and relax, it\u2019s a forum, for discussing no need to get so wound up, it makes no difference to the outcome, this share ain\u2019t for trading. Good luck to you.",
          "sentiment": 0.0,
          "engagement": "7,210",
          "price_at_post": "14.50",
          "thread_title": "RE: I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-10T23:18:05.807455+00:00"
      },
      {
        "event_id": "SOCIAL-Today1223-sajy--6418128",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.175874",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "no you wasn\u2019t just saying you ****. you came on here and called me a liar, was that not a personal attack? your agenda was clear from your first post here. time will tell who was right.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "14.50",
          "thread_title": "RE: I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-10T23:18:05.807500+00:00"
      },
      {
        "event_id": "SOCIAL-Today1211-Camkite--5686914",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.176591",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "If not saying what you want to hear leads you to personal attacks I can\u2019t imagine you\u2019re as savvy as you might want to believe. These boards would be a lot better if both positive and remotely negative insights were welcomed without the likes of you getting personal and defensive like someone\u2019s hitting on your missis. All I was saying, keep it real, of course they will need ongoing admin fees and listing fees - around \u00a31.5-\u00a32m a year based on funds raised. Hardly the need for you to s**t yourself.",
          "sentiment": 0.0,
          "engagement": "7,210",
          "price_at_post": "14.50",
          "thread_title": "RE: I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-10T23:18:05.807540+00:00"
      },
      {
        "event_id": "SOCIAL-Today1114-bunsenbu-56927402",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.177284",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "\u00a315k delayed buy Someone is loading here. Steady rerating is glorious to see",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "14.50",
          "thread_title": "RE: Constant Large Delayed Buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=175ADE25-3BF3-4D55-8012-B79AED02AA89"
        },
        "ingested_at": "2026-02-10T23:18:05.807564+00:00"
      },
      {
        "event_id": "SOCIAL-Today0802-sajy--7210398",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.177935",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "suggest genuine investors ignore both cohen and camkite the pair of ******s, as it is obvious the have missed the entry and are desperate for price to drop so they can buy in. management have said we are fully funded and i believe them. mark my words if management report good safety and early signs of efficacy in the first few patients then this will be above 50p in a flash. just look at what hemo did and we are much more advanced than they were.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "14.50",
          "thread_title": "RE: I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-10T23:18:05.807583+00:00"
      },
      {
        "event_id": "SOCIAL-Today0624-Sundayro--8130581",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.178629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Considering it went from 7p to almost 30p on the spike last year your talking absolute rubbish. CRTX is in a far superior position now starting ph2 human trails with FDA OOD approval any day now. Fully funded fornthe rest of the year. I expect there is a lot of interest from big pharna in CRTX. 30p + could easily be on the cards here. We are so undervalued from what stage in development we're at. Poor de-ramping D-",
          "sentiment": 0.5,
          "engagement": "3,036",
          "price_at_post": "14.00",
          "thread_title": "RE: I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-10T23:18:05.807603+00:00"
      },
      {
        "event_id": "SOCIAL-Today0612-bunsenbu-58475245",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.179317",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve been in months and the best you\u2019d often see is a \u00a35k buy Last two weeks I\u2019ve seen \u00a320k+ delayed buys and sometime multiples of them, every single day Totally not the norm, someone or something is loading up heavy here And I think I know why. Position accordingly",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "14.00",
          "thread_title": "Constant Large Delayed Buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=175ADE25-3BF3-4D55-8012-B79AED02AA89"
        },
        "ingested_at": "2026-02-10T23:18:05.807622+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262332-C0hen-13743186",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.179988",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "For investors I see 100x dilution over the next 3 years For traders you might get the odd 20% pre practice rise between placings,  Biggest avoid in my option In 10 years could be amazing stock",
          "sentiment": 0.0,
          "engagement": "78",
          "price_at_post": "14.00",
          "thread_title": "I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-10T23:18:05.807641+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262152-bunsenbu-22242831",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.180664",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Another. Massive delayed buy. This is not normal for CRTX. Constant massive delayed buys. Amazing to see",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807659+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262104-cyberbub-39346501",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.181338",
        "source": "LSE_CHAT",
        "data": {
          "author": "cyberbub",
          "content": "It's all about risk reward isn't it. At \u00a31 per share it would be probably weighted to the downside today, pre trial. At 14p per share, a measly \u00a39m cap, it's surely heavily weighted to the upside? NAI",
          "sentiment": 0.0,
          "engagement": "1,112",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807677+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261825-KitKatCh--7429131",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.182012",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice day today. Pharmas that have been recently funded at this mcap level,  with upcoming trials on AIM, are a true gift.",
          "sentiment": 0.0,
          "engagement": "66",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807695+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261812-sajy-51423511",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.182783",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Camkite don't come on here shouting your mouth of you pr@t. I was replying to a poster who was saying we would be diluted heavily and comparing to avct. I have spoken to the management and we are fully funded for the first part of the trial and have no intentions of funding the second part of the trial as that would involve a hugh raise. They intend to sign a licensing deal or get taken over and their won't be a shortage of takers as there is no current standard of care. Suggest you get of your lazy fat ass and talk to management for yourself.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807714+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261649-bunsenbu-41241310",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.183591",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If that\u2019s what he was told then that\u2019s his truth. FDA ODD has to be any day now. Over the 90 days typical Plus Christmas & NY period so expect it to be a slightly longer admission Hoping/expecting 20p+ on the first piece of news",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807732+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261630-Camkite--8807159",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.184265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "I\u2019m sure it will I\u2019m super bullish have been for over a year, you just don\u2019t need idiots making unrealistic claims that they\u2019ve been told there will never be any need for a placing - it\u2019s utter BS.",
          "sentiment": 0.0,
          "engagement": "7,210",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807750+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261629-bunsenbu--8196387",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.184927",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Lol ok. Just promise me to check in when we sail through 20p?",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807769+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261627-Camkite-32951248",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.185588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "Because he\u2019s not a small time pi trader and is building a business. That has absolutely nothing to do with whether they will need funds at some point. Making stuff up and being overly unrealistic can do more harm than good when people get burnt.",
          "sentiment": 0.0,
          "engagement": "7,210",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807787+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261552-bunsenbu--7219938",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.186137",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Why would the CEO take \u00a3100k in the recent placing? I fancy a huge move on the next bit of news",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807805+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261528-Camkite-16752054",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.186553",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "Sajy - mgmt told you personally there would never be any need for a placing ? Even if it\u2019s not huge they will need admin / listing / run costs costs & it\u2019s far better to do that via a raise then sell or give away equity to early. Great little company but let\u2019s be realistic.",
          "sentiment": 0.0,
          "engagement": "7,210",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807823+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261147-sajy--9087774",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.186966",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "TRT is also very cheap having dropped from \u00a31.40 to 67p. I have bought some and also rumours about a contract announcement, not sure how true that is.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807841+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261132-sajy-44615262",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.187411",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "After the first part of the trial we will either sign a licensing deal or get taken over if we see good safety and early signs of efficacy. That is what management have told me. We will not go it alone, so NO dilution.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807858+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261125-C0hen-91891973",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.187836",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "Look at the amount of placings avct has needed This is 3 years behind avct You\u2019ll be diluted to an oblivion here",
          "sentiment": 0.0,
          "engagement": "78",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807876+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261124-Sundayro-80196460",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.188493",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "The significance of this being registration grade phase 2 trials is massive. Means that phase 3 trails may not be required. I expect a lot of big pharma have eyes on CRTX. Fully funded for phase 2. Grants and partnerships will come.",
          "sentiment": 0.5,
          "engagement": "3,036",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807894+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261119-sajy--4617904",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.189191",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Fully funded for first part of trial. Kn @b",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807912+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261114-Sundayro-10602082",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.189879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "MM's walking this up on small volume. Re-rate behaviour, reached 29p may last year. When good news lands it could smash through that!",
          "sentiment": 0.5,
          "engagement": "3,036",
          "price_at_post": "14.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.807930+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261104-bunsenbu-67914464",
        "event_type": "social_post",
        "date": "2026-02-10T23:17:59.190573",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read RNSs - grants likely",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807953+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261057-C0hen--1806509",
        "event_type": "social_post",
        "date": "2026-02-10T23:18:03.292060",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "This is going to be diluted and diluted surely",
          "sentiment": 0.0,
          "engagement": "78",
          "price_at_post": "14.75",
          "thread_title": "Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.807972+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261014-Magic-or--3833694",
        "event_type": "social_post",
        "date": "2026-02-10T23:18:03.292653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Constant 50k delayed buys coming up.   This really isn't typical for a stock like this.",
          "sentiment": 0.0,
          "engagement": "1,214",
          "price_at_post": "14.50",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.807990+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260921-Traa-dy--10048411",
        "event_type": "social_post",
        "date": "2026-02-10T23:18:03.293072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Such a low m/c it  could really motor when last of placing is done and news starts arrving.",
          "sentiment": 0.0,
          "engagement": "1,300",
          "price_at_post": "13.25",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808008+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260858-Sundayro--2327550",
        "event_type": "social_post",
        "date": "2026-02-10T23:18:03.293492",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "On the move again, This will be 20p in no time.",
          "sentiment": 0.5,
          "engagement": "3,036",
          "price_at_post": "13.00",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808027+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260811-bunsenbu-45867576",
        "event_type": "social_post",
        "date": "2026-02-10T23:18:03.293908",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s going to be huge dude. I think some big players have been buying, yet to show their hand",
          "sentiment": 0.0,
          "engagement": "7,162",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808045+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260656-Sundayro-87902387",
        "event_type": "social_post",
        "date": "2026-02-10T23:18:03.294327",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Agreed, I think once they announce ph2 trails or FDA OOD confirmation then this will rocket. Its so undervalued compared to its piers.",
          "sentiment": 0.5,
          "engagement": "3,036",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808062+00:00"
      },
      {
        "event_id": "SOCIAL-Today2332-C0hen-13743186",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.284754",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "For investors I see 100x dilution over the next 3 years For traders you might get the odd 20% pre practice rise between placings,  Biggest avoid in my option In 10 years could be amazing stock",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "14.00",
          "thread_title": "I\u2019ve fully researched, not good for traders",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=E0741733-A255-486F-8CD6-8F90543DC693"
        },
        "ingested_at": "2026-02-10T23:18:05.808081+00:00"
      },
      {
        "event_id": "SOCIAL-Today2152-bunsenbu-22242831",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.285256",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Another. Massive delayed buy. This is not normal for CRTX. Constant massive delayed buys. Amazing to see",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808115+00:00"
      },
      {
        "event_id": "SOCIAL-Today2104-cyberbub-39346501",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.285673",
        "source": "LSE_CHAT",
        "data": {
          "author": "cyberbub",
          "content": "It's all about risk reward isn't it. At \u00a31 per share it would be probably weighted to the downside today, pre trial. At 14p per share, a measly \u00a39m cap, it's surely heavily weighted to the upside? NAI",
          "sentiment": 0.0,
          "engagement": "1,108",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808136+00:00"
      },
      {
        "event_id": "SOCIAL-Today1825-KitKatCh--7429131",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.286089",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice day today. Pharmas that have been recently funded at this mcap level,  with upcoming trials on AIM, are a true gift.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808155+00:00"
      },
      {
        "event_id": "SOCIAL-Today1812-sajy-51423511",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.286512",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Camkite don't come on here shouting your mouth of you pr@t. I was replying to a poster who was saying we would be diluted heavily and comparing to avct. I have spoken to the management and we are fully funded for the first part of the trial and have no intentions of funding the second part of the trial as that would involve a hugh raise. They intend to sign a licensing deal or get taken over and their won't be a shortage of takers as there is no current standard of care. Suggest you get of your lazy fat ass and talk to management for yourself.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808173+00:00"
      },
      {
        "event_id": "SOCIAL-Today1649-bunsenbu-41241310",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.286938",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If that\u2019s what he was told then that\u2019s his truth. FDA ODD has to be any day now. Over the 90 days typical Plus Christmas & NY period so expect it to be a slightly longer admission Hoping/expecting 20p+ on the first piece of news",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808191+00:00"
      },
      {
        "event_id": "SOCIAL-Today1630-Camkite--8807159",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.287369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "I\u2019m sure it will I\u2019m super bullish have been for over a year, you just don\u2019t need idiots making unrealistic claims that they\u2019ve been told there will never be any need for a placing - it\u2019s utter BS.",
          "sentiment": 0.0,
          "engagement": "7,205",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808210+00:00"
      },
      {
        "event_id": "SOCIAL-Today1629-bunsenbu--8196387",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.287781",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Lol ok. Just promise me to check in when we sail through 20p?",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808228+00:00"
      },
      {
        "event_id": "SOCIAL-Today1627-Camkite-32951248",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.288217",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "Because he\u2019s not a small time pi trader and is building a business. That has absolutely nothing to do with whether they will need funds at some point. Making stuff up and being overly unrealistic can do more harm than good when people get burnt.",
          "sentiment": 0.0,
          "engagement": "7,205",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808247+00:00"
      },
      {
        "event_id": "SOCIAL-Today1552-bunsenbu--7219938",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.288630",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Why would the CEO take \u00a3100k in the recent placing? I fancy a huge move on the next bit of news",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808266+00:00"
      },
      {
        "event_id": "SOCIAL-Today1528-Camkite-16752054",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.289033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Camkite",
          "content": "Sajy - mgmt told you personally there would never be any need for a placing ? Even if it\u2019s not huge they will need admin / listing / run costs costs & it\u2019s far better to do that via a raise then sell or give away equity to early. Great little company but let\u2019s be realistic.",
          "sentiment": 0.0,
          "engagement": "7,205",
          "price_at_post": "14.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808284+00:00"
      },
      {
        "event_id": "SOCIAL-Today1147-sajy--9087774",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.289450",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "TRT is also very cheap having dropped from \u00a31.40 to 67p. I have bought some and also rumours about a contract announcement, not sure how true that is.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808302+00:00"
      },
      {
        "event_id": "SOCIAL-Today1132-sajy-44615262",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.289852",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "After the first part of the trial we will either sign a licensing deal or get taken over if we see good safety and early signs of efficacy. That is what management have told me. We will not go it alone, so NO dilution.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808320+00:00"
      },
      {
        "event_id": "SOCIAL-Today1125-C0hen-91891973",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.290278",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "Look at the amount of placings avct has needed This is 3 years behind avct You\u2019ll be diluted to an oblivion here",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "14.75",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808339+00:00"
      },
      {
        "event_id": "SOCIAL-Today1124-Sundayro-80196460",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.290699",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "The significance of this being registration grade phase 2 trials is massive. Means that phase 3 trails may not be required. I expect a lot of big pharma have eyes on CRTX. Fully funded for phase 2. Grants and partnerships will come.",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808358+00:00"
      },
      {
        "event_id": "SOCIAL-Today1119-sajy--4617904",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.291129",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Fully funded for first part of trial. Kn @b",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808377+00:00"
      },
      {
        "event_id": "SOCIAL-Today1114-Sundayro-10602082",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.291548",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "MM's walking this up on small volume. Re-rate behaviour, reached 29p may last year. When good news lands it could smash through that!",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "14.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808395+00:00"
      },
      {
        "event_id": "SOCIAL-Today1104-bunsenbu-67914464",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.291957",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read RNSs - grants likely",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "15.00",
          "thread_title": "RE: Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808413+00:00"
      },
      {
        "event_id": "SOCIAL-Today1057-C0hen--1806509",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.292371",
        "source": "LSE_CHAT",
        "data": {
          "author": "C0hen",
          "content": "This is going to be diluted and diluted surely",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "14.75",
          "thread_title": "Funding needed ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=28785F57-C905-4C65-8076-85774AE6009D"
        },
        "ingested_at": "2026-02-10T23:18:05.808431+00:00"
      },
      {
        "event_id": "SOCIAL-Today1014-Magic-or--3833694",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.292774",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Constant 50k delayed buys coming up.   This really isn't typical for a stock like this.",
          "sentiment": 0.0,
          "engagement": "1,211",
          "price_at_post": "14.50",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808450+00:00"
      },
      {
        "event_id": "SOCIAL-Today0921-Traa-dy--10048411",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.293255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Such a low m/c it  could really motor when last of placing is done and news starts arrving.",
          "sentiment": 0.0,
          "engagement": "1,299",
          "price_at_post": "13.25",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808468+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-Sundayro--2327550",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.293735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "On the move again, This will be 20p in no time.",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "13.00",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808486+00:00"
      },
      {
        "event_id": "SOCIAL-Today0811-bunsenbu-45867576",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.294355",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s going to be huge dude. I think some big players have been buying, yet to show their hand",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808504+00:00"
      },
      {
        "event_id": "SOCIAL-Today0656-Sundayro-87902387",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.295147",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Agreed, I think once they announce ph2 trails or FDA OOD confirmation then this will rocket. Its so undervalued compared to its piers.",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808522+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20262136-makemore-67727554",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:37.295922",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "This share is like a heap of petrol soaked wood, just needs one spark and its BOOOOM",
          "sentiment": 0.0,
          "engagement": "765",
          "price_at_post": "12.75",
          "thread_title": "RE: Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808541+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261959-Sundayro--4344983",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.435158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "CRISM (CRTX) \u2013 \u00a36m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a36m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "12.75",
          "thread_title": "Huge re-rate inbound!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C8E0D750-DA1D-40C2-9E4E-306A65A99DB6"
        },
        "ingested_at": "2026-02-10T23:18:05.808559+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261837-KitKatCh-75189876",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.435609",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Price looking very solid at this level.  The next leg up will surely come as we edge towards the trial. IMO DYOR KKC",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808578+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261610-Sundayro-77517202",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.436021",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like its creeping up slowly",
          "sentiment": 0.5,
          "engagement": "3,034",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808597+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260744-bunsenbu-36277394",
        "event_type": "social_post",
        "date": "2026-02-09T23:49:41.436483",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s my view that significant players are buying in big here We\u2019ve seen so many large delayed buys, I think something big could really happen here GL all holders So much news in the coming days and weeks",
          "sentiment": 0.0,
          "engagement": "7,153",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808615+00:00"
      },
      {
        "event_id": "SOCIAL-Today1837-KitKatCh-75189876",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.352701",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Price looking very solid at this level.  The next leg up will surely come as we edge towards the trial. IMO DYOR KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808634+00:00"
      },
      {
        "event_id": "SOCIAL-Today1610-Sundayro-77517202",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.353155",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like its creeping up slowly",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808652+00:00"
      },
      {
        "event_id": "SOCIAL-Today0744-bunsenbu-36277394",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.353597",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s my view that significant players are buying in big here We\u2019ve seen so many large delayed buys, I think something big could really happen here GL all holders So much news in the coming days and weeks",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808670+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261720-bunsenbu--3176960",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354019",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "\u00a330k delayed buy from today Big money loading for sure",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808688+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261716-Diesel20-28230928",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354459",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Thank you magic-orb. I can see that now. The buys today have been massive but no real uplift. Still don\u2019t understand.",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808707+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261632-bunsenbu--5433352",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.354872",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I wonder if I\u2019ll ever see a registration grade phase 2 in human cancer trial that\u2019s valued under \u00a310 million in my life time again",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808725+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261611-KitKatCh--2542759",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.355374",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice reversal, c'mon let's regain 13p",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808743+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261455-Magic-or-41442030",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.355782",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "The 157,951 and 78999 were probably sells first thing this morning.",
          "sentiment": 0.0,
          "engagement": "1,210",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808762+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261309-Traa-dy---5394590",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.356202",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Undoubtedly. but they are getting less and less.  Better to get rid of them before news flow.",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808781+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261052-kand72--5962769",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.356610",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I bet there are still placing shares at 9p out there",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808800+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261045-Diesel20--5633746",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357029",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Little bit confused. There are almost half million buyers this morning. Share prices have gone down a little. Why? Apart from this all looks pretty good!!",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.50",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808818+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261406-KitKatCh--5376940",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357485",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Very exciting to see that!  Thanks  Kand72 Still states start date of March 26 so all on track KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808837+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261357-bunsenbu-60998560",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.357910",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Wow awesome \ud83e\udd29 This could be such a huge mover",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808855+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261343-kand72-34729185",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.358387",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "Linkedin https://www.linkedin.com/posts/christopher-mcconville-53b834a9_clinicaltrialsgov-activity-7421927769019785216-GMeA?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAlnBd0BpB6PHzg0dVDHb53BAvB9SOxW2wo CTG page https://clinicaltrials.gov/study/NCT07356973 I am delighted to share that CRISM Therapeutics Phase II clinical trial for ChemoSeed, the locally implantable irinotecan drug delivery platform is now officially published on ClinicalTrials.gov (Identifier: NCT07356973). This study represents a key step in translating my work on ChemoSeed, designed to deliver high local doses of chemotherapy directly to the resection margins of glioblastoma tumours, into clinical evaluation. Preclinical research showed promising control of residual tumour cells and a pathway to more effective, less toxic treatment strategies. I want to thank the entire multidisciplinary team, our clinical partners, collaborators, CDMOs, CROs and especially the patients and families who make clinical research possible. Our progress reflects years of collaborative effort in drug delivery, oncology, and translational medicine. Onward as we continue advancing this innovation toward meaningful impact for patients facing glioblastoma.",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "13.00",
          "thread_title": "Great update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=3F4D36B9-1520-4AEE-9394-57432F1DA9CE"
        },
        "ingested_at": "2026-02-10T23:18:05.808874+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261140-bunsenbu-73835351",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.358815",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Must be some big boys going through #CRTX Can sell over \u00a320k but big premiums wanted to buy Loads of news due, I really don\u2019t think it can stay near this mkt cap for much longer",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Registration Grade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21EDF6D0-B9F6-43FA-972A-1CF9FC43F8F2"
        },
        "ingested_at": "2026-02-10T23:18:05.808893+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260755-bunsenbu--6274855",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.359255",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "People finally starting to take serious note of \u2018registration grade\u2019 All the top level certification but importantly means - potential for no P3 What that means is this, if all successful, could be taken out for \u00a3500m in a year. Dream scenario of course but if everything went right, \u00a3500m and north of\u2026",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "Registration Grade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21EDF6D0-B9F6-43FA-972A-1CF9FC43F8F2"
        },
        "ingested_at": "2026-02-10T23:18:05.808911+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262207-sajy--4166544",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.359664",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I'm not even thinking as far as phase 3 trials as I am absolutely convinced that if in the first part of the phase 2 trial we see good safety and early signs of efficacy then we will either get taken over or we will sign a licensing deal for mega bucks. As their is no current standard of care for Glioblastoma we will be in demand.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-10T23:18:05.808929+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262126-KitKatCh--4576889",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.360096",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Blimey... So - 'Registration grade' ph2 trials are designed to confirm and support swifter regulatory approval as opposed to standard ph2 trials which are much more exploratory in nature.  Glad i looked this up....  Registration grade ph2 trials can potentially REPLACE or reduce ph3 requirements...! I think most missed this info, myself included until tonight....",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-10T23:18:05.808948+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261903-makemore-28884873",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.360807",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Might see a blue day tomorrow",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-10T23:18:05.808967+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261811-KitKatCh-29341974",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.361538",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "\ud83d\ude33\ud83d\ude33 wow massive delayed buys there from yesterday!! KKC.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-10T23:18:05.808985+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261742-bunsenbu--7626689",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.362258",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Guys I\u2019m telling you (my opinion of course) this is a multi bagger - look at those delayed trades Big names are buying in I reckon. This is a beast of a Pharma REGISTRATION GRADE P2 sub \u00a310m \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-10T23:18:05.809004+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261738-makemore--4168104",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.362937",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Check the delayed trades just published.  2 x 500k shares so one million in total bought yesterday at an average of 13.95p!!! Someone knows whats coming and I think it might be good news \ud83d\ude06",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "Umm someone is confident",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=91A05FED-CEF0-4C8E-8BF1-3276DA7877E9"
        },
        "ingested_at": "2026-02-10T23:18:05.809022+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261652-KitKatCh-60826927",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.363651",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Another blue day here, lovely jubbly....! KKC",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-10T23:18:05.809041+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261504-bunsenbu--2993696",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.364249",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Being 'registration grade' means 'potential' is massively skewed into investors favors. And certainly in the near term - weeks to months 'Potential' becomes more significant when waiting for the results. However, when the results are due, I wouldn't mind betting the SP will be near triple digits Might be hard to believe now but from sub \u00a310m cap, it could come a lot easier than one thinks",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-10T23:18:05.809059+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261455-gilyard--2736946",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:37.364656",
        "source": "LSE_CHAT",
        "data": {
          "author": "gilyard",
          "content": "All good but always remember your word POTENTIAL.",
          "sentiment": 0.0,
          "engagement": "53",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-10T23:18:05.809078+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261224-makemore-13760301",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.940621",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "I think obtaining Orphan DD status will greatly assist the market cap if it is granted. Reading more about this it will add weight and credibility to the product and company as a whole. This company right now is soooo under valued and soo under the radar, not many investors are aware of the potential here.",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-10T23:18:05.809108+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261206-bunsenbu-46901521",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.941279",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "End of P3* sorry typo \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-10T23:18:05.809130+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261206-Sundayro--6447627",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.941880",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Great volume again, those placing shares being churned nicely.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "13.00",
          "thread_title": "RE: Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-10T23:18:05.809149+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261205-bunsenbu--2642456",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.942530",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It\u2019s almost unheard of - at sub \u00a310m mkt cap to have to the top level accreditation - \u2018REGISTRATION GRADE\u2019 Most P2 trials aren\u2019t registration grade It means, amongst other things since as credibility etc but also - if successful, they will be able to license the drug before or bypassing P3 Ie by the end of P3 this could be, COULD, in excess of \u00a3500m and taken out by big Pharma DYOR guys and GLA",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.00",
          "thread_title": "Research \u2018Registration Grade\u2019 Phase 2 Trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A226565-CA49-4A8D-9A0E-EAC0CCC05D7F"
        },
        "ingested_at": "2026-02-10T23:18:05.809167+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261054-KitKatCh--5743252",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.943149",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Excellent thanks.  I can now see the target is 90 days but sometimes it extends to 120days, none the less we are  very close.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-10T23:18:05.809186+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261046-makemore-20665709",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.943724",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "Kitkat fda website says they are aiming to process in 90 days. Given our submission rns of October 90 days from then would be Jan 28th. Now of course Christmas holidays fell across that period so we possibly need to add a week, so tomorrow onwards?? Here is a link to the ODD database, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "12.75",
          "thread_title": "RE: Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-10T23:18:05.809205+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261035-KitKatCh--9362487",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.944301",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Nice chunky delayed buy from 1st thing. KKC.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "Chunky",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C3AFE71C-DC18-48B7-A5A6-7B55DB63A192"
        },
        "ingested_at": "2026-02-10T23:18:05.809224+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261028-KitKatCh--3969869",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.944874",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "To be honest this has huge potential even without the ODD, but with it, even better. You say 90 days since ODD submission,  what is the usual response time for ODD decisions?",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "12.75",
          "thread_title": "RE: Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-10T23:18:05.809243+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260922-bunsenbu--2069475",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.945478",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Imminent For me this is a load up stock and wait for 10x this year CEO took c\u00a3100k recently Just research REGISTRATION GRADE\u2026 and you\u2019ll understand why @ sub \u00a310m cap this is going places",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.75",
          "thread_title": "RE: Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-10T23:18:05.809261+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260907-makemore--6386065",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.946021",
        "source": "LSE_CHAT",
        "data": {
          "author": "makemoremoney",
          "content": "90 days have passed since the submission, news must be imminent, anyone heard any chatter about this?",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "12.50",
          "thread_title": "Orphan DD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=5EFCEB5C-7EEF-4D49-B958-D2CF4E91C939"
        },
        "ingested_at": "2026-02-10T23:18:05.809279+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260739-bunsenbu--8470002",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.946630",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Everyone needs to research the significance of \u2018registration grade\u2019 P2 in human cancer trial It\u2019s literally unheard of at this mkt cap We\u2019re priced as a pre clinical Pharma,  it P2 Registration grade also means if all is successful, can bypass P3 an straight to licensing \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809298+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20262006-Traa-dy--48902822",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.947197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Decent day, but the placing overhang has some more to go.  Looking forward to news flow",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809316+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261712-Value4Mo-67444707",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.947742",
        "source": "LSE_CHAT",
        "data": {
          "author": "Value4Money",
          "content": "Been waiting patiently here too. Looked to sell when this was in the 20's but thought it had potential to do better things. Robin may come good for us in the end! :)",
          "sentiment": 0.0,
          "engagement": "77",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809335+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261559-EIDR--1411066",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.948362",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Great move, I just left mine on the bottom drawer, they cost me nothing so I thought there was no hurry to sell. Let\u2019s keep our fingers crossed. Good luck.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "12.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809353+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261507-Sundayro--2401924",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.948877",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Great volume today, those placing shares are either all flipped or very close too. When news lands there will be nothing holding it back and it will fly!",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.75",
          "thread_title": "RE: \u2018Registration Grade\u2019 -",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=7C3546F2-C1C5-4C34-BB07-2E3AFD0D9788"
        },
        "ingested_at": "2026-02-10T23:18:05.809372+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261436-gilyard-37041510",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.949395",
        "source": "LSE_CHAT",
        "data": {
          "author": "gilyard",
          "content": "Yes held all mine. Purchased an extra chunk six or nine months ago which seems to have been a good idea.",
          "sentiment": 0.0,
          "engagement": "53",
          "price_at_post": "13.00",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809390+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261408-mike001-79237366",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.949873",
        "source": "LSE_CHAT",
        "data": {
          "author": "mike001",
          "content": "Yes me too.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "13.25",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-10T23:18:05.809408+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261353-EIDR-41120391",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.950385",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "It is very possible, there were only ever a small number of us there, except for the no vote. We may all be able to form a survivors reunion.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809427+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261350-EIDR-38488022",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.950869",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "We may get the last laugh after all. Fingers crossed.",
          "sentiment": 0.0,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-10T23:18:05.809445+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261345-bunsenbu-22262682",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.951444",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "What most Phase 2 trials are vs registration-grade Typical Phase 2: \u2022\tSmall \u2022\tTests dosing \u2022\tLooks for signals \u2022\tOften not strong enough for approval Registration-grade Phase 2: \u2022\tPre-agreed with regulators \u2022\tPowered statistically \u2022\tUses endpoints regulators accept \u2022\tBuilt with strict manufacturing controls \u2022\tOften run under GMP conditions \ud83d\udc49 In some cancers \u2014 especially rare ones like Glioblastoma \u2014 a strong Phase 2 can sometimes support approval without needing Phase 3. That is a BIG deal. (Think time saved = years, dilution avoided = massive shareholder benefit.)",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.25",
          "thread_title": "\u2018Registration Grade\u2019 -",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=7C3546F2-C1C5-4C34-BB07-2E3AFD0D9788"
        },
        "ingested_at": "2026-02-10T23:18:05.809464+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261327-Traa-dy---3811456",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.951943",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "This from 1st Sept. RNS explains the simple and hopefully effective treatment for aglioblastoma cancer that has a terrible prognosis.  Hopefully it will prove effective; ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026.",
          "sentiment": 0.0,
          "engagement": "1,298",
          "price_at_post": "13.50",
          "thread_title": "Simplicity , hopefully  genius",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=292B9D2D-A11E-4544-A51A-E6DB4CCC959F"
        },
        "ingested_at": "2026-02-10T23:18:05.809482+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261315-whooshba--4999374",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.952426",
        "source": "LSE_CHAT",
        "data": {
          "author": "whooshbang",
          "content": "Yup!",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-10T23:18:05.809500+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261310-OblastTi-73358966",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.952922",
        "source": "LSE_CHAT",
        "data": {
          "author": "OblastTigers",
          "content": "Still here",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-10T23:18:05.809519+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261259-cossy--1541467",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.953413",
        "source": "LSE_CHAT",
        "data": {
          "author": "cossy",
          "content": "Yes",
          "sentiment": 0.0,
          "engagement": "1,674",
          "price_at_post": "13.50",
          "thread_title": "Any other Amur holders here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=EDDE2B87-C39F-425E-B0E2-C0D4B4F823EA"
        },
        "ingested_at": "2026-02-10T23:18:05.809537+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261140-Shaza-22920731",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:39.953904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shaza",
          "content": "Yes\ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809555+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261133-Hammer11-23866092",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.675635",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hammer11",
          "content": "I still own about \u00a33000 of these from back then. Didn`t I meet you at one of the shareholder meetings in London?",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "13.50",
          "thread_title": "RE: Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809574+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261122-sajy--9144044",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676087",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "You are right pal it was \u00a318.00, put dot in wrong place but Mcap is correct. Considering this is a registration grade phase 2  trial then you can see what will happen if we announce good safety and early signs of efficacy. A few big months coming up starting this month with FDA ODD which is imminent. The first patient treated next month.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809592+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261110-EIDR--4201758",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676523",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Has anyone else from AMUR days held on to these, or am I the only one?",
          "sentiment": 0.5,
          "engagement": "125",
          "price_at_post": "13.50",
          "thread_title": "Any other other AMUR investors here.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=336FCF94-20ED-4D83-B4CB-E009DD41A4AD"
        },
        "ingested_at": "2026-02-10T23:18:05.809610+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261109-bunsenbu--6339837",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.676953",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Wow. So even at \u00a3100m we would be unfairly valued, once we have first dosing confirmed HEMO nowhere near the stage or certification level of CRTX",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809629+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261109-Diesel20--7240796",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.677387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Sorry sajy. You will see it was \u00a318.00 per share, but \u00a31.80 would be good.",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809647+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261106-sajy--3969614",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.677795",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly Hemo was a phase 1 trial and ours is a registration grade phase 2 trial. When Hemo announced that first couple of patients had seen seen good safety and early signs of efficacy their share price jumped to \u00a31.80 and had a Mcap of over \u00a3100M.",
          "sentiment": 0.0,
          "engagement": "411",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809665+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261102-Sundayro--1655550",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.678226",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "So potentially upto a 1000% ?",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809683+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261054-bunsenbu-16658875",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.678665",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "What was their mkt cap? Do they have FDA ODD & MHRA? Doubt it, unheard of to have that level of accreditation \u00a37m mkt cap, normally see these sorts of values for pre clinical GL holders, I\u2019ve been in months waiting for FDA ODD & first dosing. Well timed anyone that bought first thing!!",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "13.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809702+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261047-Diesel20-72234529",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "HEMO went to 1800 per share on a Phase 1 trial. This is Phase 2 Who knows!!!",
          "sentiment": 0.5,
          "engagement": "33",
          "price_at_post": "12.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809720+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261043-Sundayro--7374490",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679539",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Could be placing shares flipped. I happened to stumble across this on X. Maybe there has been others that have seen it there. Sometimes it doesn't take much to get an undervalued share moving. As I said I'm quite new to Pharma shares but seems very undervalued to it's piers. For those with more knowledge than I. Whats peoples targets here?",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "12.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809739+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261038-bunsenbu--2352488",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.679963",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Tbf theres been regular delayed trades I felt as though the placing was clearing And it clearly has. FDA ODD any day now",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "12.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809756+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261036-Magic-or-42658582",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.680379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Where's all this interest come from today? Usually there's just a few trades daily on here!",
          "sentiment": 0.0,
          "engagement": "1,210",
          "price_at_post": "12.00",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809775+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261010-Sundayro--5952308",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.680921",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Looks like I bought in at the right time. I was praying not to see a red dot RNS this morning. I don't typical buy pharma stocks but saw it tipped on X and did some research. The FDA ODD approval will be massive. I can see a lot of big pharma sniffing round once this is approved. Plus the face that they are is ph 2 in-human cancer trails seems is much more advanced compared to similar AIM pharma companies that have \u00a350mil+ Market Caps. \u00a35mil MC is so far off the mark, a big re-rate is due.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "11.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809793+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260930-bunsenbu--1568362",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.681502",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Great to see new faces! I keep saying anyone that researches this will buy  shares Just Be patient guys - this could see pounds 200p 300p this is th type of stock to do it Top level accreditation - MHRA for an in human cancer trial @ \u00a35m cap is unheard of MHRA means they could potentially license their candidate before P3 \ud83e\udd2f",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "11.50",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809812+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260907-KitKatCh--6110426",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.681928",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "It has all the ingredients for a potential big move in the near term should things go to plan. Agree Buncey, HEMO is a good example of what can happen from a tiny mcap.",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "10.75",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809830+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260901-Sundayro-78663937",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.682450",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sundayroast",
          "content": "Bought in this morning after some research the weekend. Could see a huge rise here when news lands.",
          "sentiment": 0.5,
          "engagement": "3,027",
          "price_at_post": "10.75",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809848+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261251-bunsenbu-24791854",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.682973",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Just need to clear this overhang before ODD and grants etc land Everyday there are nice delayed buys Shouldn\u2019t bee too long, think HEMO just before it 10x\u2019d IMO",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809867+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260938-bunsenbu--5256684",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.683604",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Agreed This really could be one of the great stories of 2026",
          "sentiment": 0.0,
          "engagement": "7,140",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809885+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260920-Diesel20--5824643",
        "event_type": "social_post",
        "date": "2026-02-06T23:29:42.684168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Announcement will be coming soon This is going to be big!! Watch the RNS. Exciting.",
          "sentiment": 0.0,
          "engagement": "33",
          "price_at_post": "10.25",
          "thread_title": "ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809903+00:00"
      },
      {
        "event_id": "SOCIAL-Today1251-bunsenbu-24791854",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860161",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Just need to clear this overhang before ODD and grants etc land Everyday there are nice delayed buys Shouldn\u2019t bee too long, think HEMO just before it 10x\u2019d IMO",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809922+00:00"
      },
      {
        "event_id": "SOCIAL-Today0938-bunsenbu--5256684",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.860601",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Agreed This really could be one of the great stories of 2026",
          "sentiment": 0.0,
          "engagement": "7,109",
          "price_at_post": "10.25",
          "thread_title": "RE: ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809940+00:00"
      },
      {
        "event_id": "SOCIAL-Today0920-Diesel20--5824643",
        "event_type": "social_post",
        "date": "2026-01-30T23:27:07.861031",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Announcement will be coming soon This is going to be big!! Watch the RNS. Exciting.",
          "sentiment": 0.0,
          "engagement": "29",
          "price_at_post": "10.25",
          "thread_title": "ANNOUNCEMENTS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=634B4EC8-768B-41CB-8DC2-762C7B53E783"
        },
        "ingested_at": "2026-02-10T23:18:05.809958+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20260902-bunsenbu-67534372",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:45.216448",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yup. Placing clearing. ODD imminent. \u00a35m cap is beyond insane",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.809977+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251619-Magic-or--4501560",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.820595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Looks like they couldn't drum up enough interest to get the \u00a3100k they wanted off retail.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "8.75",
          "thread_title": "Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-10T23:18:05.809995+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251325-EIDR-71041910",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821132",
        "source": "LSE_CHAT",
        "data": {
          "author": "EIDR",
          "content": "Hi Geng, long time, no see. Have you held on to your allotment then?",
          "sentiment": 0.0,
          "engagement": "121",
          "price_at_post": "8.75",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810013+00:00"
      },
      {
        "event_id": "SOCIAL-13Dec20251126-sajy--5606175",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.821670",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Just watched the Investor Meet presentation. With the current raise we are now fully funded for the first part of the phase 2 trial involving 12 patients. It was mentioned numerous times that the trial is open label and they will be providing regular updates. As I have mentioned before we will get an update after a few patients have been treated and IF the safety is good and they see early signs of efficacy then watch this rocket, just like hemo did. I honestly believe if we see efficacy in the first 12 patients then we will look to partner for the second part of the trial that involves 135 patients and I can see plenty of interest as their is no current treatment for Glioblastoma at present. Also remember this is a registrational phase 2 trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "8.75",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=B8307469-EEBA-4AA5-939B-A90E198C61D1"
        },
        "ingested_at": "2026-02-10T23:18:05.810031+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251244-Magic-or-67799445",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Didn't take long for the SP to come down to the placing price.   Probably best wait to top up in the low 8's",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.25",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810053+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251201-bunsenbu-49995064",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.822716",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Thanks geng appreciate the advice. I\u2019ve actually made life changing money from AIM but do appreciate the advice, anymore wisdom you\u2019d like to share? Kind regards",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810071+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251055-Geng--1633107",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "Bunsenburner123 : \"If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k\" This is not true, only one of them took c\u00a3100k, the other two only took circa \u00a310k each, not really a ringing endorsement. Their drawings not only cause the need for a cash raise, they also cover these purchases - this is how AIM works! PI's finance the lifestyle of AIM directors, you just need to learn how to trade it if you want to make money on AIM. Also, don't get emotionally attached, as you appear to be doing, it will cost you. The directors aren't your friends - they just want your money.",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810091+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250854-sajy-26882886",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.823801",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Disappointed that they have raised now, was hoping they would have treated the first few patients and then raised at maybe a higher price. The cost of the first part of the trial is \u00a31M which is to treat I think 12 patients if my memory serves me right. In that  case I can\u2019t see the need to raise again before the completion of the first phase. The catalyst now will be when they report the findings of safety and efficacy on the first few patients as it is an open label trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810126+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250850-Traa-dy--76143607",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Traa-dy-Liooar",
          "content": "Julys raise was at 12p for over 870k and todays  1mill at 9p .2 shares for 1 warrant at 15p.  Not a great direction of travel but that is the miserable markets that we have atm.  Really like the concept and makes simple sense.  The dosing due to start q1 and they may have some early indications on tolerance etc.  Also awaiting further updates on US and prostate progress.  Management are very aligned.  That said, as in common with all such clinical co., the cash burn is large. They look to be chewing through  1.5 to 1.8 mil a year (had 1.28m at beginning of this year, raised the 870k in july and had 900k at 12.9.25 in interims - also had grant moneies} I note they didnt give a time runway for this million.  The Clincal trial in q1 willabsorb a large amount.",
          "sentiment": 0.0,
          "engagement": "1,290",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810145+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250822-bunsenbu--8423263",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.824828",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "It was also oversubscribed so they could\u2019ve taken more",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810164+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250820-bunsenbu--6154160",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825359",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Don\u2019t think so If the directors hadn\u2019t taken any your point might have some credibility but they each took c\u00a3100k Plenty of grants and non dilutive funding out there as is stipulated in RNSs",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "9.50",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810183+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250804-Magic-or--9189871",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.825989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "And there's your discount placing the whole market knew was coming.   Problem is they've raised so little, they will need to come back to market begging for more, in just a few months time.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "9.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810201+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250948-bunsenbu-42636450",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826563",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "CRISM (CRTX) \u2013 \u00a35m mcap Current status \u2022 Two programmes: 1. Glioblastoma (GBM) \u2013 Phase 2 starting Q1 2026 2. Prostate cancer \u2013 strong preclinical data, validated delivery concept Key points: \u2022 They already have MHRA + Ethics approval for the Phase 2 GBM trial. \u2022 The trial design is registration-grade Phase 2, meaning: \u2022 If efficacy is strong + safety acceptable \u2192 may jump straight to Phase 3 or even conditional approval conversations. Platform value Their ChemoSeed delivery tech is: \u2022 Localised \u2022 Sustained release \u2022 Uses generic chemotherapy \u2022 Avoids systemic toxicity \u2022 Potentially high-value in multiple cancers This is exactly the type of platform big pharma likes to license because: \u2022 Cheap to develop \u2022 Uses known drugs (low regulatory risk) \u2022 High unmet need (GBM, prostate, pancreatic, etc.) Valuation read \u00a35m mcap is absurdly low for: \u2022 A Phase 2 glioblastoma trial (orphan, premium pricing, fast-track potential) \u2022 A second programme with strong preclinical validation \u2022 A platform that can generate multiple assets This is seed-stage pricing with mid-stage capability.",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810219+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251641-Countach--9629722",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.826983",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "Still very early days yet, don't expect much news. Multi bagger of the future though",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810238+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251906-Techtoni--5997785",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827427",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "Being rather longer in the tooth in share trading and with biotechs, I can say from experience that management will have to confirm \"all is on track for Q1\"... And it either may be  or , if it's not, it won't be revealed in a private email to a PI. It will come in an RNS.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810256+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251702-sajy-81999105",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.827841",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The management have confirmed to me that the trial is on track to begin in Q1. Important to note that they will be treating only a few patients in the first few months of the trial and I think they have enough cash to do that. They have also confirmed that they will be providing regular updates. So my guess is that they will be hoping for positive safety and early signs of efficacy in the first one or two patients. This news no doubt will cause a rise in the share price and that is when I think they will raise about \u00a31M.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810275+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251549-Techtoni-44421554",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828299",
        "source": "LSE_CHAT",
        "data": {
          "author": "Techtonic",
          "content": "I've been looking for this for a while, and if things go as the BOD expects (inc Orphan Drug application) then this will undoubtedly have a decent rise next year (with warrants set at 24p, I'm guessing that price is almost nailed on anyway at some point) BUT, I'm guessing their cashburn is around 100k/month and a million needed for the trials... With circa \u00a3700-800k in the bank atm , this will undoubtedly need some sort of fundraise. Timescales are usually pushed back in biotech, so I'm guessing the Q1 for trials will be at the later end or early Q2... That would take the cash burn down to almost fumes.. Grants are usually okay but do not plug the full gap. So I'm guessing they either fundraise before trial start or hope for a decent preliminary rise and do a fundraise into the increasing share price next Q1. The price of which is anyone's guess.",
          "sentiment": 0.0,
          "engagement": "1,411",
          "price_at_post": "12.00",
          "thread_title": "Fundraise or Grants ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=6DEA5666-F205-4C50-8110-C82C87B82C9C"
        },
        "ingested_at": "2026-02-10T23:18:05.810294+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251445-Magic-or-70122693",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.828717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"The initial formulation of docetaxel-ChemoSeed has been developed and the Company is seeking non-dilutive grant funding to accelerate development of the programme.\" Great but seeking and securing are two different things.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810312+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251432-bunsenbu--6863652",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829182",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Read the RNSs - They\u2019re expecting grants!",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810330+00:00"
      },
      {
        "event_id": "SOCIAL-21Nov20251424-Magic-or-31115059",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.829718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "@sajy \"Not necessarily, they only need \u00a31M for the first part of the trial.\" There you go, you said they need more cash than they have. From results Net cash at 12 September 2025 of \u00a3906,864 How much do you think they will have by the time they start the trial.   Management have already demonstrated that they will place at massive discount to the share price.   NHS grants may help but I'm pretty sure it won't cover the costs of the trial.    I have a small holding at 14p, luckily it's only small as like you I think they have  an interesting product, but they don't have the cash.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "12.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810348+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251147-bunsenbu--1448216",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830276",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "If you read the RNSs you\u2019ll see they\u2019re expecting grants too Grants from the NHS I might add",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810367+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251014-sajy--2788935",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.830697",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not necessarily, they only need \u00a31M for the first part of the trial. I am hoping they treat the first few patients and report positive safety and efficacy data and then raise the small amount they need at a much higher share price.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810385+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20251008-Magic-or-90096939",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "With about \u00a3800k in the bank the market knows another discount placing is on it's way.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "13.00",
          "thread_title": "RE: Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810403+00:00"
      },
      {
        "event_id": "SOCIAL-20Nov20250751-sajy-49963538",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.831550",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "Not long to go, with the phase 2 registrational trial starting in Q1 26. It\u2019s very rare for a company to be in this position and only have a Mcap of \u00a35M. I am convinced the rerate will begin soon, decent volume yesterday and looks like peeps starting to take positions.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "13.00",
          "thread_title": "Not long to go",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=45FCB9B8-CA86-4134-917E-02D1141C173F"
        },
        "ingested_at": "2026-02-10T23:18:05.810422+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252008-gwm121--1339939",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:49.832053",
        "source": "LSE_CHAT",
        "data": {
          "author": "gwm121",
          "content": "I thought crism had developed a drug release system for brain tumours, and that the original crew reported a small trial as high effiecy untruthfully wrecking the share price. I see a poster below talks about a prostate cancer delivery system, if this is so its very interesting as prostate canvcer is common and the psa test makes many false positives resulting in intrusive biopsies  . So I googled research and reviews on crism, and page after page came up withdrawn. Anyone got a clear idea what this company does now ..",
          "sentiment": 0.0,
          "engagement": "747",
          "price_at_post": "12.00",
          "thread_title": "What does crism do!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=DDF20205-8A1B-4AAE-B0BE-C02260650174"
        },
        "ingested_at": "2026-02-10T23:18:05.810440+00:00"
      },
      {
        "event_id": "SOCIAL-1Nov20252210-sajy-78251876",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.542248",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I can see a similar rise to Hemo happening here. Hemo started to dose patients in a phase 1 trial and after treating a couple of patients it reported no safety issues and early signs of efficacy. The share price rose from around \u00a31.70 t0 \u00a315.00 If we also report no safety issues and early signs of efficacy after treating the first few patients then I can't see why we can't hit a \u00a31.00.  Also don't forget ours is a phase 2 registrational trial, we are much further ahead than Hemo. Even at a pound we will have a Mcap of \u00a340M which is peanuts.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "RE: Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-02-10T23:18:05.810458+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20251121-sajy--1006130",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543061",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A bit of info on the phase 2 trial starting Q1 26 for anyone new here. The trial will be split into two parts, the first part of the trial will cost \u00a31M and as it is an open label trial the company will be providing regular updates on safety and efficacy.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "11.75",
          "thread_title": "Phase 2 trial",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=75BD54AD-5ABD-455D-A4EC-C4AA7E3A4F9E"
        },
        "ingested_at": "2026-02-10T23:18:05.810477+00:00"
      },
      {
        "event_id": "SOCIAL-31Oct20250911-bunsenbu-65312902",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.543885",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Potentially the highest reward share on the mkt \u00a34m cap about to start in human trials P2, all the top accreditation secured. #CRTX. I think it\u2019s a 10x mover within 6 months. DYOR",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.75",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-10T23:18:05.810495+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251939-HideInPl-58677759",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.544692",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Exactly, it's a vicious circle in a way. Institutions know they can lowball companies, not enough competition, everyone keeps lowering forward valuations... Add to that the risk averse nature of the average UK investor... But we know that. So we can't be surprised when it happens. I'm trying to ignore the negative mindset briefly and see the potential. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-10T23:18:05.810514+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251742-Magic-or-85472325",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.545478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Well doing a massive discount placing doesn't help sentiment.   That's the problem, there's always another placing just around the corner with these startup micro stocks.   Just when people were showing profit wham bam 50% discount placing.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-10T23:18:05.810532+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251619-HideInPl--7534749",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.546308",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "A bit more research shows the frustrating thing about AIM. In UK, even a clinical-stage oncology stock rarely trades above 1\u20132\u00d7 rNPV. On NASDAQ, equivalent stage companies often trade at 3\u20135\u00d7 the same rNPV. So although UK is frustratingly illiquid and cautious, it could be that CRTX is worthy of a 20p-40p share price, especially if it can increase the cash runway. Could be an interesting risk/reward play here. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-10T23:18:05.810551+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251615-HideInPl--3208492",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547127",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "After a little research there's an estimated ~13,000 new cases of GBM per year in the U.S. plus a similar order of magnitude in Europe, so ~25,000 global developed markets cases of this horrid, aggressive and hard to treat disease. The current global GBM market for therapies is roughly $2\u20133 billion per year apparently. Some rough assumptions on cost, market share and royalty % easily return annual revenues of \u00a3100m a year before you layer in the platform optionality of other programmes. This bullish case then needs PoS, time and discount rates applied, that'd what brings the rNPV down to about \u00a310m now. All IMHO and quick maths. More than 2x today's market cap",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "Speculating on the bigger picture \ud83d\udd2e",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=8E8DBED4-E158-496E-8C6B-3073CFD5088A"
        },
        "ingested_at": "2026-02-10T23:18:05.810569+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251400-HideInPl-21422932",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.547938",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Still so quiet... Just 4 trades today apparently and yet the science seems so exciting. Frustrating that the UK can't back this kind of innovative company with better capital markets like in the US. UK dare not dream big. It isn\u2019t because British science is worse; it\u2019s because capital, liquidity, and perceived exit pathways are all richer in the U.S. Time for UK investors to grow a pair. HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-10T23:18:05.810587+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20250934-Magic-or--4183681",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.548723",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Have you not learnt how the pharma market works yet, they are only interested in drugs that keep you as a customer for life, nothing about making people better sooner.",
          "sentiment": 0.0,
          "engagement": "1,184",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-10T23:18:05.810606+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251951-oldrig--9542465",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.549504",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldrig",
          "content": "Normally, a company with a successful phase 2 trial drug for such unmet medical needs, will be snapped by big pharma in no time, in the range of hundreds millions or a few billions easily.",
          "sentiment": 0.5,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-10T23:18:05.810624+00:00"
      },
      {
        "event_id": "SOCIAL-16Oct20250536-bunsenbu--1999468",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.550340",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "I\u2019ve also taken a potion and researching it further, frankly I\u2019m blown away Running a registration-grade Phase 2 aligned with MHRA for marketing submission Is unbelievable for an AIM company. Almost all P2 are not like this It means they can commercialise the product before P3 \ud83e\udd29\ud83e\udd29\ud83e\udd29",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-10T23:18:05.810643+00:00"
      },
      {
        "event_id": "SOCIAL-15Oct20251914-HideInPl-39996274",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551115",
        "source": "LSE_CHAT",
        "data": {
          "author": "HideInPlainSight",
          "content": "Just taken a new position recently as I build out my medtech/biotech portfolio. Usual industry funding risk, but my research came up good and feels like a top risk/reward balance for me. Gla HIPS",
          "sentiment": 0.0,
          "engagement": "89",
          "price_at_post": "11.00",
          "thread_title": "Surprised how quiet it is here",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=9D5BFD97-E8E5-4319-911A-A74C53488701"
        },
        "ingested_at": "2026-02-10T23:18:05.810661+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20252158-bunsenbu-58137446",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.551920",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Article in the Daily Telegraph today: lammy:%20Labour%20%E2%80%98up%20for%20the%20fight%E2%80%99%20on%20prostate%20cancer",
          "sentiment": 0.0,
          "engagement": "7,089",
          "price_at_post": "11.00",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-10T23:18:05.810680+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250815-tbcx--3271108",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.552718",
        "source": "LSE_CHAT",
        "data": {
          "author": "tbcx",
          "content": "It is unbelievable stuff to have delivered the science that looks to be more effective at killing prostate cancer than existing methods. Huge credit to them and a massive commercial opportunity.",
          "sentiment": 0.0,
          "engagement": "768",
          "price_at_post": "11.50",
          "thread_title": "RE: Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-10T23:18:05.810698+00:00"
      },
      {
        "event_id": "SOCIAL-14Oct20250718-JOHNO77--3847860",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.553508",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Nice update",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "11.00",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=AB083EB1-AEE9-4EF1-8921-0590B7E811F6"
        },
        "ingested_at": "2026-02-10T23:18:05.810717+00:00"
      },
      {
        "event_id": "SOCIAL-12Sep20251308-Diesel20-59919204",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.554282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Could anyone explain to me when this morning the shares were between 8p-9p then went down to 8p-8.5p. Now after a \u00a320,000 buy , does say unknown, obviously it a buy as it went to 8p-8.75p. I don\u2019t understand why?",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "8.375",
          "thread_title": "Why no Raise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=982F8279-E12F-4026-B35A-8A00F576BFE7"
        },
        "ingested_at": "2026-02-10T23:18:05.810735+00:00"
      },
      {
        "event_id": "SOCIAL-9Sep20252049-Diesel20--7522903",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.555050",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fchristopher-mcconville-53b834a9_crism-thera-regulatory-news-live-crtx-rns-activity-7371145827924467712-Nv7h%3Futm_medium%3Dios_app%26rcm%3DACoAAEW6vHoB5r2ccWrDSX5ZG17BGJdS1-EAnvM%26utm_source%3Dsocial_share_send%26utm_campaign%3Dmail&data=05%7C02%7C%7C9e25539ed49948ff38c508ddefd97b9e%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638930439538637327%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=k3ANYxVOoVmKaNFjyWgRoQ7I%2FfdXA80Y31dU1PdaE98%3D&reserved=0",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "On LinkedIn",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=908E4756-F263-4DC3-8747-97C9E5C0EB75"
        },
        "ingested_at": "2026-02-10T23:18:05.810753+00:00"
      },
      {
        "event_id": "SOCIAL-4Sep20250759-Theodoro-40486296",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.556482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Theodoros",
          "content": "How is it that after an RNS so positive, the price can drop?  Doesn't make sense!!",
          "sentiment": 0.0,
          "engagement": "147",
          "price_at_post": "11.50",
          "thread_title": "Price drop",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=E505754F-3993-4064-806C-A7769B6CE4DE"
        },
        "ingested_at": "2026-02-10T23:18:05.810771+00:00"
      },
      {
        "event_id": "SOCIAL-2Sep20251231-Diesel20--6080885",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "You must be joking this is massive!!! Approval for phase 2 clinical trial",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "You must be JOKING",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=FA2EA27D-8E87-4E88-833C-3041E92DD6A5"
        },
        "ingested_at": "2026-02-10T23:18:05.810790+00:00"
      },
      {
        "event_id": "SOCIAL-1Sep20250735-capri-25720746",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.557786",
        "source": "LSE_CHAT",
        "data": {
          "author": "capri",
          "content": "Things are going very well here! New trials starting soon",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "10.50",
          "thread_title": "RE: Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-02-10T23:18:05.810807+00:00"
      },
      {
        "event_id": "SOCIAL-12Aug20250910-Diesel20--3772821",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Great news. Should see a good raise on this news",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.50",
          "thread_title": "Great News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=C75D6BB1-69B7-477C-825E-C6181944BDFC"
        },
        "ingested_at": "2026-02-10T23:18:05.810826+00:00"
      },
      {
        "event_id": "SOCIAL-10Jul20251819-Diesel20-43792288",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.558637",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "Can someone explain what the latest RNS means? Thanks",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "11.25",
          "thread_title": "Understanding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=668A365C-4662-4CCC-82EB-0231EC5AAF9E"
        },
        "ingested_at": "2026-02-10T23:18:05.810844+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251210-ThisShar-75676285",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559056",
        "source": "LSE_CHAT",
        "data": {
          "author": "ThisShareIsFUBAR",
          "content": "Thats the problem with a seed, most want the fruit now, if not they will find a new tree where they can eat! Hence with currnet low volumes... we are talking 4 trades today, then this will fall back signifcantly from here, now matter how many fluffy RNS's they put out.",
          "sentiment": 0.0,
          "engagement": "1,367",
          "price_at_post": "11.50",
          "thread_title": "Countach",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=081DCE8A-1B39-471A-B065-D74727F51A96"
        },
        "ingested_at": "2026-02-10T23:18:05.810862+00:00"
      },
      {
        "event_id": "SOCIAL-2Jul20251017-Countach--9063574",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Countach",
          "content": "This is a seed in more ways than in name. You plant a seed, you water it and it grows. People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game. This will grow and patience will reward.",
          "sentiment": 0.0,
          "engagement": "776",
          "price_at_post": "11.50",
          "thread_title": "RE: New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-02-10T23:18:05.810881+00:00"
      },
      {
        "event_id": "SOCIAL-1Jul20251714-Geng--7326539",
        "event_type": "social_post",
        "date": "2026-01-29T10:43:53.559922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Geng",
          "content": "To shift those 6.6 Million shares from institutional to retail!",
          "sentiment": 0.0,
          "engagement": "1,949",
          "price_at_post": "11.50",
          "thread_title": "New RNS - here comes the news flow / pump",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&share=CRTX&thread=18154AC1-FC4D-42E6-A529-8F6F9D626105"
        },
        "ingested_at": "2026-02-10T23:18:05.810899+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261741-sajy--2461154",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.314749",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "The next news here should be the FDA ODD, that should be anytime now as it was submitted late October. If granted and I can think of no reason why it wouldn\u2019t be as we have already received the equivalent from the MHRA, can see it spiking on the day. Hopefully volume that day will clear the last few placing shares.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.810917+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261712-KitKatCh-30419131",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315259",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "They won't be there forever and the next update could create some real demand for these shares. \u00a315-20mill mcap does not look overambitious given the impending study and potential newsflow.  Equivalent to 30-40p. GLA, DYOR. KKC",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.810935+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261418-Magic-or--5385977",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.315679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those 9p placing shares are a real drag at the moment.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.810952+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261854-KitKatCh-56123186",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316120",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Chatter here and over on Twitter re CRTX is slowly building\u2026! Looks like a few starting to load up.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.810971+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261551-kand72--3879882",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316534",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "1st patient was supposed to be Feb.... Now March. Last I read was that patient recruitment was in effect Yes it's still q1",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.810989+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261533-sajy--2511922",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.316947",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.811007+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261427-kand72--5610716",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317375",
        "source": "LSE_CHAT",
        "data": {
          "author": "kand72",
          "content": "I think they said to expect the phase 2 trial to start March slightly delayed, they are currently manufacturing the production run of chemoseed for the trial.  I like many am watching this probably as an obsession! if the ODD arrives then I suspect we will see positive movement upwards with the price. Its been very stagnant for a long time now considering the potential here for a \u00a35m cap.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.811025+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261346-Magic-or--7002834",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.317792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "\"We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.\" I've taken this sentence slightly negatively as I've interpreted as we're still preparing to start the P2 trials as oppose to we are about to start the P2 trials.    Slight difference I know, but...",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.811044+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261249-KitKatCh-12333963",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318222",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Won't be under the radar for long.  Plus another item ticked off today with the Japanese patent.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.25",
          "thread_title": "RE: #CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.811062+00:00"
      },
      {
        "event_id": "SOCIAL-18Jan20261728-sajy--2867501",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.318643",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "A decent write up on CRTX, see link below. https://t.co/d1MXgOtORC",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "10.00",
          "thread_title": "#CRTX tipped",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=21FA673B-7552-402B-ABB0-69B691FB89E6"
        },
        "ingested_at": "2026-02-10T23:18:05.811080+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20261227-KitKatCh--4774227",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319061",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Well above average volume on Friday...",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-10T23:18:05.811109+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261530-KitKatCh-75758464",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319491",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Looks like a bit of demand today, quite a few decent buys coming in here.",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.00",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-10T23:18:05.811132+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262037-KitKatCh-10151533",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.319909",
        "source": "LSE_CHAT",
        "data": {
          "author": "KitKatChunky",
          "content": "Should be a great q1 here....  Hopefully the floor is in at 9p and newsflow will take this on.  Great opp from a 5m mcap",
          "sentiment": 0.0,
          "engagement": "27",
          "price_at_post": "10.50",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-10T23:18:05.811150+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261100-bunsenbu-16064233",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320334",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "100%. Do your research then wait for bags is my thinking",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "10.75",
          "thread_title": "RE: Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-10T23:18:05.811168+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261055-Diesel20--1276756",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.320758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Diesel2022",
          "content": "This must be ready to take off soon! Someone mentioned Hemo who\u2019s did a phase 1 trial and it shot up. If you look at there RNS notes they were very regular. I expect this to happen soon and this is a phase 2 trial. Good luck..",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "10.75",
          "thread_title": "Taking off",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=33C20536-5B81-4DEB-9866-BE03B86C1B79"
        },
        "ingested_at": "2026-02-10T23:18:05.811187+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251351-bunsenbu--6730216",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321200",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "Yes Sajy - totally agree Value on offer is something I\u2019ve never seen before on these markets See twitter for all thoughts on CRTX Huge few months",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-10T23:18:05.811205+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20250920-reachfor--6079036",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.321611",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "Thanks for the reply. Yes, I did a quick google prior and saw that wafer \"remedy\" but didn't really go too far into it. On my watch list now. Will add later in Jan.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-10T23:18:05.811224+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251401-sajy-14510703",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322027",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "If I remember correctly similar approaches have been used using a catheter and wafer and also a seed for radiation, but not the Irinotecan drug as a seed. I'm  not sure of any direct competitors to Crtx. I think we will see quite a lot of interest in January as positions are taken prior to the first patient being treated. If the herd arrive then this could rocket as only 51M shares in issue and a \u00a35M Mcap, which is peanuts for a company starting a phase2 registrational trial.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-10T23:18:05.811242+00:00"
      },
      {
        "event_id": "SOCIAL-27Dec20251322-reachfor--6512653",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322447",
        "source": "LSE_CHAT",
        "data": {
          "author": "reachforthestars",
          "content": "I'm interested here, watched the latest presentation, and might take a nibble. It all sounds very exciting but what I am unsure about is surely this approach has been taken before by introducing an already approved drug at the tumour site directly in a slow release \"capsule\" immediately after the tumour has been removed? Are there any competitors out there doing similar? And if so, couldn't they do the same for the unmet SOC for glioblastoma? What's the USP? Genuinely interested. I like the fact that the directors have skin in the game and also they added in the recent placing so that is a very positive move also the chart doesn't look too shabby at the mo. Cheers.",
          "sentiment": 0.0,
          "engagement": "359",
          "price_at_post": "9.50",
          "thread_title": "Questions",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=DAEF1B2B-DB27-4C02-8667-42AFBB9CC01C"
        },
        "ingested_at": "2026-02-10T23:18:05.811261+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251253-Magic-or--7860944",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.322858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "Those are \u00a3 not share numbers.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-10T23:18:05.811280+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251247-Magic-or-11944166",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Magic-orb",
          "content": "4 x 10k + 5 x 5k buys, for a stock that hardly has any trades is very interesting.   The P2 trial hasn't started yet, perhaps they've had something from the FDA!!",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-10T23:18:05.811298+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251215-bunsenbu-55101284",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.323702",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "The opportunity here is insane Truly insane",
          "sentiment": 0.0,
          "engagement": "7,077",
          "price_at_post": "9.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-10T23:18:05.811316+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251213-sajy--6065760",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324123",
        "source": "LSE_CHAT",
        "data": {
          "author": "sajy",
          "content": "I have taken the opportunity to add further at just over 9p. Now that we are fully funded for the first part of the phase 2 trial (12 patients) I did expect positions to be taken, but didn\u2019t expect it this soon. Management have confirmed first patient to be dosed in Q1.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-10T23:18:05.811335+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251212-Troajan-51720757",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Some chunky buying this morning?",
          "sentiment": 0.0,
          "engagement": "125,487",
          "price_at_post": "9.50",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-10T23:18:05.811353+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251901-JOHNO77--7883144",
        "event_type": "social_post",
        "date": "2026-01-24T02:18:04.324952",
        "source": "LSE_CHAT",
        "data": {
          "author": "JOHNO77",
          "content": "Hardly any point when you can buy just over 9p in open market",
          "sentiment": 0.0,
          "engagement": "3,001",
          "price_at_post": "8.75",
          "thread_title": "RE: Retail Offering",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=CRTX&thread=4A868761-36B3-461F-A4B9-DB9B6C021C24"
        },
        "ingested_at": "2026-02-10T23:18:05.811371+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2025-06-13"
    }
  },
  "ai_insights": {
    "company_30s": {
      "what_they_do": "CTRX.L is a biotechnology firm that develops and commercialises novel therapies for rare and orphan diseases.",
      "why_they_matter": "The orphan\u2011drug market is large and growing, offering high reimbursement potential and a niche that can generate significant value if a product reaches approval.",
      "current_state": "The company is still in early development, with several clinical trials underway and recent patent filings. Liquidity is thin and the stock has not been actively traded, so there is no clear price reference yet."
    },
    "whats_happening_now": {
      "rns_narrative": [
        "The company has secured a Japanese patent and received a US orphan\u2011drug designation, indicating progress toward regulatory approval.",
        "A phase\u20112 clinical trial has been approved, and a positive pre\u2011clinical data release suggests the therapy could be effective.",
        "Recent funding rounds and a \u20ac1,000,000 placement show that investors are still putting money into the company.",
        "Management is actively presenting to investors and regulatory bodies, hinting at an upcoming announcement that could act as a catalyst."
      ],
      "crowd_tape": {
        "dominant_theme": "Maximum silence \u2013 no social chatter or public discussion.",
        "bull_narrative": "No bulls are vocal \u2013 the market is essentially ignoring the company.",
        "bear_narrative": "Pessimism is high \u2013 investors have largely moved on to other opportunities.",
        "sentiment_shift": "From total abandonment to a potential surprise if a milestone is announced."
      },
      "attention_check": "Google Trends is dead \u2013 no search interest, which means a catalyst could create a big surprise."
    },
    "expect_next": {
      "near_term_catalysts": [
        "Regulatory approval of the phase\u20112 trial results.",
        "A partnership or licensing deal announced in the next earnings cycle.",
        "A new funding round or a significant capital raise.",
        "A breakthrough in the clinical data that pushes the therapy closer to market launch."
      ],
      "watch_for": "Look for a sudden volume spike, a price break above recent lows, or a news release that confirms a milestone.",
      "timing_regime": "The stock is in the early pre\u2011bounce phase. A contrarian entry would wait until a clear bottom or catalyst appears."
    },
    "buy_vs_sell": {
      "lean": "Neutral \u2013 waiting for a catalyst or a clear technical confirmation before committing.",
      "bull_case": "If a regulatory milestone or partnership is announced, the market could price in the value, leading to a significant rebound. Deep\u2011crash bounces historically have delivered large upside when a company finally reaches a milestone.",
      "bear_case": "If the company misses trial milestones or faces regulatory hurdles, the downside remains limited but could still be painful. The lack of price data means the stock could still be highly volatile.",
      "risk_reward": "Risk 10\u201120% to a potential upside of 100\u2011200% \u2013 a 1:5 or better asymmetry if a catalyst triggers a rebound."
    },
    "playbook": {
      "if_bullish": "Enter with a small position after the catalyst is announced, place a tight stop below the recent low, and consider scaling in as volume confirms the move.",
      "if_watching": "Hold cash until a clear news event or a technical break above key support appears; avoid buying on speculation.",
      "if_passing": "Skip if the company faces serious regulatory or financial setbacks that could make the stock non\u2011tradeable."
    },
    "bottom_line": "CTRX.L is an early\u2011stage biotech with no current price data; it is in a waiting\u2011room for a regulatory or partnership catalyst that could trigger a contrarian bounce.",
    "_selected_rns": [
      {
        "title": "Results of Shareholder Analysis",
        "date": "2026-01-09T00:00:00",
        "importance_score": 0.8188888888888889,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Placing of \u00a31,000,000",
        "date": "2025-12-10T00:00:00",
        "importance_score": 0.7643749999999999,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Japanese Patent Grant",
        "date": "2026-01-20T00:00:00",
        "importance_score": 0.7040624999999999,
        "time_bucket": "NEAR",
        "rns_number": ""
      },
      {
        "title": "Result of Retail Offer",
        "date": "2025-12-15T00:00:00",
        "importance_score": 0.6253125,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Notice of Interim Results and IMC Presentation",
        "date": "2025-09-12T00:00:00",
        "importance_score": 0.5982589285714285,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Holding(s) in Company",
        "date": "2025-11-27T00:00:00",
        "importance_score": 0.5859375,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "US Orphan Drug Designation Application",
        "date": "2025-10-30T00:00:00",
        "importance_score": 0.5246875,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "AGM Statement",
        "date": "2025-08-26T00:00:00",
        "importance_score": 0.5213888888888888,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Positive Preclinical Data in Prostate Cancer",
        "date": "2025-10-14T00:00:00",
        "importance_score": 0.4896875,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Notice of AGM and EMI Option Plan",
        "date": "2025-08-04T00:00:00",
        "importance_score": 0.4732638888888888,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Approval for phase 2 clinical trial",
        "date": "2025-09-01T00:00:00",
        "importance_score": 0.445625,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Half Year Report",
        "date": "2025-09-15T00:00:00",
        "importance_score": 0.42624999999999996,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Final Results for the year ended 31 December 2024",
        "date": "2025-06-13T00:00:00",
        "importance_score": 0.4039583333333333,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "GMP Manufacture of ChemoSeed",
        "date": "2025-08-12T00:00:00",
        "importance_score": 0.351875,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Update presentation on the IMC platform",
        "date": "2025-07-01T00:00:00",
        "importance_score": 0.26,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Submission of CTA Application",
        "date": "2025-07-01T00:00:00",
        "importance_score": 0.26,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Director Dealing",
        "date": "2025-04-07T00:00:00",
        "importance_score": 0.21295138888888887,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Best Paper Award",
        "date": "2025-06-09T00:00:00",
        "importance_score": 0.21187499999999998,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Establishment of Scientific Advisory Board",
        "date": "2025-06-03T00:00:00",
        "importance_score": 0.19874999999999998,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Innovate UK Grant Award",
        "date": "2025-03-27T00:00:00",
        "importance_score": 0.05,
        "time_bucket": "LONG",
        "rns_number": ""
      }
    ]
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 54.0,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 24.0,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 269% proven capacity"
      ],
      "verdict": "\u2705 Facts align with low fear - Normal risk/reward"
    },
    "crashhunter_signals": [
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Japanese Patent Grant",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Results of Shareholder Analysis",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Result of Retail Offer",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Retail Offer",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Placing of \u00a31,000,000",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "54/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "41/100",
          "pass": false,
          "icon": "\u26a0\ufe0f"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "1 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 49,
      "band": "\ud83d\udfe1 MODERATE COMPRESSION (Top 30% - GOOD SETUP)",
      "components": {
        "compression": {
          "score": 28,
          "max": 40,
          "signals_30d": 7,
          "signals_60d": 11,
          "signals_90d": 11,
          "signals_per_week": 0.85,
          "total_signals": 34,
          "rsi_extreme_count": 11,
          "rsi_ultra_count": 10,
          "escalation_count": 2,
          "density_score": 8,
          "rsi_score": 10,
          "escalation_score": 7,
          "description": "0.8 signals/week | 11 RSI<20 | 2 escalations | \u26a1 HIGH COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "DEEP CRASH BOTTOM",
            "DEEP CRASH BOTTOM",
            "DEEP CRASH BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 2,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.63,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 11,
          "max": 15,
          "best_historical_rally": 357.1,
          "avg_rally": 150.3,
          "signal_count": 34,
          "description": "SOLID MOVER - Historical 3x+ (357%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "CRTX.L",
      "signal_date": "2025-03-06",
      "total_signals_history": 34
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +12 (AI_Technical_Score=10.0/20)",
      "Drawdown reversion potential: +17 (Drawdown_Pct=86.0%)",
      "Volume confirmation: +10 (Relative_Volume=2.6)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +12 (best_rally_pct=269%)",
      "Split risk penalty: -15 (HIGH, age_factor=1.00)"
    ],
    "technical_score": {
      "points": 12,
      "ai_score": 10.0,
      "reason": "AI Technical Score 10.0/20 translates to 12/25 points"
    },
    "drawdown_score": {
      "points": 17,
      "drawdown_pct": 85.99,
      "reason": "Drawdown of 86.0% gives 17/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.63,
      "reason": "Relative volume 2.63x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 269.23,
      "reason": "Best rally of 269% gives 12/20 points"
    },
    "penalties": {
      "total": -15,
      "items": [
        "Split risk penalty: -15 (HIGH, age_factor=1.00)"
      ]
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=50.3%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2025-03-06"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.19,
    "current_run_pct": 50.31,
    "avg_historical_run_pct": 269.23
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 41/100 APEX score. Historical data shows 1 rallies averaging 269% upside. Current position: +50.3%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}